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ABSTRACT 
 
There has been a lot of interest on solid lipid nanoparticles (SLNs) as these 
colloidal submicron drug dosage forms present a promising frontier in drug 
delivery. It is possible to incorporate susceptible drugs such as protein intended 
for oral delivery. Here, we aim to develop an oral delivery system based on 
SLNs to deliver the peptide hormone, insulin using the double emulsion (W/O/W) 
solvent evaporation technique for formulating the SLNs. The choice of lipids 
was carefully selected to incorporate acceptability to biological milieu. The main 
purpose of the work was to formulate SLNs to achieve different localisation of 
insulin within the SLNs, based on the three hypothetical models proposed by 
Muller et al. (2000). Following that, the effect of this localisation on the 
propensity of the SLNs to be taken up by absorptive cells was investigated. 
SLNs was successfully fabricated to achieve two insulin localisation models, 
namely the solid solution model and the core-shell model with drug-enriched 
shell. The zeta potential measurements was used to indirectly indicate the 
appropriate insulin localisation model. The zeta potential of the unloaded SLNs, 
insulin-loaded SLNs and surface-adsorbed insulin SLNs were recorded as -51.7 
± 1 mV, -45.8 ± 1 mV and -40.8 ± 1 mV respectively. In vitro cell studies showed 
a notable difference in the Caco-2 cell lines when the cells were exposed to 
SLNs of the two different insulin localisation models. Thus, different effects seen 
on the Caco-2 cells suggests that the localisation of insulin within SLNs can 
potentially influence its uptake, stressing the importance of characterising drug 
localisation in nanoparticles, as this eventually affects drug bioavailability. 
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1.1 General Overview 
The rapid advances in the biotechnology sector in recent years has led to an 
increased production of biopharmaceuticals such as hormones, nucleic acids, 
peptide, protein, monoclonal antibodies and vaccines which offers great 
therapeutic potential. There are numerous biopharmaceuticals developed via 
recombinant technologies or chemical synthesis. Peptide and protein drugs are 
almost always administered via parenteral routes to avoid the hostile 
environment along the gastrointestinal tract (GIT) which include the presence 
of an acidic medium and proteolytic enzymes that will inactivate and digest the 
protein. Furthermore, due to their high molecular weights and lack of lipophilicity, 
proteins have poor permeability across the intestinal epithelium (Carino and 
Mathiowitz, 1999; Rekha and Sharma, 2009; Sarmento et al., 2007a). 
The oral route continues to be the most natural and convenient means to 
administer drugs, but also presents challenges to formulation scientists, 
especially for protein and other gastro-labile drugs. Nanoparticles are known to 
potentially improve the oral bioavailability of drugs, which are otherwise poorly 
absorbed from the gastrointestinal tract on their own. Nanoparticles have the 
highest surface area to volume ratio of any other dosage form. Furthermore, 
nanoparticles can potentially modify the physicochemical properties in 
comparison to the drug candidate itself, thus increasing gastrointestinal 
absorption of these peptides (Bawarski et al., 2008). 
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1.2 Biopharmaceuticals 
The terminology of biopharmaceuticals has been debated on over several years 
with different industry players; biotechnology and pharmaceutical businesses 
viewing it from their respective standpoints. However, from a broader 
perspective, biopharmaceuticals can be defined as the intersection of 
biotechnology and pharmaceuticals, in which the pharmaceutical is inherently 
biological in nature and is manufactured using biotechnological principles. 
According to the United States Food and Drug Administration (FDA), 
biopharmaceuticals cover a broad range of medicinal products such as 
recombinant proteins, monoclonal antibodies or nucleic acid-based products 
(Müller and Keck, 2004; Rader, 2008, 2005). According to Walsh (2010), 58 
biopharmaceuticals were approved by the regulatory bodies of European Union 
and/or United States from January 2006 to June 2010, totalling to just over 200 
products of biopharmaceuticals in the market until mid-2010 with many still in 
the pipeline or undergoing clinical trials (Tauzin, 2008; Walsh, 2010). 
 
1.2.1 Challenges in Delivery of Biopharmaceuticals 
Formulation of biopharmaceuticals into therapeutically effective drug delivery 
systems with optimal storage stability is indeed challenging. Particularly, the 
need to overcome barriers is crucial to improving delivery efficiency (Jorgensen 
and Nielson, 2009). The physical and chemical properties of 
biopharmaceuticals often influence how the delivery system would be 
developed, as no single system is feasible for all biopharmaceuticals.  
A common problem of biopharmaceuticals is often associated to their chemical 
nature, in particular conformational issues due to their unique structural 
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characteristics. It is also a prerequisite for the delivery system to be able to 
protect the drug under harsh degradative environment in order to exert its 
inherent biological activity (Jorgensen and Nielson, 2009; Müller and Keck, 
2004). Therefore, thorough understanding of the biopharmaceutical molecular 
structure, stability as well as its physical and chemical properties is crucial to 
develop a successful and feasible drug delivery system (Jorgensen and Nielson, 
2009). 
 
1.2.2 Insulin 
Insulin is a polypeptide hormone produced by the pancreatic beta-cells, 
secreted into the portal vein before being transported directly into the liver. It 
functions as a regulator of blood sugar levels by binding to insulin receptors 
after extraction in the liver, exerting its role in glucose metabolism (Arbit and 
Kidron, 2009; Meier et al., 2007; Satake et al., 2002). 
The introduction of biopharmaceutical recombinant human insulin therapy is 
indeed a major medical breakthrough in recent times, having been the mainstay 
of treatment for advanced-stage diabetes. Insulin was the first recombinant drug 
to be introduced in the 1970s as a healthcare product, marking a big milestone 
in the biotechnology sector (Goeddel et al., 1979; Pillai and Panchagnula, 2001). 
Since its introduction, much research has been focused on the aspects of 
production, purification, stability and delivery (Arbit and Kidron, 2009; Jain et al., 
2006). 
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1.2.2.1 Physicochemical properties 
Human insulin molecule consists of a total of 51 amino acid residues in two 
polypeptide chains, A and B, linked by two inter-disulphide bridges as shown in 
Figure 1.1. The A-chain contains 21 residues, with an intra-disulphide bond 
between A6 and A11, whilst the B-chain holds 30 amino acid residues (Fig. 1.1). 
The A-chain forms two nearly antiparallel α helices, whilst the B-chain forms a 
single α-helix and a β-strand, therefore providing a hydrophobic interior and a 
surface covered by both polar and non-polar amino acid residues (Brange, 
1994). The molecular weight of an insulin monomer is approximately 5.8kDa.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 The primary structure of human insulin.  
  (Adapted from: Beta Cell Biology Consortium)  
  (Accessed on: 10th July 2014) 
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Monomeric insulin, the biologically active form circulating in the body, exists at 
low aqueous concentration (<0.1 µM - 0.6 µg/ml). Insulin dimerises in aqueous 
solution at concentrations higher than 0.6 µg/ml, whereas if dissolved in the 
range of pH 4-8 and in the presence of zinc ions, insulin is more likely to have 
three dimers assemble together to form a hexamer (Brange, 1994).  
Figure 1.2 shows three dimers associated together with central zinc-
coordination to form a hexameric assembly. 
 
 
 
 
 
 
 
        Figure 1.2    Hexameric assembly of human insulin with  
       coordination around zinc [PDB ID: 1TRZ].  
       (Adapted from (Ciszak and Smith, 1994) 
 
 
 
 
Central                         
zinc-coordination 
Insulin dimers 
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1.2.2.2  Pharmacological properties 
Insulin plays a major role in the body’s carbohydrate, fat and protein metabolism, 
acting primarily on the liver, muscle and fat cells. A sharp rise in postprandial 
blood glucose level triggers insulin secretion from the pancreatic β-cells, 
subsequently increasing the uptake and storage of glucose, amino acids and 
fats, and hence reduces blood glucose level.  
Insulin binds to the insulin receptor on the surface of its target cells, causing a 
conformational change in the transmembrane glycoprotein complex. This 
activates the signal transduction mechanism which essentially decreases the 
blood glucose level by inhibiting glycogenolysis and gluconeogenesis and 
boosting glycolysis and glycogenesis. A maximum response of insulin effect 
can be achieved with less than 10 % of receptors being occupied with bound 
insulin (Rang et al., 2003). The insulin-receptor complex then internalises 
altogether into vesicles, and subsequently insulin is degraded in lysosomes 
whilst the receptors are recycled to the plasma membrane. Insulin is inactivated 
enzymatically in the liver and kidney with an elimination half-life of about 10 
minutes (Rang et al., 2003). 
 
1.3 Diabetes 
 
1.3.1 Definition 
Diabetes mellitus is a chronic disease which is developed when the pancreas 
does not produce sufficient insulin, or that the body is not utilising the circulating 
insulin effectively, resulting in hyperglycaemia (Association, 2010). Insulin is 
therefore necessary for maintaining normal blood sugar level in the body. 
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Diabetes is commonly divided into two types, characterized either by deficiency 
in insulin production (Type 1) or the body’s inefficient use of insulin (Type 2). 
Type 1 diabetes mellitus is caused by the patient’s own immune system which 
destroys the beta cells in the pancreas. Pancreatic beta cells are responsible 
for insulin production in the body. Type 2 diabetes mellitus is the most common 
form of diabetes that normally presents later in life. It occurs when either the 
body’s cells do not respond to insulin (insulin resistance) or when the pancreas 
does not produce sufficient insulin in order to maintain a normal glucose level. 
 
1.3.2 Prevalence 
In Malaysia, the latest population-based survey, National Health and Morbidity 
Survey 2011 (NHMS 2011) reported that the prevalence of diabetes in adults   
≥ 18 years of age has risen to 15.2 % from 11.6 % in 2006 (NHMS 2006) (Figure 
1.3) (Ministry of Health, 2012). This survey also highlighted the prevalence of 
undiagnosed diabetics at 8.0 % of Malaysian adults ≥ 18 years of age in 2011, 
almost double of that in 2006 (Figure 1.3) (Ministry of Health, 2012).  
In 2013, the International Diabetes Federation (IDF) estimated about 382 million 
people worldwide with diabetes in the adult population which represents 
approximately 8.3 % of the world’s adult population, with almost 46 % of them 
still remained undiagnosed (Figure 1.4) (IDF, 2013). 
 
By the year 2030, the number of people with diabetes worldwide is predicted to 
increase to 438 million (Unwin, 2009). A recent finding reported an estimate of 
5.1 million deaths worldwide which is attributable to diabetes in the year of 2013, 
and that one person dies from diabetes in every six seconds (IDF, 2013). The 
alarming global prevalence and high mortality rate are indeed major causes of 
concern. 
9 
 
 
 Figure 1.3     Diabetes prevalence among Malaysian adults (≥18 years)  
                               reported in NHMS III (2006) and NHMS 2011. 
            (Adapted from (Ministry of Health, 2012) 
 
 
 
 
Figure 1.4  World statistics of diabetes population in different regions of the 
 world, with estimated undiagnosed patients. 
  (Adapted from International Diabetes Federation, IDF 2013) 
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1.3.3 Pharmacological Basis of the Management of Diabetes 
Diabetes is a progressive, chronic metabolic disorder. Pharmacological 
management of diabetes in the initial stages involves the intake of oral 
hypoglycaemic agents such as sulphonylureas (gliclazides), biguanides 
(metformin), glitazones (rosiglitazone) and α-glucosidase inhibitors (acarbose) 
(Coustan, 2007; Krentz and Bailey, 2005; Rang et al., 2003). Recently, 
glucagon-like peptide (GLP-1) agonist (eg. Exenatide), an incretin mimetic, was 
newly introduced in the market as an effective alternative management for 
diabetes (Coustan, 2007; Verspohl, 2012). These extensive range of oral 
hypoglycaemic agents differ in their mode of actions, safety profiles and 
tolerability. Their mode of actions vary from stimulating insulin secretion, 
reducing hepatic glucose production, delaying digestion and absorption of 
carbohydrates to improving insulin sensitivity in the cells (Krentz and Bailey, 
2005).  
However, all oral hypoglycaemic agents are contraindicated in patients with 
Type 1 diabetes mellitus. These patients rely solely on insulin treatment to 
achieve normoglycaemic levels. As for patients with Type 2 diabetes mellitus, 
the use of oral hypoglycaemic agents is unable to delay the rate of disease 
progression. Escalating therapy is often the case for this category of patients, 
reflecting a progressive loss of beta cells function and an increase in insulin 
resistance (Krentz and Bailey, 2005). Unfortunately, there is no cure for 
diabetes. Insulin is almost always the standard treatment for Type 2 diabetic 
patients, when other oral antidiabetic agents fail to achieve optimal blood 
glucose level. These patients are therefore required to utilise a life-long insulin 
treatment.  
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1.4 Current Delivery Methods for Insulin 
Currently, patients requiring insulin therapy need to administer multiple daily 
injections of insulin subcutaneously, which can be extremely distressing. The 
patients may also experience local pain, itching, allergy and insulin 
lipodystrophy. More importantly, the strict regimen and also the unacceptability 
of injecting themselves on a regular basis have led to poor patient compliance, 
hence failure to achieve lasting glycaemic control. These disadvantages 
emphasise the need to find an alternative to subcutaneous injections, 
highlighting the possibility of oral insulin delivery as the most convenient and 
acceptable route of administration for chronic therapy.  
Several other alternative approaches of delivering insulin have been attempted 
to improve patient compliance which include inhalation, intranasal, 
buccal/sublingual and transdermal delivery systems (Flood, 2006; Mastrandrea 
and Quattrin, 2006; Owens, 2002).  
Delivery of insulin via pulmonary route became increasingly promising  when 
Exubera® was approved by regulatory authorities U.S. Food and Drug 
Administration (FDA) to be marketed in January 2006 (Heinemann, 2012; 
Lassmann-Vague and Raccah, 2006; Owens, 2002). However, the excitement 
of the revolutionary inhaled insulin, marketed by Pfizer, was short-lived. 
Exubera® did not gain acceptance of patients and physicians due to safety 
concerns and higher cost of production, and thus was eventually withdrawn 
from the market in October 2007 (Heinemann, 2012; Lassmann-Vague and 
Raccah, 2006; Mathieu and Gale, 2008).  
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1.5 Future Direction for Insulin Delivery 
Less invasive and alternative delivery routes of insulin therapy are being 
actively explored to overcome the setbacks of subcutaneous insulin injections 
currently available on the market. Among those alternative routes of 
administration being tested are intranasal administration, pulmonary, peroral, 
buccal and sublingual routes (Heinemann, 2012; Lassmann-Vague and Raccah, 
2006; Mao et al., 2009; Owens, 2002). Despite availability of these promising 
alternative routes, they have had limited success due to the absence of external 
stimuli which can facilitate absorption (Mao et al., 2009). 
Formulation of intranasal insulin was tested with numerous absorption 
enhancers such as saponin, lecithin and chitosan in gel to improve insulin 
absorption with minimal toxicity upon administration (Varshosaz et al., 2004). 
Studies have shown that a burst release of insulin was achieved, however, the 
bioavailability was found to be largely dependent on inter-individual response 
resulting in variable glucose-lowering effects among patient (Lassmann-Vague 
and Raccah, 2006; Leary et al., 2006). The setbacks of this administration route 
were a major concern, particularly nasal irritation, risk of immunogenicity (El-Etr 
et al., 1987) and possible injury to the nasal mucosa and mucocilliary system 
(Frauman et al., 1987). Hence, this route, for now, does not seem too favourable. 
Pulmonary insulin delivery appears rather promising, as the lung has a large 
surface area with good vascularisation and thin epithelial alveoli for rapid drug 
absorption, making this route far more permeable to macromolecules (Mao et 
al., 2009; Patton, 1996). Studies have shown that relative insulin bioavailability 
doubled when protease inhibitors such as trypsin, plasmin and kallikaren were 
co-administered with insulin, compared to when insulin was administered alone 
(Fukuda et al., 1995; Okumura et al., 1992). Likewise, permeation enhancers 
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are also usually required in pulmonary delivery to improve absorption of 
macromolecules across the alveoli cell layer (Hussain et al., 2004).  
Several inhaled insulin delivery systems have once progressed to clinical trial 
stages, such as AERx®, Exubera® and Technosphere® Insulin. However, the 
failure of Exubera® was extremely discouraging to the area of pulmonary insulin 
delivery, with most systems being withdrawn from clinical trials thereafter 
(Heinemann, 2012). Despite this, MannKind Corporation is still actively 
pursuing its product Technosphere® Insulin, hoping to address the constraints 
observed from clinical studies and obtain market approval in the near future 
(Heinemann, 2012; Lassmann-Vague and Raccah, 2006). 
Although these delivery routes appear promising, the question of whether the 
delivery system is feasible and effective in patients still remains unanswered. 
Thus, there is still much room for understanding and research to be carried out 
before these insulin delivery systems arrive on the market. 
Due to the limited success of alternative routes of insulin administration so far, 
oral insulin delivery has since gained interest among researchers as a safe and 
effective means of insulin delivery. Oramed® Pharmaceuticals recently claimed 
that a revolutionary oral insulin capsule developed by them is currently in Phase 
2 clinical trials in the United States (Leichman, 2013). 
 
1.5.1 Oral Insulin Delivery 
Undoubtedly, oral delivery is the most acceptable route among patients. 
Improved patient compliance and adherence are among significant benefits of 
the oral route of delivery. However, this route of administration comes with its 
own limitations. Insulin delivered orally will need to overcome both the physical 
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and enzymatic barriers of the human gastrointestinal tract (GIT) in order to 
deliver insulin effectively (Arbit et al., 2008; Mao et al., 2009).  
The physical barrier refers to the epithelial cells lining the GIT which are tightly 
bound with minimal leakage, thus limiting the drug absorption through the 
intracellular route. Due to the size constraints, permeation via intracellular route 
is virtually impossible. In addition, the microvilli (brush border) present on the 
apical surface of the epithelial cells also limits the absorption of insulin due to 
the presence of digestive enzymes on the microvilli. The glycoalyx and mucus 
layer found on top of the epithelial layer also acts as another physical barrier to 
oral insulin delivery (Arbit et al., 2008; Carino and Mathiowitz, 1999).  
The enzymatic barrier refers to the rapid presystemic enzymatic degradation 
due to secretion of high level of proteases in gastric and intestinal fluids as well 
as the membrane-bound peptidases localised on the surface of various 
mucosal tissues (Mao et al., 2009; Woodley, 1993). This contributes to a large 
amount of insulin being degraded prior to being absorbed across the intestinal 
epithelium. 
 
1.5.1.1 Potential Physiological Advantages of Oral Insulin Delivery 
Orally delivered insulin is designed to mimic the exacted physiological route as 
it is taken up from the gastrointestinal tract into the portal vein. It is anticipated 
that the oral insulin will be transported to the liver via the portal vein; be 
subjected to first-pass metabolism that gives rise to the “portal signal”, hence 
regulating the glucose metabolism (Arbit and Kidron, 2009; Satake et al., 2002).  
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This is contrary to what happens when it is administered parenterally, in which 
insulin is introduced directly into the systemic circulation, resulting in a lower 
portal-peripheral insulin gradient and a weaker “portal signal”. Thus, the 
regulation of glucose metabolism is rendered more effective in oral insulin 
versus parenteral insulin. In addition, oral insulin is also more likely to benefit 
the patient by reducing the risk of hyperinsulinaemia and hypoglycaemia, 
commonly associated to systemic insulin therapy (Arbit and Kidron, 2009; 
Satake et al., 2002). 
 
1.6 Nanoparticulate Formulations 
Colloidal nanoparticulate delivery systems are defined as particulate 
dispersions containing nanoparticles with overall size distribution within the 
range of 10 – 1000 nm (Allémanna et al., 1993). These common types of 
delivery systems include those containing lipids, such as liposomes, 
nanoemulsion, lipid nanoparticles; natural or synthetic polymeric nanoparticles, 
such as poly D,L-lactide-co-glycolide (PLGA) (Vonarbourg et al., 2006). These 
delivery systems have become particularly attractive in recent years due to their 
ability to encapsulate and deliver new, large-molecule therapeutics such as 
peptides, proteins and genes (Bilati et al., 2005b; Delie et al., 2001; Vonarbourg 
et al., 2006). In addition, nanoparticulate delivery systems are also well 
accepted for their ability to improve drug bioavailability, by means of protecting 
the drug against degradative substances (Allémanna et al., 1998). Bonduelle et 
al. (1996) reported that the oral bioavailability of cyclosporin A-loaded 
nanocapsule showed a notably elevated bioavailability of cyclosporin A, a cyclic 
peptide, and a reduced side effect of nephrotoxicity as compared to the 
commercial cyclosporin A emulsion tested in the study.  
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Several types of nanoparticulate formulations containing insulin have been 
prepared to achieve an efficacious insulin oral delivery system. Such 
formulations have been investigated using polymeric nanocarriers, lipid-based 
as well as complex hydrogel nanoformulations (Ahmad et al., 2011).  
An example of polymeric nanocarriers, composed of chitosan, was found to be 
effective in transporting insulin across the intestinal epithelium primarily due to 
the mucoadhesive properties of chitosan that caused prolonged hypoglycaemia 
seen in diabetic rats, as opposed to the insulin solution form (Chen et al., 2011). 
The modified chitosan nanoparticles, a combination of polymers chitosan and 
poly(γ-glutamic acid), formed a pH-responsive nanoparticle system. Recent 
studies reported that these nanoparticles led to a slow onset, prolonged 
hypoglycaemia in diabetic rats with a relative insulin bioavailability of 15 % 
(Sonaje et al., 2010a, 2010b), and therefore may act as a suitable alternative 
to the subcutaneous basal intermediate-acting insulin (Sonaje et al., 2010b). 
Studies on insulin have also shown that insulin-encapsulated poly(alkyl 
cyanoacrylate) (PACA) nanocapsules resulted in a reduction of glycaemia by 
72 % after nine days and 48 % after 15 days of oral administration (Damgé et 
al., 1988), as compared to only less than 0.5 % of insulin dose being detected 
when free (non-encapsulated) insulin was administered orally (Allémanna et al., 
1998). In another study, insulin-phospholipid complex loaded into PLGA 
nanoparticles for oral delivery recorded a 42.6 % reduction in plasma glucose 
with a prolonged effect of up to 12 hours post administration in diabetic rats (Cui 
et al., 2006).  
Liposomes and solid lipid nanoparticles are the different types of lipid-based 
nanoformulations used to deliver insulin orally. Liposomes are made up of 
concentric lipid bilayers, formed spontaneously by amphiphilic lipids, are 
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capable of protecting entrapped molecules within the aqueous core 
(Dapergolas and Gregoriadis, 1976). The amphiphilic lipids can be natural or 
synthetic phospholipids, such as phosphatidylcholine (lecithin), 
phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine and 
phosphatidylinositol (Vemuri and Rhodes, 1995). Insulin loaded into 
dipalmitoyl-phosphatidylcholine (DPPC)/cholesterol liposomes significantly 
reduced the blood glucose level in diabetic rats to 57 % of pretreatment values 
after 4 hours of administration (Dapergolas and Gregoriadis, 1976). However, 
a less pronounced hypoglycaemic effect was noted when insulin loaded 
phosphatidylcholine/cholesterol liposomes were administered in diabetic rats, 
highlighting the effects of different types of liposomes used (Dapergolas and 
Gregoriadis, 1976). Cetyl palmitate-based solid lipid nanoparticles (SLNs) have 
also been used to incorporate insulin for oral administration, achieving a 
significant hypoglycaemia in diabetic rats over 24 hours (Sarmento et al., 
2007a). In another study, insulin loaded lectin-modified solid lipid nanoparticles 
(SLNs) demonstrated a better protection against insulin degradation by 
digestive enzymes in vitro than that observed in insulin loaded SLNs, with 
relative bioavailabilities of 7.11 % and 4.99 % respectively in comparison to 
subcutaneous insulin, both improving the oral absorption of insulin (Zhang et 
al., 2006). 
There has also been a successful attempt to formulate oral insulin into a 
complex multi-layered nanoparticle preparation made from biodegradable, 
biocompatible, mucoadhesive and protease-protective biomaterials. Insulin 
incorporated into the alginate, dextran sulphate and poloxamer hydrogel, 
formed through ionotropic pre-gelation and polyelectrolyte complexation, was 
stabilised with chitosan and coated with albumin (Woitiski et al., 2009). This 
complex hydrogel formulation demonstrated retained bioactivity of insulin in 
18 
 
vitro as well as enhanced protection against enzymatic digestion and ultimately 
its absorption (Woitiski et al., 2009, 2011).  
 
1.7 Solid Lipid Nanoparticles (SLNs) 
Solid lipid nanoparticles (SLNs) represent lipid nanoparticulate delivery systems 
that combine the benefits of solid particles, emulsions and liposomes 
(Mukherjee et al., 2009b). The SLNs are realised by exchanging the liquid lipid 
present in emulsions to a lipid that is solid at room and body temperature. The 
lipid phase will be subsequently dispersed in water or in an aqueous surfactant 
solution (Mukherjee et al., 2009b; Müller et al., 2002a). Lipids may be selected 
from a range of triglycerides, partial glycerides, fatty acids, steroids and waxes 
(Müller and Keck, 2004). 
Since the beginning of nineties, many research groups have focused on the use 
of SLNs as an alternative colloidal carrier to polymeric nanoparticles, avoiding 
drawbacks pertaining to polymeric nanoparticles such as polymer cytotoxicity 
and the use of organic solvents (Almeida and Souto, 2007; Mehnert and Mäder, 
2001; Müller et al., 2000). Table 1.1 lists a range of pharmaceutical drugs 
having been successfully incorporated into SLNs by numerous research groups.  
Moreover, SLNs have also been reported to manifest controlled and localised 
drug release, higher drug encapsulation, better drug bioavailability and tissue 
distribution with improved stability of incorporated labile drug (Cavalli et al., 
1993; Mehnert and Mäder, 2001; Uner and Yener, 2007). A prolonged release 
of prednisolone over a 5-week duration has been demonstrated in the drug 
release studies of prednisolone-containing SLNs (Müller et al., 1995). 
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 Table 1.1 Examples of drugs incorporated into SLNs.  
   (Pathak et al., 2007) 
 
 
Drug Name References 
Clobetasol (Hu et al., 2002) 
Clozapine (Venkateswarlu and Manjunath, 2004) 
Cyclosporine (Olbrich et al., 2002) 
Darodipine (Hubert et al., 1991) 
Hydrocortisone (Cavalli et al., 1999) 
Idarubicin (Zara et al., 2002) 
Indomethacin (Calvo et al., 1996) 
Paclitaxel (Chen et al., 2001) 
Prednisolone (Müller et al., 1995) 
Progesterone (Dufresne and Leroux, 2004) 
Tobramycin (Bargoni et al., 2001) 
Tretinoin (Manconi et al., 2002) 
Ubidecarone (Bunjes et al., 2001) 
Vitamin A (Jenning et al., 2000) 
 
 
 
1.8  Preparation of Solid Lipid Nanoparticles 
SLNs are primarily made up of solid lipid, emulsifier and water/solvent. The 
lipids commonly used are triglycerides (tri-stearin), partial glycerides (Imwitor), 
fatty acids (stearic acid, palmitic acid), sterols (cholesterol) and waxes (cetyl 
palmitate). Emulsifiers are an essential ingredient in SLNs formulations to 
stabilise the lipid dispersion by forming a protective cover over the SLNs surface 
(Quintanar-Guerrero et al., 2005). Several emulsifiers, used alone or in 
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combination, can prevent particle agglomeration of SLNs efficiently to avoid 
Ostwald’s ripening phenomenon (Cavalli et al., 1993; Mukherjee et al., 2009b). 
 
1.8.1 Lipids : Palm oil 
Triglycerides are the major constituents of palm oil, with over 95 % of palm oil 
is made up of mixture of triglycerides. Major fatty acids present in palm oil are 
myristic acid, palmitic acid, stearic acid and oleic acid. Table 1.2 lists the fatty 
acids with their corresponding chemical structures and lipid numbers.  
 
Table 1.2   Example of fatty acids with chemical formulae and lipid numbers.  
       (Lipid numbers presented as C:D; where C is the number of carbon 
        atoms and D is the number of double bonds in the fatty acid) 
 
Fatty acids Chemical formula C:D 
 
Myristic acid CH3(CH2)12COOH 14:0 
Palmitic acid CH3(CH2)14COOH 16:0 
Stearic acid CH3(CH2)16COOH 18:0 
Oleic acid CH3(CH2)7CH=CH(CH2)7COOH 18:1 
 
 
Figures 1.5 and 1.6 show the chemical structures of palmitic acid and tripalmitin 
respectively. Most fatty acids are present as triglycerides, with tripalmitin being 
the predominant saturated triglyceride in palm oil (Sundram et al., 2003). 
Tripalmitin is derived from the esterification of three palmitic acid molecules and 
a glycerol molecule. Since tripalmitin is made up of palmitic acids which are 
saturated fatty acids, it is therefore presented as a solid at room temperature. 
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Figure 1.5  Chemical structure of palmitic acid   
   [CH3(CH2)14COOH]. 
 
 
 
 
 
 
Figure 1.6 Chemical structure of tripalmitin (C51H98O6). 
 
 
 
 
 
Single palmitic acid chain 
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1.8.2 Methods of Production of Lipid Nanoparticles 
Several methods for preparing SLNs have been presented since their 
introduction in the 1990s (Yazan, 2008). Among the commonly used techniques 
is the high pressure homogenisation method which can be performed in either 
hot (Schwarz et al., 1994; Westesen et al., 1993) or cold conditions (Castelli et 
al., 2005; Mühlen et al., 1998) depending on the nature of the drug. 
Ultrasonication, high-speed homogenisation (Eldem et al., 1991; Luo et al., 
2006), solvent-diffusion and solvent emulsification-evaporation methods 
(Siekmann and Westesen, 1996; Trotta et al., 2003) have also been used to 
produce solid lipid nanoparticles. These methods are commonly used to 
encapsulate lipophilic drugs. However, a double emulsion water-oil-water 
(W/O/W) method based on a modified solvent emulsification-evaporation 
technique was used to prepare SLNs for the incorporation of hydrophilic drug 
substances (Cortesi et al., 2002). The hydrophilic drug is encapsulated with a 
stabiliser to minimize partitioning of the drug into the external water phase 
during solvent evaporation (Mukherjee et al., 2009b). 
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1.9 Basic Physiology and Function of Gastrointestinal Tract (GIT) 
Orally administered insulin will pass down the stomach, in which the 
environment is very acidic and it also contains high amount of proteolytic 
enzymes which destroys the physiological activity of the protein (Figure 1.7). It 
is widely reported that low gastric pH and the presence of pancreatic enzymes 
lead to extensive particle aggregation and lipid degradation of non-coated SLNs 
(Carino and Mathiowitz, 1999; Garcıa-Fuentes et al., 2003). Insulin is therefore 
effectively stopped by the natural barriers to protein delivery as the large 
aggregated particles will not be taken up by Peyer’s patches and the insulin will 
be prematurely digested by the enzymes. To avoid this from happening, insulin 
should be protected from release within the hostile environment of the stomach. 
As it moves down the stomach into the duodenum, the pH increases to 7.4 and 
the enzymatic activity decreases, making it a more suitable location for insulin 
absorption.  
 
                   
          
  Figure 1.7 Human gastrointestinal tract. 
    (Adapted from A.D.A.M. Inc.)   
    (Accessed on 30th July 2014) 
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1.10 Present Research Theme 
The present research theme focuses on utilising lipid from palm oil which is rich 
in saturated and unsaturated fatty acids and triglycerides. There is a lot of 
potential in this area of oral drug delivery system using palm oil constituents, 
considering the fact that palm oil lipids have the potential for gastrointestinal 
uptake via the lymphatic route. Moreover, these physiological lipids are versatile 
and are non-toxic to humans.  
Palmitic acid and tripalmitin were thus investigated as potential SLNs lipid 
matrix for the delivery of insulin. Several studies have reported, either a single 
type of solid lipid or a combination of a solid and a liquid lipid as their lipid core 
of the nanoparticles (Garcıa-Fuentes et al., 2003; Trotta et al., 2003; Zhang et 
al., 2006). Liu et al. (2007) attempted to utilise a combination of two different 
solid lipids, palmitic acid and stearic acid, as the lipid core of the nanoparticles.  
To our knowledge, there has not been any attempt to investigate the 
combination of solids, a fatty acid (palmitic acid) and a triglyceride (tripalmitin), 
which are structurally different but share the same fatty acid chain in the 
formulation of solid lipid nanoparticles. This area of research is not new but is 
certainly intense and appears to be very promising, especially from the data 
reported in the literature. Previous studies have developed SLNs containing 
insulin to be delivered orally using various preparation methods, for example, 
solvent evaporation (Garcıa-Fuentes et al., 2003), solvent emulsification-
diffusion (Trotta et al., 2005), reverse-micelle double emulsion technique (Liu et 
al., 2007). These studies were mainly aimed at developing lipid nanoparticles 
encapsulating peptides and studying their physicochemical properties as well 
as in vitro stability.  
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However, little attempt has been directed towards establishing the localisation 
of insulin within the fabricated nanoparticles, and none towards correlating the 
localisation of the insulin within the SLNs with the gastrointestinal uptake of 
these SLNs.  
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1.11 Research Aims and Objectives 
The ultimate aim of the present project was to establish whether the location of 
peptide hormone insulin formulated within the SLNs influenced the in vitro 
uptake of the nanoparticles by absorptive cells.  
The above objective was realised by firstly formulating the SLNs in order to 
achieve the three drug localisation models as proposed by Müller et al. (2000) 
(Fig. 1.8). This was done by manipulating formulation and processing 
parameters. The three possible drug localisation models proposed by Müller et 
al. (2000) are (a) solid solution model (with the drug molecularly dispersed 
within the lipid matrix), (b) the core-shell model (with a drug-enriched shell and 
a lipid core) and (c) the drug-enriched core model (with the lipid matrix shell 
encapsulating the drug core) (Müller et al., 2000). 
It is believed that the location of insulin within the SLNs has a direct impact on 
the rate of uptake of the nanoparticles by the enterocytes as well as Peyer’s 
patches into the lymph and the ultimate rate of assimilation of the same in the 
lymph (Sarmento et al., 2007b). These two processes, namely the rate of 
uptake and the rate of assimilation of SLNs will influence the eventual 
bioavailability of the ultimate prototype. The above pursuit has not be reported 
in the literature and forms the core basis of this research.  
The final objective was to investigate the difference, if any, between the different 
localisation models of insulin within the solid lipid nanoparticles and the uptake 
of such lipid nanoparticles by the absorptive cells. 
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         A                B            C 
 
  A :  solid solution model (dispersion within matrix) 
  B :  core-shell models with drug enriched shell 
  C :  core-shell models with drug-enriched core 
 
 
 
Figure 1.8    A schematic diagram showing the three hypothesised 
models of drug localisation :- A, B and C.    
    (Adapted and modified from (Müller et al., 2000) 
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CHAPTER 2  
 
Stability Studies on 
Recombinant Human 
Insulin 
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2.1 Introduction 
This section details the preformulation work to establish a reliable and robust 
analytical method for insulin analysis as well as to address its stability in 
response to appropriate challenges. 
The main aim of this phase of work was to subject insulin to perceived stresses 
encountered during formulation. Therefore, a short-term accelerated stability 
testing was conducted on human recombinant insulin at various temperatures 
and pH as part of preformulation studies. A high performance liquid 
chromatography (HPLC) method was used to determine the extent of 
deamidation of insulin by measuring the degradation products. This was done 
at various storage conditions. We also utilised dynamic light scattering 
technique to detect protein aggregates or changes in particle sizes of insulin 
molecule as an indication of protein physical instability induced by different 
storage temperatures. Hence, the most suitable conditions would be used for 
the handling, storing and processing of insulin during the formulation work. 
Like any other globular proteins, insulin has a tendency to adopt a folding and 
assembly of the individual molecules, with the hydrophobic surfaces being 
buried inside and the hydrophilic residues being exposed (Brange et al., 1997). 
Any change in the native conformation will render it unstable. Therefore, 
stability issue of insulin is crucial since any inappropriate handling can 
potentially accelerate its degradation. 
Extensive studies on the physicochemical stability of insulin have been reported 
in the literature. These studies have highlighted the importance of 
understanding the drug nature in order to preserve its biological potency 
(Brange, 1994). Apart from stability and efficacy issues, maintaining the safety 
and non-immunogenicity of the protein formulation is of utmost importance 
30 
 
especially if it is to be self-administered directly by the patients (McNally and 
Hastedt, 2013; Wakankar and Borchardt, 2006).  
Insulin is subjected to chemical and physical instabilities during storage and 
usage, which can compromise the efficacy of the drug. It is known to undergo 
degradation via deamidation and aggregation (Brange et al., 1997; Lai and 
Topp, 1999; McNally and Hastedt, 2013). 
Chemical instability mainly manifests as deamidation which is hydrolytic and 
involves the deamidation of the asparagine amino acid residues to aspartic acid 
(Lai and Topp, 1999; McNally and Hastedt, 2013). HPLC is commonly used to 
separate and detect presence of insulin as well as its degradation products 
(Hoyer et al., 1995; Oliva et al., 1996). 
Physical instability often refer to changes in the protein conformational structure 
including denaturation, aggregation (fibrillation) and precipitation (Brange et al., 
1997; Lai and Topp, 1999; Manning et al., 1989; McNally and Hastedt, 2013). 
Insulin may also undergo transformation by forming intermolecular covalent 
bonds with other insulin molecules resulting in higher molecular weight 
transformation products (Brange, 1994; Oliva et al., 2000). High temperature, 
exposure to hydrophobic surfaces (air-water interface) and organic solvents can 
lead to physical instability of insulin (Brange et al., 1997; Lai and Topp, 1999; 
McNally and Hastedt, 2013). Several approaches have been used to 
characterise physical instabilities of protein samples, including size-exclusion 
chromatography (Clodfelter et al., 1999), light scattering technique (Oliva et al., 
2000) and fluorescence microscopy technique to detect protein aggregates 
(Demeule et al., 2007). 
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To address the issues of chemical instabilities of proteins, reversed-phase 
HPLC is probably the most utilised analytical method in the literature for the 
separation and determination of proteins and peptides (Aguilar, 2004; Geng and 
Wang, 2008; Sarmento et al., 2006). This technique, used for separating 
proteins by exploiting hydrophobic interactions between the column packing 
and the hydrophobic regions of the protein, is a powerful and robust method 
which has been used for quantifying insulin accurately in both artificial and 
biological environments (Moslemi et al., 2003; Oliva et al., 2000; Rajan et al., 
2006; Sarmento et al., 2006; Xu et al., 2006). Moreover, the United States, 
British as well as the European Pharmacopoeias have also recommended 
separating and determining insulin contents by using the HPLC method. 
A comprehensive literature review was done on previously developed HPLC 
assay methods for insulin and its degradation product A-21 desamidoinsulin in 
order to select a suitable HPLC method for the current work.  
Moslemi et al. (2003) developed a reversed-phase HPLC method with UV 
detection at room temperatue to simultaneously determine insulin and its main 
degradation product, A-21 desamidoinsulin. The ion-pair RP-HPLC approach, 
using tetramethylammonium hydroxide as the ion-pairing reagent, was chosen 
in order to get a well-resolved peak and reproducible retention time. Despite the 
peak shape being symmetrical, the resolution was poor. The retention time for 
this method was long, with insulin eluting at 16.76 minutes and the degradation 
product at 19.99 minutes. This would not be popular if it is necessary to analyse 
multiple samples. Some other HPLC methods also suffered the same setback 
of being too time consuming (Klyushnichenko et al., 1994; Yomota et al., 1996).  
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Several proposed HPLC methods in the literature have reported effective 
separation of insulin from its principal degradation products, A-21 and B-3 
desamidoinsulin, with a high specificity and precision demonstrated. However, 
their limitations lie in the chromatographic conditions which involved  elevated 
temperature at 40°C, which was not very desirable and compromises drug 
stability and also required a column temperature controller to maintain the 
temperature (Farid et al., 1989; Xu et al., 2006; Yomota et al., 1996).  
Prior to performing stability studies, this section of studies was therefore 
designed to develop and validate a simple yet robust HPLC method capable of 
identifying insulin and its degradation products.  
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2.2 Materials  
Pure crystalline recombinant human insulin (lyophilised powder) was 
manufactured by EMD Biosciences (San Diego, U.S.A.) and purchased from 
Merck Malaysia. HPLC-grade methanol, acetonitrile (ACN) and trifluoroacetic 
acid (TFA) were purchased from Fisher Scientific (Loughborough, UK). Both 
anhydrous sodium sulphate and phosphoric acid were purchased from Systerm 
(Belgium). Purified water was used for all solutions and dilutions. Regenerated 
cellulose (RC) 0.2 µm syringe filter membranes were purchased from Titan 
(Tennessee, U.S.A.) to filter each insulin sample prior to sample injection. 
The HPLC system comprised of a Series 200 Quaternary LC Pump Model 
200Q/410 with Series 200 Autosampler, connected to the UV/Vis Detector 
(LC200UV) from the manufacturer Perkin Elmer (U.S.A.). A TotalChrom® 
software, linked to the HPLC system, allowed chromatograms to be viewed and 
analysed on the computer. HPLC columns used were Apex™ ODS (C18, 5 µm, 
100 Å pore size, 4.6 x 150 mm) (Jones Chromatography, U.S.A.), Hypersil™ 
ODS (C18, 5 µm, 120 Å pore size, 4.6 x 250 mm) (Thermo Scientific™, U.S.A.) 
and Jupiter (C18, 5 µm, 300 Å pore size, 4.6 x 250 mm) (Phenomenex®, U.S.A.).   
Particle size analysis based on dynamic light scattering technique was carried 
out using Zetasizer Nano-ZS (Malvern Instrument, U.K.). Samples were loaded 
in disposable polystyrene cuvettes (DTS 0012) prior to analysis. 
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2.3 Methods 
 
2.3.1 High Performance Liquid Chromatography (HPLC) Assay Method 
 Development for Recombinant Human Insulin 
 
In this part of study, reported HPLC methods were reviewed in the literature for 
suitability and adaptability. We aimed to select relevant parameters that would 
enable us to produce a method that is sensitive, selective and specific with  
short  retention  times. Table  2.1  summarises  the  different  parameters  
which were explored.
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  Table 2.1  HPLC methods used at different stages of optimisation trials. 
    (Words in italic indicate modifications done to the previous method) 
Trial Method HPLC Conditions Insulin Samples HPLC Column 
1 Adapted from 
(Sarmento et al., 
2006) 
1)  Mobile phase : ACN ; 0.1 % TFA 
2)  Eluent : 
 1st – 5th minute  (gradient elution)                                                 
- ACN:TFA 30:70 to 40:60 (v/v)  
 6th – 10th minute (isocratic elution)                                                 
- ACN:TFA 40:60 (v/v) 
3)  Flow rate : 1 ml/min 
4)  UV detection wavelength: 214 nm 
 
Dissolved in  pH 4.5 
sodium acetate buffer      
(BP, 2007) 
Apex ODS (C18),   
5 µm,                  
4.6 x 150 mm  
(Jones 
Chromatography, 
U.S.A.) 
2  Adapted and 
modified from 
(Sarmento et al., 
2006) 
1)  Mobile phase : ACN ; 0.1 % TFA 
2)  Eluent : 
 1st – 5th minute  (gradient elution)                                                 
- ACN:TFA 30:70 to 40:60 (v/v)  
 6th – 10th minute (isocratic elution)                                                     
- ACN:TFA 40:60 (v/v) 
3)  Flow rate : 1 ml/min 
4)  UV detection wavelength: 214 nm 
Dissolved in pH 2 
citrate buffer 
Apex ODS (C18),    
5 µm,                 
4.6 x 150 mm  
(Jones 
Chromatography, 
U.S.A.) 
3 Adapted and 
modified from 
(Sarmento et al., 
2006) 
 
1)  Mobile phase : ACN ; 0.1 % TFA 
2)  Eluent : 
 1st – 5th minute  (gradient elution)                                                 
- ACN:TFA 30:70 to 40:60 (v/v)  
 6th – 10th minute (isocratic elution)                                                     
- ACN:TFA 40:60 (v/v) 
3)  Flow rate : 1 ml/min 
4)  UV detection wavelength: 214 nm 
 
Dissolved in pH 2 
citrate buffer 
ODS Hypersil C18, 
5 µm,                          
4.6 x 250 mm 
(Thermo Scientific, 
UK) 
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Trial Method HPLC Conditions Insulin Samples HPLC Column 
4 Adapted and 
modified from 
(Sarmento et al., 
2006) 
 
1)  Mobile phase : ACN ; 0.1 % TFA 
2)  Eluent : 
 1st – 5th minute  (gradient elution)                                                 
- ACN:TFA 30:70 to 40:60 (v/v)  
 6th – 10th minute (isocratic elution)                                                     
- ACN:TFA 40:60 (v/v) 
3)  Flow rate : 1 ml/min 
4)  UV detection wavelength: 214 nm 
 
Dissolved in 0.01 M 
HCl (pH 2) 
ODS Hypersil C18, 
5 µm,                         
4.6 x 250 mm 
(Thermo Scientific, 
UK) 
5 Adapted and 
modified from 
(Oliva et al., 
2000) 
1)  Mobile phase :  
     a. 74 % 0.2M sodium sulphate                                                   
         (adjusted to pH 2.3 with         
         phosphoric acid) 
     b. 26 % ACN 
2)  Flow rate : 1 ml/min  
3)  UV detection wavelength: 214 nm 
 
Dissolved in 0.01 M 
HCl (pH 2) 
ODS Hypersil C18, 
5 µm,                    
4.6 x 250 mm 
(Thermo Scientific, 
UK) 
6 Adapted and 
modified from 
(Oliva et al., 
2000) 
1)  Mobile phase :  
     a. 73-75 % 0.2M sodium sulphate                                                  
         (adjusted to pH 2.3 with         
         phosphoric acid) 
     b. 25-27% ACN 
2)  Flow rate : 1 ml/min  
3)  UV detection wavelength: 214 nm 
 
Dissolved in 0.01 M 
HCl (pH 2) 
ODS Hypersil C18, 
5 µm,                      
4.6 x 250 mm 
(Thermo Scientific, 
UK) 
7 Adapted and 
modified from 
(Bradshaw, 
2000) 
1)  Mobile phase :  
    (A) 0.1 % TFA in water; 
    (B) 0.1 % TFA in ACN 
    A/B : 75/25 to A/B : 35/65 in 20  
             minutes (gradient elution)                                    
2)  Flow rate : 1 ml/min  
3)  UV detection wavelength: 214 nm 
 
Dissolved in 0.1 % 
TFA (pH 2) 
Jupiter C18, 5 µm, 
300 Å pore size,   
4.6 x 250 mm 
(Phenomenex, 
U.S.A.) 
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2.3.2      Validation of HPLC Method 
The selected HPLC method deemed most reliable and suitable was subjected 
to method validation. The suitable criteria for selection are as outlined in 2.3.1. 
A primary stock solution of 1000 µg/ml was accurately prepared in 0.1 % TFA, 
followed by a series of dilutions using 0.1 % TFA to obtain seven secondary 
standard solutions. The seven insulin standard solutions were prepared over 
the following concentrations: - 100 µg/ml, 50 µg/ml, 25 µg/ml, 12.5 µg/ml, 6.75 
µg/ml, 3.125 µg/ml and 1.5625 µg/ml. Each solution was carefully filtered 
through cellulose acetate membrane syringe filter with 0.2 µm pore size. 
The linearity, accuracy and precision of the developed HPLC assay method 
were determined. For linearity, seven data points (n=3) were used for the 
calibration curve and the regression line was calculated using least squares 
method. Insulin solutions at 100 µg/ml, 12.5 µg/ml and 1.5625 µg/ml were 
accurately prepared and were injected six times for within day determinations 
of precision and accuracy. A further six injections were made for calculation of 
the inter-day precision and accuracy. In either case, the precision was 
calculated as percentage coefficient of variation (% CV) or relative standard 
deviation (RSD) (Eq. 2.1), whilst the accuracy was calculated as the percentage 
(%) error or relative standard error (Eq. 2.2). 
 
RSD =    
Standard deviation (SD)
Mean
   x    100% 
         (Eq 2.1) 
Percentage (%)Error =   
Measured − Actual Concentration
Actual Concentration
    x    100% 
          (Eq 2.2) 
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The limit of detection (LOD) and limit of quantification (LOQ) of this HPLC 
method were calculated based on the standard deviation of the response (Sy) 
of the calibration and the slope (S). The LOD was calculated as 3.3 x (Sy/S), 
whilst LOQ was calculated as 10 x (Sy/S).  
 
2.3.3      Effects of pH and Temperature on Stability of Insulin 
 
2.3.3.1     HPLC 
Insulin samples were prepared at 100 µg/ml in 0.1 % TFA (pH~2.2) and stored 
in clear glass vials at various storage conditions :- a) -20 ºC (freezer) ; b) 2 ºC 
(refrigerator) ; c) 25 ºC in darkness ; d) 25 ºC in bright light (laboratory room 
illumination) ; e) 45 ºC (processing temperature). Samples a) to d) were left for 
11 days at the respective storage conditions. For exposure at storage 
temperature 45 ºC, 30 minutes of run time was deemed sufficient to match 
similar processing times during formulation work. 
Samples were analysed based on the optimised chromatographic conditions of 
the validated HPLC method as described in Section 2.3.1 and 2.3.2. 
 
2.3.3.2  Particle Size Analysis 
The average hydrodynamic size (z-average) of insulin in samples was 
measured by photon correlation spectroscopy using Zetasizer Nano-ZS 
(Malvern Instrument, U.K.). Samples were loaded in disposable polystyrene 
cuvettes (DTS 0012). All measurements were performed at 25 ºC, with an 
equilibrium time of 2 minutes. Each value reported is the average of three 
measurements, consisting of 10 subruns per measurement. 
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Samples for stability studies were freshly prepared in pH 2 and pH 7 buffers at 
a concentration of 1 mg/ml and were each divided into three portions and stored 
at temperatures :- a) 2 ºC (refrigerated); b) 25 ºC (room temperature); c) 45 ºC 
(processing temperature).  
100 µL aliquots were withdrawn from each sample at specified sampling time 
intervals over 14 days and frozen at -20 ºC until analysis. Samples were thawed 
to room temperature prior to particle size measurements. Each sample was 
diluted to 1 ml with respective buffer, which had already been filtered with 0.2 
µm Sartorius Polyethersulfone (PES) membrane filter. 
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2.4 Results and Discussion 
 
2.4.1 Optimisation of HPLC Methods 
Initially, HPLC runs were performed according to the method described in              
Table 2.1, as adapted from Sarmento et al. (2006). Insulin peaks appeared 
inconsistently at various retention times, due to carry-over from previous 
sample injections. For example, some peaks appeared prior to the mobile 
phase front, whilst some chromatograms did not display any drug peak 
throughout the run, even at high concentrations of 1000 µg/ml.   
Insulin was prepared in sodium acetate buffer pH 4.5, where a non-
homogenous suspension was formed instead of a clear solution. It has been 
reported that pH has much influence on the chemical stability of insulin during 
storage, since it can potentially affect the charge on insulin as well as the folding 
and association of insulin molecules (Brange and Langkjaer, 1992). Chemical 
transformation involving the formation of covalent dimers and oligomers is 
favoured at around pH 4 (Brange, 1994), hence compromising the stability of 
insulin which is likely to have contributed to the inconsistencies of the insulin 
peaks. 
In the second trial, insulin was dissolved in pH 2 citrate buffer instead of pH 4.5 
buffer as used in the first trial. Solutions were prepared carefully to obtain the 
exact pH to avoid any fluctuations which may result in unwanted insulin phase 
changes (Brange and Langkjaer, 1992). Here, insulin dissolved readily in pH 2 
citrate buffer to form a solution. The chromatogram revealed no peaks during a 
run time of 20 minutes. 
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It was unlikely that the insulin had degraded, since it had been freshly prepared 
and kept at 2 °C between runs. Previous studies had indicated that insulin was 
stable at 2 °C over a period of up to 72 hours (Hoyer et al., 1995). The HPLC 
analytical method reported by Sarmento et al. (2006) which was adapted and 
modified for the present study, utilised a column with 250 mm in length. 
However, the column utilised for our study was 150 mm. Subsequently, a 250 
mm ODS Hypersil™ (C18, 5 µm, 4.6 mm x 250 mm) was used but the peaks 
obtained were inconsistent as shown in Figure 2.1. Furthermore the retention 
time of insulin was not consistent between the morning and afternoon runs. The 
peaks obtained during the afternoon analysis (Fig. 2.1B) appeared totally 
different from the peak seen in the morning (Fig. 2.1A). In addition to these 
inconsistencies, the retention time for insulin using this method was about 20 
minutes, which was significantly longer as compared to approximately 6 
minutes as reported in the literature by Sarmento et al. (2006). 
In an attempt to improve this method, insulin was dissolved in 0.01 M 
hydrochloric acid (HCl) (pH 2) instead of pH 2 citrate buffer and the HPLC 
conditions were retained. A peak resulting from this modification was seen at 
approximately 19 minutes with prominent tailing (Fig. 2.2) and therefore not 
satisfactory. 
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Figure 2.1  Sample chromatograms (A-C) obtained from Trial 3. 
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  Figure 2.2   Chromatogram of insulin from Trial 4. 
 
 
Oliva et al. (2000) reported an HPLC method in which both insulin and 
degradation peaks were well-resolved and highly selective at retention times of 
approximately 8 and 9 minutes respectively. Using this method, we obtained a 
single insulin peak with no degradation peaks (Fig. 2.3). For the first sample 
injection of insulin, the peak eluted at approximately 6 minutes, with minimal 
peak tailing. However, in subsequent runs the tailing effect seemed to be more 
pronounced. The first injection produced a retention time of approximately 6 
minutes (Fig. 2.3A), the second injection eluted at approximately 7 minutes (Fig. 
2.3B), and subsequent injections eluted at approximately 9.4 minutes (Fig. 2.3C) 
and 11.4 minutes (Figure. 2.3D). A trend of drifting of approximately 2 minutes 
of the retention time was observed between each injection. 
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Figure 2.3       Chromatograms of insulin from Trial 5. 
  Note the drifting retention times (Rt) by approximately 1 to 2 
  minutes for each subsequent insulin injection from (A) to (D). 
 
(C) 
 (D) 
Rt ≈ 9 min 
Rt ≈ 11 min 
Rt ≈ 6 min 
Rt ≈ 7 min  
Insulin 
Time (min) 
S
ig
n
al
 (
m
V
) 
Time (min) 
S
ig
n
al
 (
m
V
) 
Time (min) 
S
ig
n
al
 (
m
V
) 
Time (min) 
S
ig
n
al
 (
m
V
) 
45 
 
The effect of temperature on elution of analytes is well documented (Dolan, 
2002; Hertzog et al., 2002). Temperature changes are associated with poor 
reproducibility of retention times. It was noted that the room temperature was 
28 °C in the afternoon and 23 °C in the morning, and this difference in 
temperature could be the cause of the drifting of the retention time. This further 
emphasises the sensitivity of the protein insulin to temperature.  
During the preparation of mobile phases 76 % 0.2 M sodium sulphate and 24 % 
ACN in Trial 5 previously, it was observed that a white precipitate was formed 
upon mixing of both solutions. Preparation of mobile phase for HPLC assay has 
been detailed in the monograph for human insulin in the British Pharmacopoeia, 
2007. Here, the method for preparing the mobile phase was adapted from BP, 
2007 in order to address the inconsistency of the retention times and also to 
avoid the formation of the precipitates. Being an endothermic process, 
precipitation will occur during the mixing of mobile phases sodium sulphate with 
acetonitrile, hence it is necessary to keep the solutions at least above 20 °C 
(British Pharmacopoeia Commission, 2007). 
With this modification, intraday injections were more consistent, although the 
retention time was still not optimal. Therefore, the flow rate was increased in 
order to achieve a shorter elution time. The retention time for insulin was 
approximately 13 minutes and 10 minutes at flow rates of 1 ml/min and 1.5 
ml/min respectively.  
The composition of mobile phases 0.2 M sodium sulphate and ACN were varied 
at different ratios of Na2SO4/ACN, namely 76/24, 74/26 and 73/27, in order to 
increase the polarity to achieve shorter retention times. The peaks obtained 
from this modification (Fig. 2.4) appeared inconsistent for composition of 
Na2SO4/ACN mobile phase at 76/24. No elution was observed for mobile phase 
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composition of 73/27 and 74/26. Figure 2.4 demonstrates poor inter- and intra-
days repeatability for mobile phase composition 76/24, highlighting the issue of 
inconsistency of the HPLC method.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2.4     Inconsistent peaks for mobile phase at composition 
   76/24 (Na2SO4/ACN). 
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A review of the literature indicates that not much work has been ascribed to the 
effect of pore size of the column on elution efficiency. Only a handful of reports 
have specified that the HPLC column used for separating proteins and peptides 
had pore sizes in  the order of 300 Å (Hoyer et al., 1995; Oliva et al., 1996; 
Purcell et al., 1995). This pore size specification is much larger than those used 
in the present study. After careful consideration of various HPLC columns, a 
Phenomenex Jupiter C18, 5 µm, 300 Å pore size, 4.6 x 250 mm column was 
chosen for further analysis based on reports on its ability to separate proteins 
and peptides efficiently, in particular, the model drug insulin. The HPLC 
conditions used to separate insulin were adapted and modified from Bradshaw 
(2000) as described in Table 2.1.   
With the new column, the retention time was more consistent at approximately 
10 minutes. Furthermore, it was possible to separate insulin from its 
degradation product (A-21 desamidoinsulin) as shown in Figure 2.5, which was 
useful for stability studies of insulin. 
Subsequently, attempts were made to achieve better peak resolution and 
therefore several parameters including flow rate and mobile phase gradient 
were varied (Fig. 2.6). A flow rate of 1 ml/min was found to be optimal at a 
mobile phase gradient of 2 % per minute (from 75 % to 49 %) for mobile phase 
0.1 % TFA in water over the run time of 13 minutes. These parameters were 
optimal for a good peak resolution. 
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(A) Mobile phase gradient : 2 %/min (0.1 % TFA in water) 
 Flow rate          : 1 ml/min 
 
   
(B) Mobile phase gradient : 3 %/min (0.1 % TFA in water) 
 Flow rate       : 1 ml/min 
 
   
(C) Mobile phase gradient : 4 %/min (0.1 % TFA in water) 
 Flow rate        : 1 ml/min 
 
 
Figure 2.6       Chromatograms from optimisation of HPLC conditions showing
  well-resolved insulin peaks for (A) mobile phase gradient 
  2 %/min.                           
Insulin and degradation 
product peaks are well-
resolved 
Insulin and degradation 
product peaks are not 
well-resolved 
Insulin and degradation 
product peaks are not 
well-resolved 
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2.4.2  Validation of HPLC Method 
Subsequent to the optimised procedure, the method was validated using seven 
insulin standard solutions at different concentrations:- 1.5625 µg/ml, 3.125 
µg/ml, 6.25 µg/ml, 12.5 µg/ml, 25 µg/ml, 50 µg/ml and 100 µg/ml. These 
standard solutions were prepared in 0.1 % trifluoroacetic acid. Analyses were 
done in triplicates using the peak area.  
A good linearity (R2 > 0.99) was achieved in the range of study as shown in the 
calibration curve in Figure 2.7.  
 
  
  
 Figure 2.7  Calibration curve demonstrates the linearity of the  
   HPLC method. 
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     Table 2.2 Precision and accuracy of this HPLC method.  
 
 
 
 
  
 
 Standard insulin 
concentration 
(µg/ml) 
Concentration of insulin measured (µg/ml) 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 
        
 
Intra-day      
1.5625                                      0.60 0.61 0.62 0.61 0.58 0.61 
12.5 10.95 10.83 10.60 10.78 10.62 10.75 
100 103.00 99.94 101.48 98.25 98.36 101.45 
        
        
 
Inter-day 
1.5625 0.60 0.61 0.67 0.65 0.65 0.77 
12.5 10.91 10.92 10.86 10.88 10.52 10.68 
100 98.62 100.01 98.23 100.05 98.06 99.60 
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Three concentrations of insulin, namely 1.5625 µg/ml, 12.5 µg/ml and 100 µg/ml, 
were analysed with six injections for each concentration within the same day 
and over six different days under the same conditions (Table 2.2). The precision 
of the assay, calculated as RSD, was determined from the analyses of the intra-
day and inter-day variation samples. The intra-day RSD was found to be at 2 %, 
1.2 % and 1.9 % for concentrations 1.5625 µg/ml, 12.5 µg/ml and 100 µg/ml 
respectively. For the same insulin standard concentrations, inter-day RSD 
values of 9.4 %, 1.5 % and 0.9 % were registered respectively. These RSD 
values are within the acceptable limits of 15 %, indicating that this analytical 
method is very precise at these concentration (Bressolle et al., 1996). Our RSD 
values were close to those reported by Sarmento et al. (2007) for 
concentrations 12.5 µg/ml and 100 µg/ml, as their inter-day RSD were recorded 
as 2.55 % and 0.25 % respectively. 
As for accuracy of this method, the relative standard errors were calculated as 
14 % and 0.4 % (intra-day) and 13.6 % and 0.9 % (inter-day) for concentrations 
12.5 µg/ml and 100 µg/ml respectively. These results demonstrated that this 
method is very accurate at both these concentrations, as they are within ±15 % 
deviation of the nominal value (Bressolle et al., 1996). However, for the 
concentration of 1.5625 µg/ml, the relative standard errors in both intra-day and 
inter-day measurements were calculated to be rather high at above 50 %, 
demonstrating a low accuracy of this method at this concentration. The LOD 
and LOQ values for this HPLC method were found to be 2.2 µg/ml and 6.7 µg/ml 
respectively. 
All in all we can conclude that the method is precise and accurate for the 
concentrations (12.5 µg/ml and 100 µg/ml) analysed and is comparable to those 
reported in the literature.  
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2.4.3 Stability-indicating studies using HPLC analyses 
Stability-indicating HPLC methods for the assay of insulin and its importance in 
separating and identifying insulin degradation products have been previously 
described in the literature (Hoyer et al., 1995; Moslemi et al., 2003; Oliva et al., 
2000). The optimised and validated HPLC method as described in the present 
study was deemed suitable for a stability indicating study on insulin since it was 
possible to resolve degradation peak as well. In this context, the extent of insulin 
degradation after exposure to different stresses will be correlated with the 
extent of reduction of the insulin peak area in the chromatogram. Figure 2.8 
shows the HPLC chromatogram of freshly prepared insulin. Prior to the stability 
studies, the freshly prepared insulin concentration was 100 µg/ml. It can be 
observed that negligible degradation product (A-21 desamidoinsulin) was 
present when the freshly prepared insulin was injected. 
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Figure 2.10 HPLC chromatograms of insulin at various storage conditions :- 
  (a) -20 ºC, (b) 2 ºC, (c) 25 ºC in dark, (d) 25 ºC in light, on Day 
  11 of study period. 
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The average room temperature was 24.8 ºC and the average refrigerator and 
freezer temperatures were 2.5 ºC and -20.2 ºC respectively. Figure 2.9 shows 
the decrease in amount of insulin over 11 days of storage at the various 
temperatures, whilst Figure 2.10 shows the chromatograms of insulin and the 
degradation products at the respective temperatures. 
It was observed in Figure 2.10(b) that insulin solution stored in the refrigerator 
at 2 ºC remained relatively stable during 11 days of storage, with a negligible 
degradation peak. Insulin was stable at 2 ºC throughout the duration of study of 
11 days (Fig. 2.10b). On the other hand, at -20 ºC, degradation peaks in the 
chromatogram were observed (Fig. 2.10a) which did not appear in others (Fig. 
2.10b, c, d). This observation has not been reported in the literature and indicate 
that freezing and thawing insulin solution may lead to the production of 
degradation products. Therefore, storing insulin solution at sub-zero 
temperatures should be avoided. 
Referring to Figure 2.10(c) and 2.10(d), both HPLC chromatograms displayed 
a significant A-21 desamidoinsulin degradation peak for insulin stored at room 
temperature in the dark and light respectively. It was found that the insulin peak 
decreased at a faster rate when stored at 25 ºC in light (Fig. 2.9d), as compared 
to being stored at 25 ºC in the dark (Fig. 2.9c) with peak signals of 1,999,304 
mV versus 2,140,795 mV respectively at day 11 of the stability studies. This 
data is in good agreement with the findings of Hoyer et al. (1995), demonstrating 
that presence of light does affect the stability of insulin solution.  
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For stability studies carried out at 45 ºC, it was found that after 30 minutes of 
exposure, insulin remained relatively stable with concentration analysed at 
approximately 99 µg/ml from an initial concentration of 100 µg/ml. However, the 
concentration of the peak for A-21 desamidoinsulin increased with time as well 
(Fig. 2.11), indicating that exposure to heat also speeds up the rate of 
degradation of insulin. Interestingly, as shown in Figure 2.11, there was a linear 
(R2 > 0.99) increase in the percentage change in the concentration of A-21 
desamidoinsulin over the duration of 30 minutes of storage at 45 °C. This 
indicates that the formation of A-21 desamidoinsulin increased linearly as a 
function of time, despite the fact that the insulin concentration was not much 
affected by the heat during the study period. 
Another interesting finding was that the rate of chemical degradation was not 
directly related to a decrease of insulin concentration. This points to a possible 
complex degradation kinetics (Jacob et al., 2006; Pearlman, 1993). Thus, the 
decrease in insulin concentration was not solely contributed by deamidation 
reaction and thus insulin concentration remained relatively stable over the study 
period of 30 minutes, although the amount of A-21 desamidoinsulin had 
increased. We may conclude that insulin solution will remain stable during 
subsequent formulation work, when exposed to a temperature of 45 ºC for less 
than 30 minutes. 
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Figure 2.11 Percentage changes of A-21 desamidoinsulin concentration as 
  a function of time for insulin solution stored at 45 °C (n=3). 
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2.4.4 Stability-indicating studies using Dynamic Light Scattering 
 analyses 
 
Dynamic light scattering technique is not routinely used for stability studies. 
However, it was utilised here due to the ability of this method to discriminate 
between particles of protein aggregates or changes in particle sizes, which can 
be used to infer physical instabilities. Insulin was observed to be completely 
soluble in pH 2 buffer (clear solution). However, it was practically insoluble in 
pH 7 buffer, appearing as suspension. It has been reported that insulin exists 
in different oligomeric forms as a result of variation in pH. Monomeric or dimeric 
conformation was reported to be favoured at low pH, whilst at neutral pH, insulin 
exists largely in hexameric form (Darrington and Anderson, 1995; Whittingham 
et al., 2002). These different configurations are related to relative size, with 
monomers being smaller and hexamers larger in size. 
 
The z-average values for insulin in pH 2 buffer, measured using Zetasizer, at 3 
different storage temperatures as a function of time at 2 °C, 25 °C and 45 °C 
are shown in Figure 2.12.  
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An increase in z-average values was observed with increasing storage 
temperatures as well as duration. Protein aggregation is indicated by an 
increase in intensity-weighted mean particle sizes. This clearly indicates that 
protein aggregates were formed over the experimental period and is in concert 
with what has been reported in the literature. High temperature with prolonged 
storage or mechanical shaking of insulin can result in the formation of high 
molecular weight aggregates, observed as larger-sized particles (Oliva et al., 
1996). The insulin sample kept in the refrigerator (2 °C) showed the slowest 
rate of protein aggregation, followed by those stored at room temperature, then 
at 45 °C. It is important to note that protein aggregation (physical instability) 
would occur over storage irrespective of the temperature. The difference in the 
extent and rate of protein aggregation is determined by the storage temperature 
as observed. 
 
Table 2.3 Z-average values for insulin sample in pH 7 buffer stored at 3 
  different temperatures 2 °C, 25 °C, 45 °C taken at fixed sampling 
  days (n=3).   
 
Day 
Z-Average (nm) 
2 °C 25 °C 45 °C 
0 Undetectable Undetectable Undetectable 
1 Undetectable 417 ± 39.8 160 ± 9.5 
4 604 ± 37.9 357 ± 12.4  
14 459 ± 34.1   
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Table 2.3 summarises the z-average values for insulin in pH 7 buffer stored at 
various temperatures (2 °C, 25 °C and 45 °C). Contrary to the results shown 
earlier, the particle sizes of insulin in pH 7 decreased with time and storage 
temperature. At day 0, particle sizes were too large to be detected. Due to its 
poor solubility in pH 7 buffer, insulin remained suspended upon addition to the 
buffer solution. The decrease in particle size over storage period could be due 
to an increase in dissolution of the particles in the buffer with time. There is also 
the possibility of hydrolysis at B3-asparagine residues in the neutral pH 7 buffer 
(Pearlman, 1993). The decrease in size was most rapidly seen at 45 °C, 
followed by 25 °C and 2 °C. 
From the results obtained, it can be concluded that insulin samples stored at all 
temperatures displayed a certain degree of protein degradation, with the most 
occurring at 45 °C, whilst samples stored at refrigeration (2 °C) were relatively 
the more stable. 
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2.5  Concluding remarks  
A simple and reliable HPLC method for detecting insulin was developed and 
validated with respect to linearity, precision, accuracy, limit of detection and limit 
of quantification. The HPLC method parameters are summarised as follows:  
 
 
 
 
The rate of degradation of insulin depends on the storage conditions, with 
exposure to heat and light being observed to be one of the main contributing 
factors that speed up the degradation reaction. HPLC and dynamic light 
scattering technique have been useful in detecting physically or chemically 
degraded products of insulin. 
On the basis of above, pH 2 was considered most suitable to dissolve insulin 
and a storage temperature of 2 °C most optimal for insulin storage. 
 
 
 
 
 
Column                :   Phenomenex Jupiter C18, 5 µm, 4.6 x 250 mm 
Mobile Phase A   :   0.1 % TFA in water 
Mobile Phase B   :   0.1 % TFA in ACN 
Flow rate      :   1.0 ml/min 
Gradient      :   75-49 % mobile phase A in 13 minutes 
Detection λ          :   214 nm 
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CHAPTER 3  
 
Formulation and 
Characterisation                        
of Optimised                   
Insulin-containing                
Solid Lipid Nanoparticles 
(SLNs)  
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3.1 Introduction  
 
3.1.1 SLNs from palm oil lipid constituents 
Solid lipid nanoparticles (SLNs) are colloidal drug delivery systems which have 
received increasing attention of late because they are made from 
physiologically compatible lipids and therefore are a promising alternative to 
polymeric nanoparticles (Garcıa-Fuentes et al., 2003; Hu et al., 2006; Liu et al., 
2007; Müller et al., 2000; Ruckmani et al., 2006; Souto and Müller, 2010; Zhang 
et al., 2006). Commonly used lipids can be highly purified triacylglycerols, 
complex acylglycerol mixtures or waxes (Souto and Müller, 2007). Many studies 
have demonstrated that the safest lipids are glycerides composed of fatty acids 
and lecithin (Fangueiro et al., 2013; Souto et al., 2011). Palm oil lipid 
constituents have been used in the fabrication of SLNs lipid matrix, namely 
tripalmitin (Helgason et al., 2009; Weiss et al., 2008) and palmitic acid (Xie et 
al., 2011b). SLNs are favoured over conventional polymeric particulate systems 
due to better safety, tolerability and release profile attributes as well as their 
ability to protect labile drugs (Müller et al., 2000; Sarmento et al., 2007a).  
In particular, the successful incorporation of hydrophilic drugs in SLNs have 
been reported to improve bioavailability of drugs, prolong residence time as well 
as increase the propensity of uptake of nanoparticles and transport through the 
intestinal mucosa (Garcıa-Fuentes et al., 2003). Studies have previously used 
insulin, salmon calcitonin, lysozyme and bovine serum albumin as model 
hydrophilic peptide drugs  encapsulated  in  SLNs  for  either  oral  or  pulmonary  
delivery  systems (Garcıa-Fuentes et al., 2003; Hu et al., 2006; Liu et al., 2008; 
Sarmento et al., 2007a; Trotta et al., 2005; Xie et al., 2008; Zhang et al., 2006). 
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The present work utilises palm oil lipidic components: triacylglycerol (tripalmitin) 
and single chain fatty acid (palmitic acid) to form the lipid matrix of the SLNs, 
as these offer potential advantages as described above in the incorporation of 
protein insulin which is hydrophilic in nature. Specifically, the solid mixture of 
single chain fatty acid with the triacylglycerol offers the potential of conforming 
to a disordered matrix upon formation, which can help prevent the expulsion of 
insulin from the SLNs during storage, as observed in nanostructured lipid 
carriers (NLCs). 
 
3.1.2 SLNs preparation technique 
There are several methods used to prepare nanoparticles reported in the 
literature including high pressure homogenisation, either hot (Al-Haj and 
Rasedee, 2009) or cold (Mehnert and Mäder, 2001), solvent emulsification 
evaporation method (Garcıa-Fuentes et al., 2003) as well as solvent diffusion 
technique (Trotta et al., 2005). Other methods include gas-assisted melting 
atomisation (GAMA) (Salmaso et al., 2009) and particles from gas saturated 
solutions (PGSS) process using supercritical carbon dioxide (Elvassore et al., 
2001). 
Hot homogenisation technique has inherent disadvantages which include 
exposure to high shear stress and high temperatures as well as formation of 
microparticles. Cold homogenisation on the other hand minimises thermal 
exposure but also produces particles with larger particle size and broader size 
distribution (Trotta et al., 2003). The broad particle size distribution can lead to 
Ostwald ripening, resulting in physical instabilities during storage.  
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Solvent emulsification evaporation technique involves evaporating-off water-
immiscible organic solvent which is included in the formulation to dissolve lipidic 
components, hence leaving precipitates of SLNs in an aqueous environment 
after evaporation. Besides, this method does not involve any heat exposure for 
long durations, hence an efficient way of loading unstable and hydrophilic drugs 
(Liu et al., 2007; Morel et al., 1998). 
In the present study, ultrasonic energy was utilised in the production of the SLNs 
due to the higher efficiency of dissipated energy when this method is employed 
and the ability to produce nanoparticles of narrower particle size distribution. 
Although temperature of the entire formulation could rise during the process of 
ultrasonication, the duration of thermal exposure is relatively short and any heat 
generated is rapidly dissipated. 
 
3.1.3 Particle size and zeta potential 
For a nanoparticulate colloidal dispersion system, particle size distribution and 
zeta potential are crucial parameters which influence the formulation stability 
(Goeddel et al., 1979; M. Hu et al., 2004) as well as the in vivo fate of the 
nanoparticles (He et al., 2010). Dynamic light scattering (DLS) technique, also 
known as the photon correlation spectroscopy (PCS), is commonly employed 
to measure the size of the particles, dispersed in a liquid. DLS measurements 
are calculated based on the random Brownian motion of particles (Kaszuba et 
al., 2008; Pecora, 2000). The size of a particle is termed the hydrodynamic 
diameter as it refers to how a particle diffuses within a fluid. It is calculated from 
the translational diffusion coefficient by using the Stokes-Einstein equation      
(Eq. 3.1):-  
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   𝑑(𝐻) =
𝑘𝑇
3𝜋𝜂𝐷
     
            (Eq. 3.1) 
 
 
where d(H) = hydrodynamic diameter; D = translational diffusion coefficient;               
k = Boltzmann's constant; T = absolute temperature; η = viscosity. 
 
 
 
 
 
 
Figure 3.1  Optical configuration of the Zetasizer Nano-ZS.  
[Adapted and modified from (Malvern Instruments Ltd., 2014a)] 
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Figure 3.1 shows the optical configurations of the Zetasizer Nano-ZS system. 
The laser beam provides a light source that illuminate the sample contained in 
a cuvette. The particles present within the sample scatter the laser beam at all 
angles. A detector, positioned at 173°, will measure the intensity of the 
scattered light. 
Polydispersity index (PdI) values as measured by DLS can indicate the 
heterogeneity of the nanoparticle sample. PdI is represented by the width of the 
size distribution profile. A low PdI value represents a monodisperse sample, 
whilst a polydisperse sample is indicated with a high PdI value. PdI values are 
very sensitive to the presence of aggregates or dust (Kaszuba et al., 2008).  
An interfacial charge is formed instantly when a solid surface is in contact with 
aqueous media. A layer of immobile counter-ions adjacent to the charged 
particle surface at the solid-liquid interface is known as the compact layer, whilst 
the mobile balancing counter-ions in the liquid outside the compact layer is 
called the diffuse layer. Both compact layer and the diffuse layer form the 
electrical double layer. The electrostatic potential at the interface of the compact 
layer and the diffuse layer is known as the zeta potential, which is an important 
parameter especially in nanoparticle characterisation, as it acts as an indicator 
of particle surface charge (Sze et al., 2003). The magnitude of zeta potential is 
able to predict the potential long-term stability of the colloidal system. It is 
generally accepted that zeta potentials for stable suspensions falls within the 
region of +30 mV or  -30 mV. Thus, particles with zeta potentials greater than ± 
30 mV are normally considered as stable colloidal system (Malvern Instruments 
Ltd., 2014b).  
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Zeta potential values are calculated based on Smoluchowski equations (Eq. 3.2) 
to determine the electrophoretic mobility of nanoparticulate samples (Sze et al., 
2003). 
 
𝜐E =    4π𝜀0𝜀r 
𝜁 
6𝜋𝜇
 (1 +  𝜅𝑟)     (Eq. 3.2) 
 
Where υE = mobility; ε0 = relative dielectric constant; εr = electrical permittivity 
of vacuum; ζ = zeta potential; μ = viscosity; κ = Debye–Hückel parameter; r = 
particle radius. 
 
 
3.1.4 Thermal analysis 
Differential scanning calorimetry (DSC) is one of the most commonly used 
methods of thermal analysis in pharmaceutical science. Melting behaviour is 
often studied, where the change in state is accompanied by a change in the 
temperature dependence of the free energy, as the system changes from solid 
to the liquid state at the melt temperature (Craig and Reading, 2006). 
Change in entropy (∆S) at the onset of melt (Tm) is calculated from the change 
in enthalpy (∆H), using the equation below (Eq. 3.3) (Folmer and Franzen, 
2003):- 
   ∆S =  
∆H
Tm
     (Eq. 3.3) 
The magnitude of entropies at melt (∆S) gives an indication of the disruptive 
index within the system, being higher for more orderly structures (York and 
Grant, 1985). 
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3.1.5 Microscopy imaging 
With polarised light microscopy (PLM) technique, we are able to obtain 
information on particle aggregation and colloidal stability indicated by sample 
homogeneity. This technique is also used for checking the presence of 
nanometric lipid structures (Fangueiro et al., 2013; Severino et al., 2012). 
Particle size measurements made using static light scattering techniques such 
as laser diffractometry can sometimes overlook larger-sized particles or 
aggregated particles (Keck and Müller, 2008). Therefore, light microscopy with 
or without polarised light is useful to provide additional characterisation insights 
on possible large particles apart from being able to view the shape of the 
particles (Fangueiro et al., 2013; Obeidat et al., 2010). 
However, to view particles at a submicron level, scanning electron microscope 
(SEM) and transmission electron microscopy (TEM) are used to characterise 
and examine the nanoparticulate samples. SEM uses a focused beam of high-
energy electrons to generate a range of signals at the surface of solid particles. 
The signals acquired from the interaction between the electrons and the particle 
surface can provide information about the sample, such as the external 
microstructure morphology (texture) as well as chemical composition of the 
material.  
TEM, on the other hand, work on the principle of a beam of electrons transmitted 
through an ultrathin specimen. These electrons interact with the specimen as it 
passes through it to form a high-resolution image. TEM is routinely used in the 
area of nanotechnology owing to its capability to allow examination of fine 
details of the particles. 
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3.1.6 Aims and objectives 
This part of study was aimed at formulating SLNs delivery system containing 
insulin using solvent emulsification evaporation technique. Processing and 
formulation parameters of the SLNs were studied in order to achieve desirable 
physical properties, which were then characterised appropriately.  
 
3.2 Materials  
Crystalline recombinant human insulin (lyophilized powder) was manufactured 
by EMD Biosciences (San Diego, USA) and purchased from Merck Malaysia. 
Solid lipids tripalmitin (99 % purity) and palmitic acid (98 % purity) were both 
purchased from Acros Organics (Geel, Belgium). L-α-phosphatidyl choline (soy 
lecithin) and Poloxamer 188 (Lutrol F68) were purchased from Fluka (Australia) 
and BASF (Germany) respectively, both used as surfactants. Analytical-grade 
dichloromethane (DCM) was purchased from R&M Chemicals. Trifluoroacetic 
acid (TFA) and methanol (MeOH) were purchased from Fisher Scientific 
(Loughborough, UK).   
 
3.3 Methods 
 
3.3.1   Preparation of SLNs Formulations  
The SLNs were prepared using the W/O/W double emulsion solvent 
evaporation technique as described by Garcίa-Fuentes et al. (2003) with slight 
modification.  Lipid  nanoparticle  formulations  without  insulin,  referred  to  as 
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insulin-free SLNs, were prepared as follows. Different amounts of solid lipids 
and lecithin was dissolved in 1 ml of dichloromethane (DCM) to form the oily 
phase of the pre-emulsion. For the inner aqueous phase, 100 µL of distilled 
water was added to the oily phase. On the other hand, 100 µL of insulin solution 
(1 mg insulin dissolved in 100 µL of 0.1 % TFA) was added to the oily phase for 
the insulin-containing SLNs. The mixture was dispersed using an ultrasonic 
probe (750 W Vibra Cell VCX Series, Sonics Inc., U.S.), equipped with a 
titanium 13 mm diameter probe, for 15 seconds at 20 W to produce a primary 
W/O emulsion. 2 % Poloxamer 188 solution (outer aqueous phase) was added 
into the primary emulsion and was further ultrasonicated for 1 minute at 20 W, 
forming a W/O/W double emulsion. The double emulsion was diluted to 10 ml 
with 1 % Poloxamer 188 solution. Finally, the solvent was evaporated and 
nanoparticles were isolated and stored until characterisation.  
 
3.3.2 Particle size analysis 
The average diameter (z-average) and polydispersity index (PdI) of SLNs were 
measured using Zetasizer Nano-ZS (Malvern Instruments Ltd., U.K.), which 
was equipped with a 4 mW He-Ne laser (633 nm). The measurements were 
performed at 25 °C at a measurement angle of 173°. Freshly prepared samples 
were diluted with purified water at a dilution factor that was optimised, prior to 
loading into a clear disposable zeta cell (DTS 1060C). Each sample was 
analysed in triplicates at 10 subruns of 10 seconds each. Each z-average value 
reflects the intensity mean diameter, whilst the polydispersity index (PdI) 
indicates the particle size distribution of the SLNs. 
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3.3.3 Determination of Zeta potential  
The same sample as described in Section 3.3.2 was also subjected to zeta 
potential determination using Zetasizer Nano-ZS® (Malvern Instruments Ltd., 
U.K.). Each measurement was carried out at 25 °C in triplicates and the zeta 
potential values were calculated based on Smoluchowski equations (Eq. 3.2) 
using Malvern Zetasizer Software 6.01®, as determined by the electrophoretic 
mobility of the samples.  
 
3.3.4 Differential scanning calorimetry (DSC) analyses 
DSC analyses were performed using a Mettler Toledo Differential Scanning 
Calorimeter 823E. The change in enthalpy (∆H) of the endothermic peak was 
integrated with the built-in STARe software Version 9.01®. The melting 
endotherms were used to assess the entropies at melt for the nanoparticles, 
which were calculated using Equation 3.3. Approximately 5 mg of lipid 
nanoparticle samples were placed on standard aluminium pans, covered and 
then hermetically sealed. The sample was scanned at a heating rate of 
5 °C/minute from 25 °C to 100 °C. Analysis was performed in triplicates under 
a nitrogen purge. An empty sealed pan was used as a reference pan. 
 
3.3.5 Determination of encapsulation efficiency   
The encapsulation of insulin within the SLNs was estimated by dissolving 5 mg 
of freeze-dried insulin-SLNs samples in 1 ml of 0.1 % TFA and 0.5 ml methanol 
(MeOH) in 2 ml microcentrifuge tubes. The sample was vortex-mixed for 1 
minute. The supernatant was separated from the precipitate by centrifugation 
(Microfuge® 16, Beckman-Coulter Inc., U.S.A.) at a speed of 14800 rpm for 15 
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minutes to precipitate the lipids. The supernatant was then decanted and 
filtered through 0.2 µm regenerated cellulose (RC) membrane syringe filters. 
Thereafter, the filtered sample was analysed for insulin content within the SLNs 
using the validated HPLC method as described in Section 2.4.2. Analyses were 
performed in triplicates and the percentage encapsulation efficiency (%EE) of 
the insulin-SLNs was calculated as follows:- 
  
% Encapsulation Efficiency  =    
Amount of insulin in precipitate
Total insulin added
   ×     100% 
                    (Eq. 3.4) 
 
3.3.6 Polarised light microscopy (PLM) analysis 
 
For the test of sample homogeneity, a drop of SLNs was placed on a clean 
glass slide and air-dried prior to viewing under an Olympus CX 31-P Student 
Polarised Light Microscope (PLM) at a magnification of 100x.  
 
3.3.7 Field emission - Scanning electron microscopy (FE-SEM) 
The size and morphology of insulin-containing and insulin-free SLNs were 
ascertained using a FE-SEM (Supra 55VP Gemini, Zeiss, Germany) at an 
accelerating voltage of 3 kV. Each sample was placed on a carbon tape and 
was air-dried for 24 hours. Thereafter, the sample was gold-coated using Biorad 
SC500 sputter coater (U.K.) for 1.5 minutes in argon to impose a conductivity 
of 30 mA on the sample. Each sample was prepared once on the aluminium 
stub. 
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3.3.8 Transmission electron microscopy (TEM) 
The internal structure of the SLNs was viewed using a TEM (912AB Energy 
Filter, LEO). Prior to observation, the samples were negatively stained using 1% 
phosphotungstic acid (PTA). Thereafter, the fixed samples were placed on 
Formvar-film copper grids and allowed to air-dry for an hour. Each sample was 
prepared once on the Formvar-film copper grids. 
 
3.3.9 Statistical analyses 
 
Statistical analyses were performed using GraphPad Prism Software Version 
5.02® to determine statistical significance by means of Student’s t-test. In all 
cases, results with p-values < 0.05 are considered statistically significant. 
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3.4 Results & Discussion 
3.4.1 Selection of lipid core compositions  
The selection of suitable lipid core composites during the initial stages of 
formulation development is particularly important to identify the most 
appropriate combination for the most desirable properties of the nanoparticulate 
formulations.  
In this part of the study, nanoparticles were prepared using different 
compositions of the solid portions of palm oil lipids, namely tripalmitin 
(triglyceride) and palmitic acid (single-chain fatty acid) as shown in Table 3.1.  
 
Table 3.1    Lipid nanoparticle formulations Fa1 – Fa5 containing varying 
 amounts of tripalmitin and palmitic acid. 
 
 
 
 
Formulation Lipids (mg) Lecithin 
(%w/w of 
total lipid) 
Poloxamer 
188 (2 %w/w) 
(ml) 
Poloxamer 
188 (1 %w/w) 
(ml) Tripalmitin Palmitic 
acid 
 
Fa1 
 
100 
 
0 
 
50 
 
3.5 
 
to 10 
Fa2 75 25 50 3.5 to 10 
Fa3 50 50 50 3.5 to 10 
Fa4 25 75 50 3.5 to 10 
Fa5 0 100 50 3.5 to 10 
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The unique feature in the chemical structures of tripalmitin and palmitic acid is 
that the fatty acid chains in both the lipids are identical, ie. contain a C16 
saturated fatty acid chain (Section 1.8.1). 
The influence of lipid composition on physical properties of the SLNs 
formulations was investigated by employing either tripalmitin (formulation Fa1) 
or palmitic acid (formulation Fa5) as the sole lipid, or a combination of both at 
different ratios (formulations Fa2, Fa3 and Fa4).  
It has been reported that SLNs based on a single lipid entity may exhibit a 
limitation to drug loading capacity as a result of possible crystallisation of the 
lipid into the more stable β-configuration and subsequently, drug expulsion from 
the SLNs (Westesen et al., 1997). This is annotated in Figure 3.2(a). This 
limitation has led to the evolution of the so-called nanostructured lipid carriers 
(NLCs) in an attempt to address this constraint. NLCs, in contrast to SLNs, are 
produced by controlled association of liquid lipid within the solid lipid domain 
(Fig. 3.2b). As a result, the solid lipid crystalline network is disrupted, hence 
minimising drug expulsion and favouring higher drug loading (Müller et al., 
2002a, 2002b). A prerequisite for good drug loading is the presence of larger 
distances between the fatty acid chains of the triglyceride. This can be achieved 
by using glycerides which are structurally different (Müller et al., 2002a, 2002b) 
or by incorporating liquid lipids into the solid lipid composites so that as the 
nanoparticles are formed at solidification, crystallisation is impeded. 
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 Figure 3.2 Crystallisation process during storage over time in                 
   (a) SLNs and (b) NLCs.  
   [Adapted and modified from (Müller et al., 2002b)] 
 
The ratio of solid lipid compositions were varied, in this instance a triglyceride 
and a single chain fatty acid, to investigate whether composites of structurally 
different solid lipids but having identical fatty acid chains (C16), could be utilised 
in creating mutual disorder in the solidified matrix. Here, the single chain 
palmitic acid will act as a substitute to the liquid lipid, which is the case in NLCs.  
We theorised that the association between both these lipids would be weak and, 
if any, could arise only between the polar moieties of both lipids. Triglycerides, 
are polar, and therefore can participate in hydrogen bonding with the carboxylic 
drug  
time 
Liquid lipids  
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group of the fatty acids. Such interactions would leave more room between the 
fatty acid chains (C16), which could potentially manifest more disorder and 
hence favour drug loading. 
A possible model of association between the lipids which generates spatial 
freedom between the chains is shown in Figure 3.3. 
 
 
 
 
Figure 3.3  A possible model of association between tripalmitin and  
  palmitic acid chain.  
  (blue dotted line represent possible weak dynamic interactions) 
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3.4.1.1   Particle size and zeta potential 
The intensities of size distribution of these SLNs formulations (Fa1 – Fa5) are 
shown in Figure 3.4. It is important to note that the scale on the abscissa-axis 
is not linear, hence as the particle size increases, the sample polydispersity 
seemed less apparent in the size distribution profile. As shown in Figure 3.4, 
the use of tripalmitin as the sole lipid (Fa1) produced a smaller-sized particle 
population with lower PdI values. Conversely, when the sole lipid was palmitic 
acid (Fa5), the z-average was significantly higher than Fa1 and also a slightly 
higher PdI value was obtained. A similar trend was also observed when the two 
lipids were used in combination, in which increasing palmitic acid content from 
Fa2 through to Fa4 led to a shift in z-average values to the right indicating an 
increase in mean particle diameters and relatively polydispersed samples as 
opposed to formulation Fa1 containing solely tripalmitin. 
Table 3.2 shows the recorded z-average, PdI values and zeta potentials for 
formulations Fa1 to Fa5 (insulin-free SLNs). The data is presented graphically 
in Figure 3.5 which indicates that as the ratio of palmitic acid to tripalmitin was 
increased (Fa2 – Fa4), the z-average particle size also increased significantly 
(p<0.05). It is also observed that inclusion of palmitic acid in these formulations 
(Fa2 – Fa4) produced more polydispersed samples, as seen from the larger PdI 
values, in contrast to that from formulation Fa1(p<0.05). For the same 
formulations (Fa2 – Fa4), however, there was a reduction in PdI for formulation 
Fa4, though it was still more polydispersed than formulation Fa1 containing 
solely tripalmitin. Zeta potentials recorded for all formulations investigated (Fa1 
– Fa5) followed a trend similar to that of z-average (Table 3.2), where the 
inclusion of palmitic acid in these formulations (Fa2 – Fa5) led to an increase in 
the magnitude of zeta potentials.  
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 Fa1           Fa2 
    
 Fa3           Fa4 
 
              Fa5 
 
Figure 3.4 Size distribution profiles (n=3) of SLNs formulations Fa1 – Fa5. 
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Table 3.2 Z-average(nm), polydispersity index and zeta potential (mV) 
  for formulations Fa1 – Fa5 (insulin-free SLNs) (n=3).  
 
 
 
 
Figure 3.5  Z-average (bars) and PdI values (line) for SLNs formulations 
  (Fa1 – Fa5) (n=3). 
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Formulations
Formulation Z-average (nm) 
[mean ± SD] 
PdI                
[mean ± SD] 
Zeta potential (mV) 
[mean ± SD] 
 
Fa1 
 
293.3 ± 5.2 
 
0.30 ± 0.03 
 
-39.9 ± 1.3 
Fa2 610.4 ± 7.1 0.62 ± 0.06 -39.6 ± 1.7 
Fa3 847.0 ± 7.5 0.66 ± 0.07 -40.0 ± 1.2 
Fa4 1028.7 ± 7.8 0.46 ± 0.05 -44.0 ± 1.3 
Fa5 699.0 ± 6.5 0.33 ± 0.03 -50.6 ± 1.6 
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Studies have previously indicated that the physicochemical properties of SLNs 
are largely affected by the lipid nature and composition (Mehnert and Mäder, 
2001). The fatty acids (tetradecanoic acid (C14), palmitic acid (C16) and stearic 
acid (C18)), with different lengths of carbon chains, influenced the 
physicochemical properties of SLNs, where stearic acid-SLNs registered a 
larger particle size, PdI value and higher zeta potential as compared to the other 
two fatty acids (Xie et al., 2011a).  
We have shown that using structurally different lipids, namely tripalmitin 
(triglyceride) and palmitic acid (fatty acid), influenced the particle size diameters 
and PdI values of the SLNs (Fig. 3.5). Formulation Fa1, which contained 100 
mg tripalmitin, registered a z-average and PdI value of 293.3 ± 5.2 nm and 0.30 
± 0.03 respectively (Table 3.2), both being the lowest amongst the formulations 
studied. As mentioned above, increasing the ratio of palmitic acid led to a 
significantly higher z-average (p<0.05). This trend was not surprising as it was 
observed in Fa5 that when palmitic acid was used as the sole lipid core, the 
particles registered a significantly higher z-average (699.0 ± 6.5 nm) when 
compared to tripalmitin as the sole lipid core (Fa1) (p<0.05) (Table 3.2). The 
PdI values between Fa1 (0.30 ± 0.03) and Fa5 (0.33 ± 0.03) were found to be 
not statistically significant (p>0.05), where the low PdI values indicate good 
sample homogeneity for both these formulations. For the structurally different 
tristearin-SLNs and stearic acid-SLNs, different z-average values were also 
reported for both these SLNs, with the former being slightly larger (Paliwal et 
al., 2009).  
The inclusion of palmitic acid in the formulations (Fa2 – Fa5) produced larger-
sized particles and more polydispersed samples. This interesting observation 
has not been reported elsewhere in the literature, though the use of palmitic 
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acid as the lipid matrix in itraconazole-loaded SLNs resulted in the production 
of nanoparticles with a wide particle size distribution, demonstrated by a high 
PdI value of more than 0.6 (Mukherjee et al., 2009a).  There seems to be a 
synergistic effect when these two structurally different lipids (tripalmitin and 
palmitic acid) are present as it was observed that the z-average values 
increased significantly beyond the values obtained when palmitic acid was the 
sole lipid, from Fa2 through Fa4 (p<0.05) (Fig. 3.5). Therefore, this increase 
can be attributed mostly to the presence of palmitic acid. A possible explanation 
is that palmitic acid chain is able to form weak dynamic interactions via 
hydrogen bonding with tripalmitin as postulated in Figure 3.3. Thus, this 
generates more spatial freedom in the lipid matrix and consequently higher z-
average will be obtained for these formulations (Fa2 – Fa4). As such, the 
increase seen was closely related to the amount of palmitic acid incorporated 
into the formulations (Table 3.2). The PdI values for these formulations (Fa2 – 
Fa4) were all significantly higher than the formulations containing sole lipids 
(Fa1 and Fa5) (p<0.05), although no significant differences were noted between 
the values for Fa2 and Fa3. This indicates that the co-presence of two 
structurally different lipids resulted in the production of nanoparticles with a 
wider particle size distribution, due to a possible explanation similar to that of 
the z-average as discussed. 
The zeta potentials for all formulations investigated indicate that they are within 
the acceptable range for electrostatic stability (Table 3.2). It is currently 
accepted that zeta potentials above |30 mV| are needed for full electrostatic 
stabilisation, thus particle aggregation is rather unlikely to occur due to electric 
repulsion caused by the surface charges (Heurtault et al., 2003).  
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Based on Table 3.2, there were no significant differences observed between 
the zeta potential values for formulations Fa1, Fa2 and Fa3 (p>0.05), which 
indicates that varying the tripalmitin content from 50 % to 100 % of the 
formulation had not significantly impacted the zeta potentials of these 
formulations. However, the zeta potential of formulation Fa5 containing solely 
palmitic acid was -50.6 ± 1.6 mV, being significantly higher than the value                
(-39.9 ± 1.3 mV) recorded for formulation Fa1 (p<0.05). The negative value of 
zeta potential is due to the presence of a carboxyl group –COOH at one end of 
the single chain palmitic acid, which is capable of forming a negatively charged 
carboxylate ion (COO-) when deprotonated. These values are also in concert 
with those reported for stearic acid-SLNs and tristearin-SLNs, where stearic 
acid-SLNs recorded a more negative value of zeta potential attributable to the 
highly negative charge distributed at the surface of the fatty acid SLNs (Paliwal 
et al., 2009).  
Similarly to the increase in z-average due to palmitic acid content, there was an 
increase in zeta potential values for formulations Fa2 through to Fa4 (Table 3.2). 
Though an increasing trend, the zeta potential values for Fa2 (-39.6 ± 1.7 mV), 
Fa3 (-40.0 ± 1.2 mV) and Fa4 (-44.0 ± 1.3 mV) were all significantly lower than 
that of formulation Fa5 (-50.6 ± 1.6 mV), which consists of solely palmitic acid 
(p<0.05). This indicates that the zeta potential of the nanoparticles can be 
significantly affected when palmitic acid was used in combination with tripalmitin. 
It is also interesting to note that the presence of tripalmitin, however, tended to 
counterbalance the negative charge effects due to palmitic acid (Fa2 – Fa4). 
This is likely to be due to the interaction between the two types of lipids at the 
carboxylic acid moieties which are capable of participating in hydrogen bonding 
(Fig. 3.3).   
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Table 3.3 Z-average(nm), polydispersity index and zeta potential (mV) 
  for formulations Fa1-ins to Fa5-ins (insulin-loaded SLNs) (n=3).  
 
 
 
Insulin-loaded SLNs formulations were prepared as described previously, 
labelled as Fa1-ins to Fa5-ins. Table 3.3 shows the z-average, PdI and zeta 
potential values recorded for these insulin-loaded nanoparticles. Interestingly, 
with insulin incorporated into the nanoparticles, it was observed that the particle 
size recorded for all the 5 formulations were generally smaller than their 
corresponding insulin-free SLNs counterparts. The difference in z-average 
between the insulin-free SLNs and insulin-SLNs counterparts were statistically 
significant for all formulations (p<0.05). This suggests that incorporation of 
insulin into the formulations led to the production of nanoparticles which were 
more compact in size as opposed to without insulin. A similar trend was also 
observed here for insulin-loaded SLNs, where an increase in z-average values 
was noted when the palmitic acid content was high. This corresponds to the 
findings obtained from the insulin-free SLNs, which further ascertain that the 
particle size increase was solely attributed to the presence of palmitic acid.  
Formulation Z-average (nm) 
[mean ± SD] 
PdI                
[mean ± SD] 
Zeta potential (mV) 
[mean ± SD] 
 
Fa1-ins 
 
185.0 ± 6.8 
 
0.21 ± 0.04 
 
-36.9 ± 1.3 
Fa2-ins 345.4 ± 7.2 0.59 ± 0.03 -40.4 ± 1.4 
Fa3-ins 440.4 ± 9.8 0.54 ± 0.05 -43.7 ± 1.5 
Fa4-ins 559.1 ± 8.5 0.50 ± 0.08 -47.5 ± 1.5  
Fa5-ins 658.8 ± 8.7 0.41 ± 0.05 -45.8 ± 1.7 
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SLNs can form an architectural arrangement where a polar core with the polar 
heads of the triglycerides are oriented towards the aqueous phase, much like 
chylomicrons. This chylomicron-like behaviour can be potentially achieved for 
SLNs with particle sizes that are similar (Paliwal et al., 2009). Therefore, insulin 
incorporated into such SLNs can potentially associate with the polar region of 
the lipid nanoparticles. The size decrease observed for all insulin-SLNs versus 
the insulin-free counterparts can be attributed to the insulin being held closely 
to the polar regions of the nanoparticles, where positively charged insulin 
interacts with the negatively charged SLNs resulting in a more compact, and 
hence smaller particle sizes. Insulin has an isoelectric point of 5.3 (Park, 1999). 
Having been dissolved in an acidic environment (~ pH 2), insulin therefore 
carries a net positive charge.   
In terms of particle size distribution, the PdI values did not exhibit any statistical 
significance between the respective counterparts of insulin-free SLNs and 
insulin-loaded SLNs for all formulations studied (p>0.05). This suggests that 
incorporation of insulin into the SLNs did not affect the sample homogeneity of 
the formulations. Instead, the differences seen in PdI values between each 
formulation were predominantly influenced by the lipids used to prepare the 
SLNs. 
The insulin-loaded formulations (Fa1-ins and Fa5-ins), which consists of sole 
lipid in the formulation, registered significantly lower zeta potentials compared 
to corresponding insulin-free SLNs formulations (p<0.05) (Table 3.3). 
Incorporation of insulin into the formulation resulted in the decrease in zeta 
potential possibly due to the modification of the surface charge by the positively 
charged insulin. However, the zeta potential values for formulations with 
combination of lipids (Fa2-ins, Fa3-ins and Fa4-ins) were generally higher than 
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their insulin-free SLNs counterparts. The increase in the zeta potential values 
were significantly higher for Fa3-ins vs Fa3 and Fa4-ins vs Fa4 (p<0.05), 
although there was no significant difference in the values recorded for 
formulation Fa2-ins vs Fa2 (p>0.05). This increase is possibly attributable to the 
spatial freedom generated between the hydrophobic chains, as proposed in 
Figure 3.3, where insulin is able to fit into the spaces between, and as a result 
the surface charges of these formulations (Fa2-ins, Fa3-ins and Fa4-ins) were 
not counterbalanced by the incorporation of insulin into the formulation. 
 
 
 
 
Figure 3.6 Various states and configurations of nanoparticles in dry state 
  and when dispersed in liquids.    
  [Adapted and modified from (Jiang et al., 2008)] 
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In terms of physical stability, all these prepared SLNs formulations may be 
deemed to be stable and free from particle aggregation based on the zeta 
potential measurements. However, the zeta potential of nanoparticle 
dispersions depends on other factors such as the ionic strength and the solution 
pH both of which can influence the stability and agglomeration behaviour of the 
nanoparticles (Jiang et al., 2008). The surface characteristics can affect the 
particles ability to agglomerate or aggregate as illustrated in Figure 3.6 (Jiang 
et al., 2008), which can in turn influence the uptake and translocation of 
nanoparticles by the cells (Hoshino et al., 2004). It has also been shown that by 
using unstable and agglomerated nanoparticle dispersions in an in vitro and in 
vivo experiment could lead to significant implications in the assessment of 
nanoparticle toxicity (Warheit et al., 2004). Therefore, it is crucial to address the 
issue of particle agglomeration or aggregation during the SLNs formulation 
stage.  
Visual observation of the SLNs formulations is vital in investigating the physical 
stability of formulations by means of agglomerates or aggregates formation 
during storage. The images of formulations (Fa1 – Fa5) are illustrated in Figure 
3.7. Seven days after production, Fa1 (Fig. 3.7(a)) appeared homogenous and 
did not exhibit any aggregated particles and the consistency remained the same 
for 45 days. 
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      Figure 3.7  Visual observation of formulations Fa1 – Fa5 (insulin-
   free SLNs) on day 7 of production. 
   [ (a) = Fa1; (b) = Fa2; (c) = Fa3; (d) = Fa4; (e) = Fa5 ]        
 
Conversely, for Fa5, large aggregates were formed at the time of production 
which correlated with the high PdI and z-average values (Table 3.2). 
Furthermore, within 7 days of storage, white precipitates were seen on the walls 
of the vial which could not be redispersed upon vigorous shaking or sonication 
in water bath (Fig. 3.7(b)). This demonstrates physical instability despite zeta 
potential value of -50.6 ± 1.6 mV, which indicated good electrostatic stability. In 
addition, formulations Fa2, Fa3 and Fa4 which comprised of increasing 
amounts of palmitic acid respectively, also showed signs of physical instability 
during storage at ambient temperature for 7 days, where sediments and large 
aggregated particles were formed (Fig. 3.7 (b), (c) and (d) respectively). These 
aggregates also did not redisperse on shaking or bath sonication. 
Therefore, contributing factors other than electrostatic stability clearly have a 
role in the tendency of the SLNs to agglomerate or aggregate. The stability of 
White precipitates on the wall 
      (a)          (b)            (c)   (d)      (e) 
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nanosuspensions strongly depend on the thermodynamics of the dispersed 
system which can be termed as metastable and therefore has the tendency to 
coalesce eventually in order to reduce the excess surface free energy (Kipp, 
2004). Instability of nanosuspensions may be due to a shift in particle size 
distribution from smaller to larger sizes (Ostwald ripening), irreversible 
agglomeration or aggregation (Kipp, 2004). In the event where interparticle 
repulsive forces due to electrostatic barriers cannot overcome the inertia of 
particle collision, formation of heavy aggregates will result in rapid 
sedimentation (Kipp, 2004). 
Figure 3.8 shows the images of the insulin-loaded SLNs formulations (Fa1-ins 
to Fa5-ins) after 7 days of storage. In this study, Fa1-ins seemed to be the 
formulation which exhibited considerable physical stability.  
 
  
 
      
     Figure 3.8  Visual observation of formulations Fa1-ins – Fa5-ins 
   (insulin-loaded SLNs) on day 7 of production. 
   [ (a) = Fa1-ins; (b) = Fa2-ins; (c) = Fa3-ins; (d) = Fa4-
   ins; (e) = Fa5-ins ] 
 
        (a)          (b)           (c)   (d)     (e) 
 
White precipitates on the wall 
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Figure 3.9  Polarised light microscopy analysis of SLNs formulation Fa1 
  (left) and Fa1-ins (right) viewed at 100x magnification. 
 
 
Formulation Fa1 (insulin-free SLNs) and Fa1-ins (insulin-loaded SLNs) when 
viewed under polarised light microscopy, demonstrated a relatively 
homogenous matrix, with no phase separation observed (Fig. 3.9). No obvious 
particle aggregation was detected in both insulin-free and insulin-loaded SLNs 
formulations containing solely tripalmitin (Fig. 3.9). 
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3.4.1.2  Influence of sample dilution factor 
The nanoparticle dispersions prepared according to the method described 
above appeared milky-white and were concentrated. In order to perform particle 
size analysis on the Zetasizer Nano-ZS® (Malvern Instruments Ltd., UK), the 
sample had to be diluted to allow the laser beam to penetrate the dispersion. 
Therefore, an optimal sample dilution factor was sought, in order to standardise 
the dilution for all samples prior to measuring the z-average, polydispersity 
index and zeta potential of subsequent formulations. Formulation Fa1 
containing 50 mg (0.5 %w/w) lecithin, used as the model formulation, was 
diluted with deionised water by various dilution factors, ie. 0.1, 0.04, 0.02, 
0.0125 and 0.01.  
Figure 3.10 shows the z-average and PdI of formulation Fa1 at the respective 
dilution factors. It can be seen that the diluted and undiluted samples gave 
contrasting z-average and the polydispersity index of the formulation. Undiluted 
formulations registered a higher z-average value since the nanoparticles in the 
lipid dispersion were very much crowded and have the tendency to agglomerate. 
Similarly, the PdI indicated that the sample had low homogeneity due to the 
close proximity of the individual nanoparticles. 
 
 
  
96 
 
 
 
 
Figure 3.10 Z-average (bars) and polydispersity index (line) of formulation 
  Fa1 at various dilution factors 0.01 - 1 of the lipid dispersion. 
 
 
Conversely, samples being diluted registered significantly lower z-average and 
PdI values (Fig. 3.10). Furthermore, the results of the z-average and PdI were 
more consistent for diluted samples in contrast to the more concentrated ones 
as seen in Figure 3.10. Diluted samples appeared as pale white and translucent 
in contrast to undiluted samples that appeared milky-white (Fig. 3.11).  
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 Figure 3.11 Appearance of an (a) undiluted and (b) diluted of  
   formulation Fa1. 
 
No significant differences in the z-average particle size was observed between 
dilution factors of 0.1 to 0.0125 (p>0.05). Therefore, a dilution of 1 in 10 (factor 
of 0.1) was considered optimal and was used for subsequent sample dilutions 
in the PCS analysis. However, at excessively high dilution factor (0.01), a slight 
rise in z-average and PdI was observed, possibly due to the concentration of 
the stabiliser added to the formulation being excessively diluted. A stabiliser is 
added to the formulation in order to stabilise the emulsion formed during 
nanoparticle production. Since it adsorbs at the boundary layer between the 
water phase and the organic phase during particle formation (Cassidy et al., 
1999), a change in the stabiliser concentration may cause an increase in the 
particle size (Vandervoort and Ludwig, 2002). In this instance, at high dilution 
factor, the solubilisation phenomenon of poloxamers included in the formulation 
was disrupted which promoted the separation of the stabiliser into the 
continuous phase and leading to a less stable nanosuspension with larger 
particle size and PdI (Binks, 2002). 
        (a)                                    (b) 
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3.4.1.3  Influence of lipid compositions on thermal behaviour  
Differential scanning calorimetry is a useful analytical tool used to evaluate the 
physical state of materials. It has been used to study the physicochemical 
properties and thermodynamic stability of SLNs dispersions (Souto and Müller, 
2006). In the present study, we aimed to investigate whether composites of 
structurally different solid lipids, ie. tripalmitin and palmitic acid, could be utilised 
to create mutual disorder within the solidified matrix by way of evaluating the 
changes in entropy of fusion of the system. Entropy of fusion (∆S fusion) was 
calculated according to the Second Law of Thermodynamics as described in 
Equation 3.3 (Folmer and Franzen, 2003). The magnitude of ∆Sfusion gives an 
indication of the disruptive index, being higher for more orderly structures (York 
and Grant, 1985). Conversely, a lower disruptive index represents a more 
disordered structure.  
Figure 3.12 displays the typical DSC thermograms, indicating the melting 
endothermic peaks, as measured for these formulations. Individual DSC 
thermograms for bulk tripalmitin and insulin-free tripalmitin SLNs (formulation 
Fa1) are shown in Figure 3.13. Melting events were observed in all formulations, 
confirming the crystalline attributes of these formulations. A single distinctive 
endothermic peak for bulk tripalmitin recorded at 63.6 °C seen in Figure 3.13(a) 
indicates the tripalmitin melting peaks observed in both insulin-free formulation 
Fa1 (Fig. 3.13(b)) and insulin-containing formulation Fa1-ins (Fig. 3.12). The 
melting temperatures palmitic acid were recorded as 58.5 °C (Fig. 3.12). These 
values are in good agreement with previous studies on: tripalmitin (65.53 °C) 
(Garcia-Fuentes et al., 2005a) and palmitic acid (64.5 °C) (Cedeno et al., 2001).  
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(a) bulk tripalmitin 
 
 
 
(b) formulation Fa1 
 
 
Figure 3.13 DSC thermograms for (a) bulk tripalmitin and (b) formulation 
  Fa1 
 
 
^exo 
^exo 
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Accordingly, there was another melting endotherm observed in all insulin-
containing formulations at approximately 50-52 °C (Fig. 3.12), which was also 
present in insulin-free formulation Fa1 (Fig. 3.13(b)). This peak can be 
attributed to the melting temperature of the excipient Poloxamer 188 which 
corresponds with that previously reported in the literature at 50.9 °C (Passerini 
et al., 2002).  
Interestingly, with reduced tripalmitin content, the intensity of the melting peak 
described above decreased in Fa2-ins and was almost completely absent in 
Fa4-ins (Fig. 3.12). There was also a reduction in melting temperatures for lipid 
formulations Fa2-ins to Fa4-ins, with decreased tripalmitin content. Tripalmitin 
has a slightly higher melting point compared to the single-chained palmitic acid 
and therefore, the reduction in melting temperatures and peak intensity 
observed in Fa2-ins to Fa4-ins is due to the decline in tripalmitin content. This 
could be attributed to the composite of lipids used which led to the formation of 
imperfect crystals. Mixtures of mono-, di- and triglycerides and also fatty acids 
of different chain length have been reported to form less perfect crystal structure 
with many imperfections when used in combination (Müller et al., 2000). 
Furthermore, the lipid mixtures are potentially associated via weak dynamic 
interactions between tripalmitin and palmitic acid chains, as suggested in Figure 
3.3. As a result of the spatial freedom having been formed into a less densely 
packed structure, reduced melting point is manifested (Israelachvili, 2011). In 
addition, these intermolecular forces of attraction are relatively weak and do not 
pose structural constraints during heating and therefore will naturally contribute 
to a decrease in the melting point of these formulations.  
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Figure 3.14     Melting enthalpy (endothermic) and melting temperature for
      SLNs formulations. 
 
 
Figure 3.14 shows the enthalpy of fusion (endothermic) and temperature at melt 
for the insulin containing SLNs formulations. Formulation Fa1-ins (sole 
tripalmitin) recorded the highest melting enthalpy (62.0 ± 2.2 J/g) and melting 
temperature (64.0 ± 2.9 °C) amongst the formulations studied. In contrary, the 
melting enthalpy for Fa5-ins containing palmitic acid was the lowest recorded 
(13.8 ± 0.9 J/g), and likewise for the melting temperature (54.3 ± 2.5 °C). When 
both lipids are present at different ratio within the formulations, a significant 
decrease in melting enthalpy (p<0.05) was observed with increasing palmitic 
acid content (Fa2-ins to Fa4-ins). The melting temperatures for the same series 
of formulations (Fa2-ins to Fa4-ins) showed no significant differences (p>0.05), 
despite a shift of Tm towards lower temperatures when palmitic acid content is 
increased. The decreasing trend seen in the melting temperatures was clearly 
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noted in formulation Fa5-ins, containing solely palmitic acid in the absence of 
tripalmitin within the formulation. This clearly indicates that the inclusion of 
another structurally different solid lipid into the formulation can influence the 
melting enthalpy and temperature of the lipid nanoparticles, as a result of 
changes in the structural packing, as explained earlier. 
 
 Table 3.4 Change in entropy of the respective insulin-SLNs  
   formulations (n=3). 
 
 
 
 
 
 
 
 
 
 
 
Based on the above findings shown in Table 3.4, as palmitic acid content is 
increased, the ∆Sfusion decreases, in the direction of a less ordered structure. 
The inclusion of palmitic acid into the tripalmitin lipid nanoparticles (Fa1-ins) 
significantly reduced the entropies of formulations Fa2-ins to Fa4-ins (p<0.05), 
which suggests that palmitic acid interrupts the structural orderliness within the 
particles of Fa1-ins. Conversely, ∆Sfusion increases with the increase in 
tripalmitin which indicates a less disrupted or a more crystalline structure. This 
further shows that the type of lipids used, whether alone or in combination, has 
Formulation ∆Sfusion (-Jg
-1°C-1) 
[mean ± SD]  
 
Fa1-ins 
 
0.97 ± 0.04 
Fa2-ins 0.72 ± 0.05 
Fa3-ins 
Fa4-ins 
0.31 ± 0.04 
0.24 ± 0.02 
Fa5-ins 0.25 ± 0.03 
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a direct influence on the disorderliness of the packing structures of the 
nanoparticles. 
Comparing the entropies between the insulin-free SLNs and insulin-SLNs, the 
∆Sfusion for Fa1 (insulin-free SLNs) and Fa1-ins (insulin-SLNs) were found to be 
-0.77 ± 0.02 Jg-1°C-1 and -0.97 ± 0.04 Jg-1°C-1 respectively. This indicates that 
the incorporation of insulin into tripalmitin lipid nanoparticles does make the 
SLNs more crystalline.  Fa1 (insulin-free SLNs) which is composed of tripalmitin 
as sole lipid matrix instead exhibited a less orderly and more amorphous nature, 
in comparison to Fa1-ins (insulin-SLNs). However, this was not the case for 
palmitic acid nanoparticles, where ∆Sfusion for both Fa5 and Fa5-ins were found 
to be similar, 0.25 ± 0.02 Jg-1°C-1 and 0.25 ± 0.03 Jg-1°C-1 respectively. Hence, 
we observed that type of lipids used can also influence the effect insulin has on 
the entropy changes of the nanoparticles. Fangueiro et al. (2013) reported that 
there was a difference in the melting endotherm for Softisan®100 insulin-free 
SLNs and insulin-SLNs, with the insulin-free SLNs showing a higher melting 
endotherm at 14.3 J/g, thus demonstrating that the incorporation of insulin can 
indeed influence the thermal behaviour of SLNs. In the present study, we 
recorded a higher melting endotherm for Fa1 (insulin-free SLNs) at 48.47 J/g, 
as opposed to Softisan®100 insulin-free SLNs reported by Fangueiro et al. 
(2013), where both these formulations were composed of different types of 
lipids.  
Another interesting observation noted was that for all formulations, the 
decrease in z-average due to increase in tripalmitin content as shown in Table 
3.3 were found to be in contrast to the values of ∆S fusion (Table 3.4). SLNs 
formulation with smaller particle size was found to display a larger ∆Sfusion, which 
indicates a more orderly and closely packed structure within the particles. 
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Formulation containing solely tripalmitin (Fa1-ins) had the largest ∆Sfusion (Table 
3.4). This can be explained by the tendency of SLNs composed of a monoacid 
triglyceride to form highly crystalline structure with a perfect lattice due to its 
chemical nature (Müller et al., 2000). Therefore, the decrease in ∆Sfusion of 
formulations Fa2-ins to Fa4-ins with the incorporation of palmitic acid into the 
lipid mixture, further supports the proposed association model (Figure 3.3), 
where the generation of spatial freedom between the chains of the lipid disrupts 
the orderliness of the structural arrangement of the lattice. 
 
3.4.1.4  Influence of lipid compositions on encapsulation efficiency  
 
The encapsulation efficiency (%) of insulin within the SLNs formulations are 
listed in Table 3.5. 
 
Table 3.5   Encapsulation efficiency (%) of respective formulations (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation Encapsulation Efficiency (%) 
[mean ± SD] 
Fa1-ins 38.1 ± 1.2 
Fa2-ins 40.6 ± 0.8 
Fa3-ins 
 
41.3 ± 1.5 
 Fa4-ins 34.7 ± 1.3 
Fa5-ins 44.7 ± 0.9 
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The drug encapsulation efficiency does not appear to correlate with the state of 
disorder of the lipid nanoparticles, based on the data from the ∆Sfusion described 
in section 3.4.1.3. It was previously reported that mixture of chemically diverse 
lipids showed better drug incorporation capacities owing to the formation of 
imperfect crystals lattices that offer more space to accommodate the drugs 
(Müller et al., 2000). We found that encapsulation efficiency of insulin was not 
necessarily dependent on the state of disorderliness of the crystal lattice within 
the SLNs. Drug encapsulation efficiency in nanoparticles is also influenced by 
the lipophilicity of the incorporated drugs (Barichello et al., 1999), production 
technique (Almeida and Souto, 2007) as well as the temperature condition of 
the dispersed aqueous phase (F.Q. Hu et al., 2004).  
Generally, as shown in Table 3.5, the encapsulation efficiencies derived from 
the formulations studied were not particularly high, but these are acceptable 
values in view of the drug being a hydrophilic protein being incorporated into a 
lipophilic matrix. Barichello et al. (1999) achieved an encapsulation efficiency of 
7-12 % for insulin-loaded PLGA nanoparticles, which was much lower than that 
obtained in this study, although it must be noted that the nanoparticles were 
made from PLGA polymer. The stability and the encapsulation efficiency of the 
loaded protein/peptide are the key concerns faced in the preparation of micro- 
and nanoparticulate formulations (Xu and Zhang, 2007). Lower encapsulation 
efficiency observed is attributable to the hydrophilicity of the proteins, which 
tends to be expelled out from the hydrophobic nanoparticle (Mundargi et al., 
2008). Other studies on encapsulation efficiencies of insulin in SLNs have also 
been reported to be relatively low with a maximum at approximately 58 % (Xue 
et al., 2013; Zhang et al., 2009), also attributable to drug expulsion. 
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3.4.2 Influence of emulsifier (lecithin) content 
Soy lecithin in SLNs has been shown to be useful as an emulsifier which 
ensures the production of stable nanoparticle dispersions (Hatziantoniou et al., 
2007; Schubert and Müller-Goymann, 2005). It has been reported in the 
literature that at least 10 %w/w lecithin is necessary in the lipid matrix, as the 
colloidal dispersion would not be stable below this lecithin concentration. 
Lecithin is commonly used as an emulsifier due to its reported safety and 
tolerability in humans, apart from being able to delay the transitions of lipids 
from the less stable α-form to the stable β-polymorphs (Bunjes and Koch, 2005; 
Schubert and Müller-Goymann, 2005). It has been postulated that lecithin tends 
to form a monolayer core surrounding the triglyceride core of the nanoparticles 
(Bunjes and Koch, 2005). At optimal lecithin concentrations, lecithin appeared 
strongly bound to the nanoparticle surface and thus by having limited mobility, 
particle agglomeration was less likely to occur. On the other hand, excessive 
lecithin concentration has been found to destabilise SLNs dispersion in terms 
of agglomeration and particle growth due to possible accumulation of lecithin 
multilayers on the particles’ surface or formation of liposomes within the 
aqueous phase (Schubert and Müller-Goymann, 2005).   
Therefore a series of formulations comprising of varying amounts of lecithin 
were formulated in order to study the effect of lecithin content (Table 3.6) on the 
stability of the SLNs. These formulations are subsequently labelled as Fb1 – 
Fb5. The amount of lecithin in each formulation was varied from 25, 50 and 100 
mg.  
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Table 3.6   Varying amount of lecithin content in formulations Fb1 to Fb5.  
 
 
 
 
 
Figure 3.15 Z-average (nm) of the lipid nanoparticles for formulations 
Fb1 – Fb5 with varying amounts of lecithin (n=3). 
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Formulation Lipids (mg) Surfactant (oily) 
(mg) 
Tripalmitin Palmitic acid Lecithin 
 
Fb1 
 
100 
 
0 
 
25 / 50 / 100 
Fb2 75 25 25 / 50 / 100 
Fb3 50 50 25 / 50 / 100 
Fb4 25 75 25 / 50 / 100 
Fb5 0 100 25 / 50 / 100 
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Figure 3.15 illustrates the z-average values for formulations Fb1 to Fb5 with 
varying amounts of lecithin. Formulation Fb1, containing solely tripalmitin, 
recorded a significantly higher z-average value for lecithin content 25 mg and 
100 mg, in comparison to 50 mg of lecithin (p<0.05). Fb5 (palmitic acid only) 
also recorded a trend similar to that of Fb1, but there were no significant 
differences in the z-average values for lecithin content 25 mg and 50 mg 
(p>0.05). As observed in section 3.4.1.1, an increase in palmitic acid content in 
these series of formulations (combination of tripalmitin and palmitic acid) also 
led to an increase in the z-average of formulations Fb2 to Fb4. These 
formulations containing 25 mg lecithin saw an increasing trend in z-average, 
but the increase was insignificant between formulations Fb3 and Fb4. On the 
other hand, a significant increase in z-average was observed in all three 
formulations with increasing palmitic acid content (Fb2 to Fb 4) for lecithin 
content of 50 mg and 100 mg respectively (p<0.05). Interestingly, this increase 
in z-average was most apparent in formulation containing 100 mg of lecithin as 
emulsifier.  
At 25 mg lecithin, there was possibly insufficient coverage over the crystallised 
nanoparticles. This sets the stage for agglomeration of smaller size 
nanoparticles into larger ones due to Ostwald ripening. On the other hand, when 
the amount of lecithin was high (100 mg), there was a saturation of emulsifier 
over the surface of the formed nanoparticle, thus increasing the Helmholtz layer 
and consequently the z-average. In these circumstances, the mobility of lecithin 
increases with increasing lecithin concentrations resulting in multi-layered SLNs 
and formation of liposomal structures around the particles due to constant 
Brownian motion. Fusion of the lecithin bilayers as well as particles 
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agglomeration are likely to occur, which would increase the z-average size of 
the SLNs (Schubert and Müller-Goymann, 2005). 
There were no visually aggregated particles for formulation Fb1 containing        
50 mg lecithin, however aggregated particles were formed in formulation Fb2 
and Fb5 containing 50 mg lecithin. Formulations Fb1, Fb2 and Fb5 containing 
25 mg and 100 mg lecithin had aggregated particles which were not 
redispersible upon shaking, indicating that the amount of lecithin was not 
optimal. Fb3 and Fb4 showed comparatively larger z-average values with 
corresponding amounts of lecithin incorporated. This showed that the average 
particle sizes for Fb3 and Fb4 were possibly more influenced by the type of 
lipids used instead of the amount of lecithin. 
It was also observed that the extent of aggregation depended on the amount of 
lecithin, such that formulations containing 50 mg lecithin had smaller and less 
aggregated particles. On the other hand, formulations containing 25 mg and 
100 mg lecithin had relatively large aggregates, which is consistent with the z-
average data shown in Figure 3.15. 50 mg lecithin (50 %w/w) was found to be 
an optimal amount to be incorporated into the formulations in view of lower z-
average values (Fig. 3.15).  
Based on the above, formulation Fb1 containing 50 mg lecithin was 
subsequently selected for further evaluation. 
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Table 3.7    Zeta potential of formulation Fb1 at different ratio                      
  of tripalmitin:lecithin (n=3). 
 
 
 
 
 
 
   
 
A further variation in the lecithin content of formulation Fb1 was evaluated and 
the zeta potential as well as the ratio of tripalmitin:lecithin varied are shown in 
Table 3.7. The zeta potentials of all these formulations can be considered to be 
physically stable (above |30| mV), in terms of the electrostatic repulsion 
(Heurtault et al., 2003). The zeta potential measured for the formulation Fb1 
containing lecithin at the ratio of 1:0.5 (50 mg lecithin) was -54.2 ± 1.5 mV, 
which was predicted to be the most stable formulation. Formulation Fb1 
containing lecithin at the ratio of 1:1 (tripalmitin:lecithin) was not selected 
despite recording an electrostatically stable zeta potential value of -53.9 ± 1.2 
mV, as the high lecithin content (100 mg) led to an increase in the z-average 
size of the SLNs (Fig. 3.15).  
Based on the data from this part of formulation study, formulation Fa1 
containing 100 mg tripalmitin and Fb1 containing 50 mg lecithin as emulsifier 
was selected for further work.   
Ratio of 
tripalmitin:lecithin 
Zeta potential (- mV)    
[mean ± SD]                          
 
 
1 : 0.25 
 
35.3 ± 1.2 
1 : 0.5 54.2 ± 1.5 
1 : 0.75 48.3 ± 1.1 
1 : 1 53.9 ± 1.2 
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3.4.3 Influence of other processing variables on physical properties of 
 the SLNs 
 
Ultrasonication energy is a common dispersion technique used to produce solid 
lipid nanoparticles (Sharma et al., 2009; Xie et al., 2011b; Zhang et al., 2009). 
The principle is based on dissipation of energy in the form of cavitation 
generated within the dispersion due to ultrasonic energy (Parhi and Suresh, 
2010). In this study, probe sonication technique was utilised which is capable 
of producing a powerful 20 kHz ultrasound radiation during the formation of the 
particles. This sonochemical reaction can rupture chemical bonds by means of 
the creation, growth and collapse of a bubble that is formed in the liquid 
(Gedanken, 2004). Ultrasonication method is reported to produce a more 
uniform particle size distribution of nanoparticles (Awati et al., 2003) and yield 
smaller particles (Yin et al., 2002). It has been reported that particle uptake is 
very much dependent on the size of the particles, with larger-sized particles 
found to be taken up at a slower rate and retained for longer periods of time in 
Peyer’s patches compared to smaller sized particles (Jani et al., 1989). The 
selected formulation Fa1 was prepared according to the double emulsion 
technique. The two-step emulsification process involved the use of a probe 
sonicator to mix the immiscible water and oil phases. This technique is mainly 
useful for encapsulation of hydrophilic drugs such as peptides, as it avoids any 
heating processes.  
Referring to the schematic diagram in Figure 3.16, the method involves two 
emulsification steps. The first step is to obtain a water-in-oil (W/O) primary 
emulsion, which consists of the lipid, an oily surfactant and the drug that is 
dissolved in the aqueous phase. This freshly prepared W/O primary emulsion 
is then re-emulsified in the second step with an excess of hydrophilic surfactant 
to obtain the final W/O/W emulsion. 
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Figure 3.16  Schematic diagram of two-steps emulsification method to  
  produce W/O/W double emulsion. 
     
 
 
 
  
 Figure 3.17 (a) z-average and (b) PdI values for the primary  
   emulsion of Fa1 prepared at different ultrasonic  
   amplitude (n=3). 
    (a)            (b) 
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The aim here was to optimise the ultrasonic processing variables in order to 
obtain nanosize range particles with desirable physical characteristics. We also 
aimed to establish a method that was reproducible. Consequently, the 
dispersion was subjected to ultrasonication at various amplitudes 25 %, 30 %, 
35 % and 40 % during formulation of the primary (W/O) emulsion. 
Ultrasonication amplitude can be translated into specific energy input, which is 
a parameter combining both power and time, both of which are vital in 
deagglomeration of particles (Sauter et al., 2008). From Figure 3.17, it was 
observed that at the ultrasonication amplitude of 25 %, SLNs with a smaller z-
average (180.9 nm) and polydispersity value (0.24) were produced. However, 
instability of the primary emulsion post-sonication was observed where phase 
separation of the primary emulsion occurred with the formation of two distinct 
layers (Fig. 3.18 (a)). Furthermore, when this formulation was viewed under the 
SEM, isolated nanoparticles were not seen (Fig. 3.17). Instead, oily droplets 
were observed in Figure 3.18(a), indicating that SLNs did not formed. This 
observation can be explained taking into account the fact that the ultrasonic 
amplitude of 25 % was insufficient in generating requisite sonic energy 
necessary in the formation of the SLNs.  A previous study outlined the 
importance of primary emulsion stability, as a prerequisite for a successful 
stabilisation of a multiple emulsion as well as for drug loading (Nihant et al., 
1994). These observations are in concert with those of Nihant et al. (1994), 
where an unstable primary emulsion that exhibited phase separation post-
sonication subsequently led to the formation of SLNs with undesirable physical 
properties. 
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  (a) Amplitude 25 %    (b) Amplitude 30 % 
Figure 3.18    Primary (W/O) emulsion and SEM micrograph of formulation 
  Fa1 prepared by ultrasonication at (a) Amplitude 25 % and (b) 
  Amplitude 30 %. 
 
The z-average values at amplitudes 30 % and 35 % were recorded as             
194.5 nm and 196.0 nm respectively. For the same amplitudes, the PdI values 
were registered as 0.25 and 0.23 respectively (Fig. 3.17). There was no phase 
separation observed when the formulation was ultrasonicated at amplitude 
30 %, and the SLNs were successfully formed as observed under SEM (Fig. 
3.18(b)). At a higher amplitude of 40 %, it was expected that the z-average 
Phase 
separation Well 
emulsified 
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would be smaller since the power and energy input into the system was higher, 
however the z-average and PdI values increased in proportion (Fig. 3.17). This 
can be explained by the fact that when the vibration amplitude increases, the 
cavitation created grows too large to the extent that the time available in the 
adjacent rarefaction cycle is not sufficient for them to collapse (Sauter et al., 
2008). Therefore, there will actually be less energy generated in the system due 
to the collapse of the bubble. Clearly then, a higher ultrasonication amplitude at 
40 % was not desirable in the deagglomeration of nanoparticles. Based on 
these findings, ultrasonication amplitude of 30 % was selected for further 
optimisation.  
 
 
 
 
 
       Figure 3.19  (a) z-average and (b) PdI values for formulation Fa1 
   prepared at varying duration of ultrasonication of the 
   primary (W/O) emulsion (n=3). 
 
The duration of ultrasonication can also directly influence the specific energy 
input into the system. An increase in the duration of ultrasonication is expected 
    (a)            (b) 
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to increase the amount of specific energy within the system and therefore cause 
the droplets to be broken down more readily due to the increased shear stress 
generated which results in particle size reduction (Budhian et al., 2007). It has 
been previously reported that by increasing the power and/or the duration of 
sonication, the mean diameter of PLGA polymeric nanoparticles was reduced 
and the particle size distribution was altered from bimodal to unimodal (Budhian 
et al., 2007; Mainardes and Evangelista, 2005). Contrary to this, the findings in 
the present study showed a rising trend in z-average and polydispersity as the 
duration of ultrasonication of the primary (W/O) emulsion was extended from 
15 seconds to 40 seconds (Fig. 3.19). When the primary emulsion was 
subjected to 15 seconds of ultrasonication, the z-average and PdI value was 
324.1 nm and 0.43 respectively. At 20 seconds of ultrasonication, the z-average 
and PdI was recorded as 500.4 nm and 0.55 respectively. Here we observed 
that an additional 5 seconds of ultrasonication resulted in a significant increase 
in both these parameters. For 30 and 40 seconds of ultrasonication time, the 
recorded z-average were 545.5 nm and 876.9 nm respectively. PdI values were 
registered at 0.63 and 0.69 for the respective durations of 30 and 40 seconds. 
This increase in the particle size diameter and the polydispersity of the 
distribution can be explained based on the collisions that occur when there is 
an increase in the energy being imparted into the system. Some of such 
collisions are likely to result in agglomeration of the particles and subsequently 
an increase in z-average. Since this phenomenon is selective (ie. not all 
particles necessarily particulate), there is thus a differential of particles-type 
which is what accounts for the rise in PdI as well. 
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 Figure 3.20 (a) z-average and (b) PdI values for formulation Fa1 
   prepared at varying vortex mixing duration prior to  
   ultrasonication of the primary (w/o) emulsion (n=3). 
 
 
We aimed to investigate the effect of vortex-mixing, in addition to ultrasonication, 
prior to the first emulsification step to prepare the primary (W/O) emulsion on 
the physical properties of the SLNs. Some studies have utilised vortex-mixing 
during the initial emulsification step to successfully prepare nanoparticles (Bilati 
et al., 2005b; Laroui et al., 2007; Zambaux et al., 1999). Optimisation of this 
parameter involved the introduction of vortex-mixing step for 1, 3, 5 and 10 
minutes prior to emulsification using ultrasonicator. There was no apparent 
trend observed when the duration of vortex-mixing was increased (Fig. 3.20). 
However, when the mixture was vortex-mixed for 1 and 3 minutes, an 
instantaneous phase separation of the primary emulsion was observed. The 
instability of the primary emulsion seen in this case due to the additional energy 
input from the vortex-mixing, has shown that the stability of the formulation was 
compromised and thus not as conducive in the successful formation of SLNs. 
The importance of the stability of primary emulsion has been outlined previously.  
    (a)            (b) 
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It was also observed that the z-average and PdI values of nanoparticles 
subjected to 3 minutes of vortex-mixing was the highest recorded (364.5 nm 
and 0.61 respectively), as compared to the other durations. The process of 
emulsification operated by vortex-mixing is less stable than by ultrasonication 
(Zambaux et al., 1999). Therefore, ultrasonication of nanoparticles is necessary 
in conjunction with vortex-mixing in order to improve stability of the SLNs. 
However, when there is additional input of energy imparted into the system by 
means of vortex mixing, there is also an increased tendency of particles to 
agglomerate as a result of high collision rates between rapidly moving particles. 
This could possibly be the reason for the significant increase in z-average and 
PdI when the primary emulsion was vortex-mixed for 3 minutes (Fig. 3.20). 
Unexpectedly, when the duration of vortex mixing of the primary emulsion was 
extended to 5 minutes, the z-average and PdI reduced to 242.9 nm and 0.34 
respectively. This observation can be attributed to the presence of high shear 
stress being contributed by the prolonged vortex mixing leading to 
deagglomeration of any previously agglomerated particles and hence a 
reduction in z-average.  
In summary, 5 minutes of vortex mixing of the primary emulsion prior to 15 
seconds of ultrasonication at 30 % amplitude was favourable in the preparation 
of optimal SLNs. 
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3.4.4  Microscopy imaging 
3.4.4.1     FE-SEM Imaging    
The initial stages of the preformulation work indicated that scanning electron 
microscopic (SEM) imaging of the lipid nanoparticles needed some optimisation. 
The sample preparation method as well as the intrinsic properties (eg. melting 
point) of the lipids present researchers with challenges in order to obtain 
satisfactory SEM images of SLNs. Therefore, much work has been done during 
the preformulation in order to optimise the method for sample preparation as 
well as the parameters used for imaging. 
SEM images of insulin-free and insulin-loaded SLNs of formulation Fa1 
(containing 100 mg tripalmitin) are shown below in Figure 3.21. The particles 
were freeze-dried directly from colloidal lipid dispersion prior to imaging. The 
freeze-dried particles were then placed on a carbon sticky tape which was 
secured on an aluminium stub. The sample was gold-sputter coated before 
imaging.  
 
   
 
Figure 3.21    SEM images of solid lipid nanoparticles (a) insulin-free SLNs 
            and (b) insulin-SLNs. (Scale bar of 200 nm) 
             (a)            (b) 
200 nm 200 nm 
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Referring to Figure 3.21, the shape and morphology of the lipid nanoparticles 
were observed to be flat, flaky and of amorphous nature and not the spherically-
shaped particles commonly seen in SEM images of the SLNs (Hatziantoniou et 
al., 2007; Liu et al., 2007; Mukherjee et al., 2009b). Furthermore, the particles 
appeared agglomerated.  
Due to the particles being non-spherical in shape, the size of the particles would 
not be representative. It was theorised that the change in shape and 
morphology was due to the freeze-drying process which exerted stress on the 
nanoparticles during abstraction of water, causing the particles to flatten out. A 
similar observation has been described by Jores et al. (2003) who showed flat 
needle structures from the side view of the particles in a TEM picture, calling 
those as “spoon structure” or “nanospoon”. The authors suggested that the 
structures seen were due to the lipid hydrophobic tail of tripalmitin sticking out 
on the SLNs surface. On another note, suspensions of platelet-like shaped 
tripalmitin nanocrystals stabilised by the pure lecithin dilauroyl 
phosphatidylcholine (DLPC) and the lecithin blend S100 have also recently 
been studied as potential drug delivery systems, exploiting the large surface 
area available for drug incorporation (Schmiele et al., 2014). 
A close examination of the SEM images in Figure 3.21 shows a sticky matrix 
adjoining the particles. This is likely to be due to the presence of high 
concentration of Poloxamer 188, which was imposed by the freeze-drying 
process. Poloxamers are water-miscible polymeric surfactants with high 
viscosities (Karmarkar et al., 2008), and thus it is possible for a sticky matrix to 
be formed during drying of the sample which appeared as a network of trapped 
nanoparticles. 
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In order to further optimise the sample preparation method for the SEM imaging, 
the nanoparticle formulations were viewed without freeze-drying and were 
diluted to low concentration (1 in 5 dilution). As opposed to 1 in 10 dilution used 
in particle size analysis, a dilution factor of 1 in 5 was selected for SEM sample 
preparation in order to view a reasonable number of nanoparticles in the 
samples. At the same time, freeze-dried particles were also viewed as an 
experimental control. Instead of viewing the freeze-dried particles directly as 
previously done, these particles were suspended in 50 ml purified water and 
then sonicated for 30 minutes in an ultrasonic bath.  
Figure 3.22 displays SEM image of diluted (1 in 5 dilution) lipid nanodispersion, 
where it can be observed that spherical nanoparticles had been formed for the 
sample derived directly from the diluted colloidal lipid dispersion. However, it 
seemed that these existed as large agglomerates of smaller nanoparticles.  
 
 
Figure 3.22    SEM image of diluted formulation Fa1. 
           (Scale bar of 100 nm) 
 
100 nm 
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SEM images of freeze-dried nanoparticles (insulin-free and insulin-loaded) 
which were suspended in water and sonicated prior to viewing are shown in 
Figure 3.23. For the freeze-dried SLNs suspended in water and sonicated 
thereafter, the insulin-free nanoparticles (Fig. 3.23(a)) looked similar to the 
nanoparticles seen in Figure 3.21(a), but agglomerated. Interestingly, the 
insulin-loaded freeze-dried nanoparticles were observed to be completely 
different from the other freeze-dried counterparts (Fig. 3.23(b)). The image 
resembled the nanoparticles from the diluted fresh colloidal lipid dispersion (Fig. 
3.22).  
 
 
 
Figure 3.23 SEM micrographs of freeze-dried nanoparticles 
  (a) insulin-free and (b) insulin-loaded (post-sonication). 
 
These findings indicate that the presence of insulin in the formulation appear to 
negate the effects of the freeze-drying process. It has been reported in the 
literature that entrapped drug in nanoparticles may in certain cases influence 
the freeze-drying of nanoparticles in a positive or negative manner when water 
is being abstracted during the freeze-drying process (Abdelwahed et al., 2006). 
           (a)            (b) 
100 nm 1 µm 
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In this case, we observed a positive effect of freeze-drying on drug-loaded SLNs 
containing insulin, in which the quality of reconstituted nanoparticles had been 
retained. 
Being lipidic in nature with low melting points, samples were found to be 
extremely sensitive to the electron beam, resulting in the location of interest 
being damaged by the electron beam focused on that area. Beam damage on 
lipid substance is common since high-energy electron beam causes local 
heating of the area, thus altering the surface structure (Aguilera and Stanley, 
1999). Therefore, the accelerating voltage of the electron beam was decreased 
to below 5 kV. 
Routinely, samples are coated with gold prior to viewing under the SEM. 
However, gold coating procedure has its own drawback as the gold layer may 
mask the true surface morphology of the nanoparticles and obscure fine details. 
The particles could also be entirely buried underneath the coat if the right 
parameters are not sought (Aguilera and Stanley, 1999). If the lipid 
nanoparticles were not gold-coated, there was another problem faced due to 
the similarities seen between the lipid nanoparticles (Fig. 3.24(a)) and the 
carbon nanoparticles of the carbon sticky tape used in SEM imaging (Fig. 
3.24(b)). The carbon sticky tape was used as the substrate to secure the sample 
on the aluminium stub. However, without gold-coating, the carbon nanoparticles 
from the carbon sticky tape would be imaged on the SEM as seen in Figure 
3.24(b). This posed a problem as it was necessary to clearly differentiate the 
solid lipid nanoparticles from those due to the carbon sticky tape. 
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Figure 3.24 SEM image of (a) lipid nanoparticles (uncoated with gold) and 
  (b) blank carbon sticky tape used as sample substrate. 
 
 
 
In order to further optimise the sample preparation method, the lipid droplet was 
placed directly onto an aluminium stub, instead of on the carbon sticky tape as 
before and the nanoparticles were not coated. Figure 3.25 shows the optimised 
SEM image of the uncoated lipid nanoparticles, although the nanoparticles were 
largely agglomerated. 
 
 
 
Figure 3.25 SEM image showing a bunch of agglomerated nanoparticles. 
      (a)                      (b) 
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In order to address the issue of agglomeration, the lipid dispersion was 
sonicated in a sonic bath for 30 minutes. The resulting SEM image shows 
isolated spherical lipid nanoparticles, with central indentation in some of the 
particles (Fig. 3.26). The average size diameter of the isolated nanoparticles 
was approximated at 250 nm, which corroborated with the z-average data 
measured using the Zetasizer.   
 
 
Figure 3.26 SEM image showing isolated lipid nanoparticles.    
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3.4.4.2    TEM Imaging 
Numerous studies on solid lipid nanoparticles use TEM to characterise the 
morphology and internal structure of their formulations (Bayat et al., 2008; 
Garcıa-Fuentes et al., 2003; Sarmento et al., 2007a). As described, 
optimisation of SEM imaging was found to be challenging. In order to improve 
and complement the images obtained from SEM, TEM imaging was also 
pursued to shed some additional insights on the morphology and investigate 
the internal structure of the lipid nanoparticles. 
The lipid samples were negatively stained using osmium tetraoxide 0.1 M to 
enhance the image of the sample. The images obtained were not particularly 
satisfactory although it was possible to demonstrate that the size was 
approximately 250 nm and the spherical/ellipsoidal shape of the nanoparticles 
(Fig. 3.27) was consistent with the particle size obtained from SEM image in 
Figure 3.26. 
 
 
     Figure 3.27        TEM micrograph of lipid nanoparticles. 
          (Scale bar of 200 nm) 
 
200nm 
200nm 
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3.5 Concluding remarks 
Insulin-containing solid lipid nanoparticles, comprising of palm oil lipids, have 
been successfully fabricated using W/O/W double emulsion solvent evaporation 
technique.  
Production and processing parameters were optimised to obtain desirable 
particle size range, polydispersity index and zeta potential as well as physical 
properties of the formulation. Based on the findings here, the most desirable 
formulation to be pursued further was that containing 100 mg tripalmitin as lipid 
and 50mg lecithin as emulsifier. 
Sample preparation method for SEM and TEM had been optimised to obtain 
clear images of isolated nanoparticles in the micrographs. The shape and 
morphology of the nanoparticles were ascertained, with the particle size 
measured from the microscopy images corroborated with that determined using 
Zetasizer, hence being valuable complementary characterisation tools in the 
present work. 
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CHAPTER 4  
 
Identification of Insulin 
Localisation Model within 
the Optimised SLNs 
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4.1 Introduction  
4.1.1 Drug Localisation Models   
Many studies have explored the possibility of incorporating drugs into SLNs in 
a bid to improve the loading capacities within the SLNs. However, limited 
information is available about the drug release from these SLNs, particularly the 
release mechanisms involved (Cavalli et al., 1999; Mühlen and Mehnert, 1998; 
Yang et al., 1999). Drug release profiles are influenced by the particle size and 
the nature of lipid matrix (Mühlen and Mehnert, 1998). The drug release profiles 
from SLNs can be modulated to achieve a prolonged release with or without an 
initial burst release (Müller et al., 2000). As a result of the variations obtained in 
drug release profiles, three different drug incorporation models (Fig. 1.8) have 
been proposed (Müller et al., 2000). Based on these models, the solid solution 
model (Fig. 1.8A), in which the drug is molecularly dispersed in the lipid matrix, 
is often produced by cold homogenisation technique, in the absence of 
surfactant or drug-solubilising surfactant. The drug-enriched shell model (Fig. 
1.8B) in which the drug is released from the particle surface and hence often 
manifest as a burst release. For the drug-enriched core model (Fig. 1.8C), 
where the drug is located in the inner core shielded by the lipid shell, the drug 
is released in a prolonged manner and based on diffusion through the matrix. 
Müller and his co-workers proposed the drug incorporation models (Fig. 1.8) for 
lipophilic drugs, which are soluble in the lipid matrix of the SLNs systems.  
The production of protein-loaded SLNs formulations, eg. insulin (Xie et al., 2008; 
Yang et al., 2011) and salmon calcitonin (Garcia-Fuentes et al., 2005c; Martins 
et al., 2009), have been designed in order to achieve a sustained drug release 
profile with minimal burst release. Whilst sustained protein release has been 
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achieved in the preceding cases, there has been no attempt to establish the 
possible location of the hydrophilic drugs (eg. peptides, like insulin) within the 
formulated SLNs to our knowledge, unlike for lipophilic drugs. The drug 
localisation models, apart from helping to decipher the possible release 
mechanisms of the hydrophilic payload from the SLNs, also sheds some light 
on the propensity of the SLNs to be taken up within the gastrointestinal tract. 
 
4.1.2 Aims and Objectives 
The main aim of this part of study was to fabricate insulin-containing SLNs, in 
order to achieve the three hypothetical drug incorporation models as illustrated 
in Figure 1.8. Following the fabrication, suitable techniques will be employed to 
distinguish the different types of drug localisation models achieved. 
 
4.2 Materials  
Pure crystalline recombinant human insulin (lyophilised powder) was 
manufactured by EMD Biosciences (San Diego, USA) and purchased from 
Merck. Solid lipid tripalmitin (99 % purity) was purchased from Acros Organics 
(Geel, Belgium). L-α-phosphatidyl choline (soy lecithin) and poloxamer 188 
were purchased from Fluka (Australia) and BASF (Germany) respectively were 
used as surfactants. Dichloromethane, hydrochloric acid, sodium chloride and 
disodium hydrogen phosphate and potassium dihydrogen phosphate were 
supplied by R&M Chemicals. Trifluoroacetic acid (TFA) and acetonitrile (both 
HPLC grades) were purchased from Fisher Scientific (Loughborough, UK). All 
the other solvents used were of analytical grade and the materials were used 
as received. 
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4.3 Methods 
4.3.1  Preparation of insulin-containing SLNs 
The formulations were prepared using solvent-evaporation emulsification 
technique, adapted from (Garcıa-Fuentes et al., 2003). The SLNs (Model A) 
was prepared based on the optimised method outlined in Chapter 3. Briefly, 
solid lipid tripalmitin and soy lecithin were dissolved in dichloromethane (DCM), 
forming the oily phase. 1 mg of human recombinant insulin (Calbiochem, USA) 
was dissolved in 100 µL of 0.1 % trifluoroacetic acid and added to the oily phase. 
The emulsion was first mixed with a vortex mixer for 5 minutes, then 
subsequently dispersed with an ultrasonicator probe (750 W VCX Series, 
Sonics Inc., USA) for 15 seconds to produce a primary W/O emulsion. A 2 % 
Poloxamer 188 solution in distilled water was added subsequently, followed by 
ultrasonication to form a W/O/W double emulsion. The resultant double 
emulsion was made up to a final volume of 10 ml with 1 % Poloxamer 188 and 
the solvent was evaporated off. For the insulin-loaded SLNs (Model A), insulin 
solution was incorporated in the suspension prior to ultrasonication. For the 
physically-adsorbed insulin formulation (Model B), the insulin solution was 
added to the unloaded SLNs dispersion after the solvent was evaporated off. 
The drug-enriched core model (Model C) was not studied due to the formulation 
constraints of the ingredients used that did not permit formation of this model. 
It is not possible to achieve all three incorporation models at once using the 
same ingredients without introducing additional variables into the system. 
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4.3.2 Zeta potential measurements 
The zeta potential of the SLNs formulations were measured using Zetasizer 
Nano-ZS (Malvern Instruments Ltd., U.K.). Samples were loaded in a clear 
disposable zeta cell (DTS 1060C) for measurement at 25 °C, performed in 
triplicates. The zeta potential values were calculated based on Smolochowski 
equations (Eq. 3.2) using Malvern Zetasizer Software 6.01®, as determined by 
the electrophoretic mobility of the samples. 
 
4.3.3 In vitro drug release studies 
In vitro insulin release studies were evaluated in phosphate-buffered saline 
(PBS) buffer (pH 7.4), maintained at 37 °C under stirring at 50 rpm. Samples 
were removed at pre-determined time intervals over 1 hour for both formulations, 
followed by quantification using high pressure liquid chromatography (HPLC) 
as well as zeta potential measurements. 
 
4.3.4 Scanning Transmission Electron Microscopy (STEM) Imaging 
Sample nanoparticles were placed on Formvar-film copper grids and stained 
using 1 % phosphotungstic acid (PTA) solution. Formulations were 
subsequently viewed using STEM detector (FEI Quanta 400F, U.S.). 
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4.4 Results and Discussion 
4.4.1 Preparation of insulin-containing SLNs 
Some modifications had to be made to the formulation procedure for insulin-
containing SLNs as indicated in Figure 4.1 in order to achieve the different drug 
incorporation models (Fig. 1.8). The procedure used to prepare insulin-
containing SLNs using method 1 (Fig. 4.1) is described in Section 3.4. For 
method 2 (Fig 4.1), a slight modification was made to the addition step of insulin 
solution. The insulin solution was added into the w/o/w emulsion of the SLNs 
formulation, instead of being added at the initial step to form the primary w/o 
emulsion.  
 
    
 Method (1)    Method (2) 
 
Figure 4.1 Methods (1) and (2) to prepare insulin-containing SLNs, with 
  modification steps, to achieve different drug incorporation  
   models. 
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This loading technique via adsorption of proteinaceous drug onto preformed 
system has been widely utilised in polymeric nanoparticulate carriers (Almeida 
and Souto, 2007; Couvreur et al., 1979; Soppimath et al., 2001). It is desirable 
in the present context due to the availability of a large surface area offered by 
nanoparticles for protein adsorption (Almeida and Souto, 2007). Furthermore, 
proteins such as bovine serum albumin (Gualbert et al., 2003) and calcitonin 
(Garcia-Fuentes et al., 2005b) have been loaded onto preformed SLNs surface 
by means of this physical adsorption technique. Surface chemistry of the solid 
surfaces can influence its interaction with the protein molecules. For example, 
it was suggested that albumin, which undergoes adsorption via a single step 
process of protein-surface interactions, exhibits a stronger affinity towards –CH3 
hydrophobic surface compared to the –OH terminated hydrophilic surface 
(Roach et al., 2005). Surface modification of SLNs using amphiphilic lipid 
lecithin and non-ionic emulsifier has been used to improve loading capacities of 
the protein bovine serum albumin (Schubert and Müller-Goymann, 2005).  
In this regard, each tripalmitin molecule, which consists of three long aliphatic 
chains (C16), is capable of interacting with the proteins. These long aliphatic 
chains of the SLNs can contribute to the adsorption of protein onto the –CH3 
hydrophobic surface via weak attractive Van der Waals interactions, though not 
particularly favourable due to the susceptibility of surface-induced structural 
alteration (Lee et al., 2011). The inclusion of surfactants in the formulation offers 
protein-stabilising effect against adsorption loss by reducing the surface activity 
of the lipid nanoparticles. The hydrophobic tail of lecithin has a strong affinity 
towards the long aliphatic chains of tripalmitin, which enables the lecithin to bind 
preferentially to the lipids at interfaces. The ionised phosphate hydrophilic 
groups present in lecithin can contribute negative charges (PO4
-) to the lipid 
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nanoparticles. Therefore, the positively charged insulin molecules are 
electrostatically attracted to the SLNs. Furthermore, the presence of –OH group 
in Poloxamer 188 can also participate in the formation of hydrogen bonds with 
the insulin at the interface of these SLNs where the proteins adsorbed. This 
procedure of surface adsorption of proteins on SLNs is particularly 
advantageous as it offers a promising alternative which can minimise the 
exposure of proteins to harsh processing conditions during SLNs production 
(Almeida and Souto, 2007; Schubert and Müller-Goymann, 2005).  
Here, we have successfully prepared insulin-containing SLNs formulations 
conforming to two of the three types of proposed drug incorporation models as 
described earlier in Section 4.1.1. It was not possible to achieve the drug-
enriched core model (Model C) without significantly modifying the protocol 
which would have made the comparing between them difficult. As mentioned 
earlier, formulation constraints of the ingredients used did not permit this model 
from being materialised. In the following section, both of these formulations 
which conform to the localisation models (Model A and B) will be characterised 
accordingly in order to ascertain the insulin localisation models. 
 
4.4.2 Ascertaining the Location of Insulin within SLNs 
Following the production of the two types of the SLNs with different localisation 
of insulin, the next crucial step was to confirm the insulin localisation models 
(Model A and B). It is indeed challenging to determine the drug location within 
a nanoparticle in view of its small size (Benita, 2005); thus our approach was 
based on indirect means such as spectroscopy, fluorescence imaging and zeta 
potential measurements. 
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4.4.2.1    Energy Dispersive X-Ray (EDX) spectroscopy 
Energy Dispersive X-ray spectroscopy (EDX) is a powerful technique used for 
elemental analyses as well as mapping of distribution of elements. Fernandez-
Hervas et al. (1998) and Edge et al. (1999) had previously applied this 
technique to identify and map the distribution of elements present in their 
formulations. This technique was utilised on the basis of identifying elements 
solely present in insulin and mapping of these elements across the surface and 
inner regions of the nanoparticles in order to establish the location of insulin 
within the fabricated nanoparticles. 
The analysis and mapping of elements were carried out using an FE-SEM, 
equipped with EDX functionality. The element of interest potentially detectable 
in pure insulin is sulphur, which is found in cysteine amino acid residues. 
Sulphur is absent from the lipid matrix of the SLNs, therefore eliminating any 
possibility of interference due to the lipid materials during analysis. 
 
 
 
 
 Figure 4.2   Pure insulin (a) SEM image and (b) EDX spectrum 
   (Pt represents platinum-coated) 
  (a)              (b) 
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Pure recombinant human insulin displayed crystalline structures when viewed 
under FE-SEM (Fig. 4.2(a)). Figure 4.2(b) shows the EDX spectrum for pure 
recombinant human insulin which confirmed the presence of sulphur in the 
sample. Therefore, the element sulphur which was exclusive to insulin, was 
utilised as a means of indirectly identifying insulin in the sample. 
Figure 4.3 and 4.4 illustrate the EDX spectra for insulin-free and insulin 
containing lipid nanoparticles respectively. Despite the high intensity for sulphur 
in the pure insulin sample (Fig. 4.2), sulphur was not detected within the insulin-
containing SLNs. This could possibly be due to the amount of sulphur in the 
SLNs being below the threshold of sensitivity for the equipment. The 
concentration of insulin present in the formulation was 100 µg/ml and only a 
drop of the dispersion was used  for  EDX  sampling, hence  the  level  was  too  
low  for  detection. Typical theoretical detection limits in SEM-EDX 
measurements are accepted as approximately 0.08 wt.% (Kuisma-Kursula, 
2000). Another explanation could possibly be due to insulin being already 
encapsulated within the nanoparticles, resulting in low available sulphur 
concentration on the surface of the nanoparticles. Due to the constraint 
mentioned above, mapping of sulphur for the purpose of detecting the 
localisation of insulin within the SLNs could not be performed across the surface 
and inner region of the nanoparticles. Therefore, the EDX analysis was not used 
for further analysis. 
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Figure 4.3 EDX spectrum for insulin-free lipid nanoparticles.                                   
(Au represents gold-coat)  
 
 
                  
Figure 4.4 EDX spectrum for insulin-containing lipid 
nanoparticles.   (Au represents gold-coat) 
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4.4.2.2   Fluorescence spectroscopy 
The presence of aromatic amino acid tyrosine in the insulin molecule contribute 
to its fluorescence characteristics. Aqueous insulin solution has been reported 
to emit the highest fluorescence intensity at band maxima λmax 304 nm 
wavelength, consistent with other tyrosine-containing proteins such as 
ribonuclease, prolamine and ovomucoid (Teale, 1960). Therefore, we theorised 
that this intrinsic fluorescence attribute of insulin can be exploited in order to 
predict its location within the SLNs. This approach has previously been adopted 
to study the structural, physicochemical and functional properties of proteins 
(Permyakov et al., 1982). Although insulin solution is capable of autofluorescing 
(Bekard and Dunstan, 2009), it typically displays low intrinsic emission at λex/λem 
= 276/300 nm (Gök and Olgaz, 2004). Ideally, insulin is routinely tagged with a 
fluorophore, such as fluorescein isothyocianate (FITC), by binding to the amine 
groups of the protein molecules to probe their extrinsic emission for in vivo 
studies (Gök and Olgaz, 2004; Trotta et al., 2011). However, tagging of payload 
can significantly alter the physicochemical properties of the SLNs. 
In our attempt to establish the location of drug within the SLNs, we anticipated 
that the fluorescence intensity would vary between the two different models as 
shown in Figure 4.5 so that a qualitative comparison of relative fluorescence 
intensities can be used as an inference.  
Figure 4.6 shows the emission spectra of insulin for insulin solution, insulin-free 
SLNs and insulin-containing SLNs excited at λex= 255 nm. Excitation 
wavelength was fixed at 255 nm to minimise interference from solvents. All 
three emission spectra displayed a unique λem = 293 nm either in the presence 
or absence of insulin in the samples. Accurate measurement or detection of 
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insulin fluorescence intensity can be hindered due to the presence of 
background fluorescence at wavelength 293 nm. Contributing factors such as 
autofluorescence or spectral overlap can lead to the occurrence of background 
fluorescence (Hulspas et al., 2009). Therefore, this technique of comparing 
relative fluorescent intensities was found to be inconclusive. 
 
 
      
     
Figure 4.5 Prediction of tyrosine fluorescence intensity of insulin through 
  relative comparison for drug localisation models A and B  
  (+ indicates low intensity; ++ indicates high intensity) 
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Figure 4.6 Fluorescence emission spectra of insulin at λex= 255 nm              
             for (i) insulin solution, (ii) insulin-free SLNs and (iii) insulin- 
  containing SLNs 
 
(i) Insulin solution 
 
 
 
 
 
 
 
 
(ii) Insulin-free SLNs 
 
 
 
 
 
 
(iii) Insulin-containing SLNs   
 
 
 
F
lu
o
re
s
c
e
n
c
e
 i
n
te
n
s
it
y
 
Wavelength (nm) 
F
lu
o
re
s
c
e
n
c
e
 i
n
te
n
s
it
y
 
Wavelength (nm) 
F
lu
o
re
s
c
e
n
c
e
 i
n
te
n
s
it
y
 
Wavelength (nm) 
λem = 293 nm 
λem = 293 nm 
λem = 293 nm 
  
143 
 
 
4.4.2.3     Confocal Laser Scanning Microscopy (CLSM) 
Confocal laser scanning microscopy (CLSM) (Olympus FV1000 Fluoview) has 
the ability to image nanoparticles under microscopy and simultaneously provide 
information on the fluorescence intensity of the SLNs particles upon laser 
stimulation. CLSM imaging of the nanoparticles was based on insulin’s 
autofluorescence ability due to the presence of tyrosine residues (Figure 4.5) 
as well as based on fluorescent lipid probe Nile Red incorporated within the lipid 
tripalmitin in SLNs. Erni et al. (2002) labelled lipid tripalmitin at 0.1 %w/w Nile 
Red fluorescent dye with respect to the mass of tripalmitin to evaluate the 
potential of cationic solid lipid microparticles as an efficient carrier system in the 
delivery of therapeutic macromolecules to phagocytic cells. The qualitative 
comparison of fluorescence intensity as expected for insulin is shown in Figure 
4.5, while for Nile Red-labelled SLNs the intensity prediction is as shown in 
Figure 4.7. Figure 4.7 indicates that the fluorescence intensities are predicted 
to be higher for the solid solution model (Model A) as compared to the drug-
enriched shell model (Model B) which was expected to display the least 
brightness. 
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Figure 4.7 Prediction of fluorescence intensity of Nile Red-labelled lipid
  through relative comparison for each drug localisation models  
  (+ indicates low intensity; ++ indicates high intensity) 
 
 
 
As shown in Figure 4.8, the CLSM images of both insulin-containing SLNs and 
insulin-free SLNs displayed fluorescence emission upon laser stimulation. This 
interesting observation was not expected as insulin-free SLNs also fluoresced 
in the same manner as insulin solution, therefore it would be impossible to 
differentiate the fluorescence intensities when both particles and drug of interest 
fluoresces intensely at any wavelengths of laser stimulation. Dissolving the 
fluorophore Nile Red in lipid tripalmitin also did not yield any differences (Fig. 
4.9). These findings using CLSM did not appear conclusive. 
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      (a)         (b) 
 
Figure 4.8 Image acquired from CLSM imaging of (a) insulin-containing 
  SLNs and (b) insulin-free SLNs  
 
 
 
 
 
 
 
 
Figure 4.9 Image acquired from CLSM imaging of insulin-containing  
  SLNs tagged with lipid fluorescent dye Nile Red at   
  λex/λem = 530/590 nm 
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4.4.3 Zeta Potential Measurements 
Zeta potential measurement was used as a further means to help in indirectly 
deciphering the different location of insulin within the SLNs. A study by 
Aboubakar et al. (1999b) adopted the zeta potential measurements in order to 
predict the location of drug within colloidal particles, by means of a differential 
gradient in zeta potential values. The measurements were carried out to 
determine whether insulin was completely encapsulated within the core of the 
nanocapsules or that it was simply adsorbed onto the surface of the 
nanocapsules. This novel use of zeta potential measurements suggested that 
it is indeed possible to determine the insulin location within 
poly(isobutylcyanoacrylate) polymeric nanocapsules prepared by interfacial 
polymerisation method, since surface-adsorbed insulin caused a decrease in 
zeta potential value (Aboubakar et al., 1999b). In their work, the formulated 
insulin-loaded nanocapsules recorded an almost identical zeta potential value 
of -19 mV as the unloaded nanocapsules. Thus, it was hypothesised that the 
insulin was completely encapsulated within the core of the nanocapsules with 
respect to the identical zeta potential values (Aboubakar et al., 1999a, 1999b). 
This thus formed the basis for the use of zeta potential measurements in the 
present study as a potential indirect indicator of the location of insulin within the 
SLNs. The SLNs formulations prepared here fitted just two of the three 
hypothesised drug incorporation models (Fig. 1.8), as it was impractical to 
achieve all three possibilities due to formulation constraints, as explained earlier.   
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Figure 4.10 Zeta potential values of unloaded, insulin-loaded and  
  physically-adsorbed insulin SLNs formulations (n=3). 
 
 
The mean zeta potential value of insulin-free SLNs was found to be -51.7 ± 1 
mV. The insulin-loaded SLNs formulation and the physically-adsorbed insulin 
SLNs were -45.8 ± 1 mV and -40.8 ± 1 mV respectively (Fig. 4.10). 
In the absence of insulin within the SLNs formulation, the zeta potential of the 
unloaded SLNs was the highest in magnitude and negative (-51.7 ± 1 mV). This 
negative magnitude in zeta potential is ascribable to lecithin (emulsifier), which 
contains two alkyl chains and an ionised phosphate hydrophilic group, which 
bears a net negative charge (Kunitake and Okahata, 1978).  
Zeta potential is influenced by small changes within the electrical properties of 
the particle surface, due to the adsorption of peptides, proteins, or any other 
polyelectrolytes at the surface of the colloidal particles (Aboubakar et al., 
Unloaded Insulin-loaded Physically-adsorbed
-60
-40
-20
0
Z
e
t
a
 
p
o
t
e
n
t
ia
l 
(
m
V
)
  
148 
 
1999a). With the incorporation of insulin within the SLNs formulations (insulin-
loaded SLNs), there was a significant decrease in mean zeta potential value to 
-45.8 ± 1mV (p<0.05). The physically-adsorbed insulin SLNs showed further 
decrease in zeta potential value (-40.8 ± 1 mV) as compared to the unloaded 
SLNs (p<0.05). This most certainly is due to the positive charge contribution by 
insulin that neutralises the negative charge induced by lecithin and indicates 
that most of the insulin is surface-based. Insulin carry a net positive charge 
when their pH is below the isoelectric point, and vice versa. The isoelectric point 
for insulin is 5.3 (Park, 1999), therefore when dissolved in an acidic environment 
(~ pH 2), it carries a net positive charge. This finding is consistent with that 
reported by Aboubakar et al. (1999b) who described the presence of surface-
adsorbed insulin could induce variation in zeta potential to the more positive 
range in a concentration-dependent manner. The decrease in zeta potential 
value of SLNs due to physically-adsorbed insulin can be attributed to the 
neutralisation of the negative charge on insulin-free nanoparticle as a result of 
insulin molecules adsorbing on the surface of the SLNs. The adsorption occurs 
in the Stern layer of the colloidal particle, where the net electrical charge of the 
surface becomes less negative as reflected from the zeta potential 
measurements. The decrease in the zeta potential value therefore appeared to 
be more prominent in the physically-adsorbed insulin SLNs formulations. This 
further suggests that the protein-surface interaction is governed by electrostatic 
attraction of the insulin and the lipid nanoparticles.  
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4.4.4 In vitro drug release studies 
In vitro drug release studies can be used to reflect the accessibility of the drug 
to the dissolution medium (Mühlen et al., 1998), as mentioned in Section 4.1.1. 
This section describes results on the two insulin-containing SLNs formulations 
(Section 4.4.1) in order to further support the observations made in Section 
4.4.3.  
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Figure 4.11 Insulin release profile over 1 hour of in vitro drug release  
  studies for both SLNs formulations (n=3).  
 
 
Here, the in vitro insulin release studies for both SLNs formulations were 
evaluated using two different methods, namely HPLC analysis and zeta 
potential measurements. For HPLC analysis, release of insulin from the SLNs 
formulations was quantified and subsequently presented as percentage (%) of 
insulin release over a study period of 1 hour (Fig. 4.11). It was, however, 
observed here that no significant differences were demonstrated in the insulin 
  
150 
 
release profiles for both insulin-loaded SLNs formulations and physically-
adsorbed insulin SLNs (p>0.05) (Fig.4.11). The amount of insulin released from 
the respective SLNs formulations were comparable in this instance and 
therefore, it was not possible to differentiate the release profiles between both 
these formulations and to deduce information accordingly. Here, the findings 
from HPLC analysis did not appear to be conclusive, as the small quantity of 
released insulin from both SLNs formulations displayed differences which were 
deemed insignificant. 
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Figure 4.12   Zeta potential measurements over 1 hour of in vitro drug  
  release studies for both SLNs formulations (n=3).  
 
 
Apart from evaluating the release of insulin using HPLC analysis, zeta potential 
measurements were also performed on both SLNs formulations over the same 
study duration. Zeta potential values reflect the surface charges on the lipid 
nanoparticles, as described earlier. Any changes in the zeta potential values 
suggest that the nanoparticles surface charges have been modified, and that 
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these changes correspond to the rate of insulin released from the nanoparticles. 
The figure shows an increase in zeta potential values as a function of insulin 
release from both types of nanoparticles (Fig. 4.12). As described previously, 
the presence of insulin on the surface of the nanoparticle contributes to a 
positive magnitude in zeta potential values. Therefore, the reverse is true when 
insulin is released from the nanoparticle surface.  
Interestingly, both insulin-containing SLNs formulations exhibited distinctively 
different release profiles when evaluated using zeta potential measurements 
(p<0.05) (Fig. 4.12), despite that being not evident in the profiles shown in 
Figure 4.11. Based on Figure 4.12, the changes seen in the zeta potential 
values clearly indicate that there were indeed changes in the surface charges 
of the nanoparticles over the study duration of 1 hour as a result of insulin being 
released from the SLNs. This is a particularly interesting finding where a small 
amount of insulin released from the different SLNs formulations can be reflected 
as distinctive differences in the zeta potential values, otherwise not 
demonstrated when using HPLC analysis in this instance.  
Insulin-loaded SLNs formulation (Model A) displayed a release trend consistent 
with controlled release behaviour over a drug release period of 1 hour. In 
contrast, the physically-adsorbed insulin SLNs formulation had an initial burst 
release for the first 10 minutes of study, then gradually decreased and adopted 
a release profile similar to a sustained-release mechanism (Fig. 4.12).  
The release profile of insulin-loaded SLNs formulation demonstrates that insulin 
was molecularly dispersed within the matrix of the SLNs. A gradual increase in 
zeta potential from –9.2 mV to –10.8 mV over an hour duration was recorded 
(Fig. 4.12). No distinctive burst release was observed in this instance, but a 
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slow and sustained insulin release (Fig. 4.12). This prolonged release profile is 
indicative of a longer path length that insulin diffuses through before reaching 
the dissolution medium and confirms that this formulation has an architectural 
arrangement that conforms to the solid solution model (Model A) illustrated in 
Figure 1.8. Unless the zeta potential of the insulin-loaded SLNs is recorded to 
be almost similar to that of unloaded SLNs due to complete encapsulation of 
insulin within the core of the nanoparticles, the model is ascribable to the solid 
solution model. Mühlen et al. (1998) also reported a similar controlled release 
profile where slow diffusion of the drug out from the lipid matrix was consistent 
in SLNs formulation that fits the homogenous solid solution model.  
On the other hand, for the physically-adsorbed insulin-SLNs, the zeta potential 
value increased rapidly from –5.75 mV to –11.5 mV within 10 minutes of drug 
release studies, reflecting the initial burst release of insulin observed in Figure 
4.12. Insulin physically-adsorbed on the SLNs permitted ease of insulin release 
into the aqueous phase, hence the initial burst release. The occurrence of initial 
burst release is that the adsorbed insulin is released unimpeded when the SLNs 
come into immediate contact with the dissolution media, thus confirming that 
insulin is present on the surface of the SLNs, forming a drug-rich outer shell 
(Model B) as illustrated in Figure 1.8. 
Based on the results from the in vitro drug release studies by means of zeta 
potential measurements, we can conclude that the two types of drug 
incorporation models (Fig. 1.8), namely the solid solution model (Model A) and 
the drug-enriched shell core-shell model (Model B), have been successfully 
formulated. 
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4.4.5 STEM imaging 
The STEM images of unloaded SLNs as well as insulin-loaded SLNs and 
physically-adsorbed SLNs are presented in Figure 4.13, 4.14(A) and 4.15(A) 
respectively, showing the rounded morphology of the SLNs. Prior to the insulin 
release studies, insulin-loaded SLNs (Fig. 4.14(A)) and insulin physically-
adsorbed SLNs (Fig. 4.15(A)) appeared morphologically similar to those with 
unloaded SLNs (Fig. 4.13). However, it was observed that after these SLNs 
were subjected to 60 minutes of in vitro drug release studies, the physically-
adsorbed insulin SLNs displayed a different morphology with a rough surface 
(Fig. 4.15(B)). The insulin-loaded SLNs post insulin release (Fig. 4.14(B)), 
however, seemed to have retained its shape.  
Generally, drug release process from nanoparticles is governed by the (1) drug 
desorption of surface bound/adsorbed drug, (2) drug diffusion through the 
nanoparticle matrix or (3) nanoparticle matrix erosion/degradation (Dinda et al., 
2013; Mudshinge et al., 2011). The external morphology of nanoparticles are 
subject to changes as a result of drug release from the nanoparticles. A 
spontaneous modification of the external morphology of the octreotide acetate-
loaded PLGA polymeric microspheres was observed during the release of the 
peptide, where a porous appearance on the microsphere surface was apparent 
(Wang et al., 2002). Degradation of the PLGA microspheres during the release 
of bovine serum albumin resulted in external morphological changes of the 
microspheres with the surfaces becoming wrinkled with several pores (Yang et 
al., 2000).  
The burst release of insulin from the physically-adsorbed SLNs is due to 
desorption of the surface bound insulin from the nanoparticles within a short 
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duration. This also indicates the presence of a weak interaction between the 
insulin and the lipid nanoparticle which allows easy dissociation of insulin. It has 
been reported that drug release can also be affected by the ionic interaction 
between the drug as well as the auxiliary ingredients in the formulations 
(Mudshinge et al., 2011). Both tripalmitin and lecithin have the ability to form 
hydrogen bonding due to the presence of hydrophilic –OH functional groups 
and the polar head group of the lecithin, which contributes to the formation of 
weak hydrogen bonds between insulin molecule and the components of the 
SLNs. It is also possible for insulin to be electrostatically attracted to the 
negatively charged SLNs due to the opposing surface charges (Aboubakar et 
al., 1999b), which formed the basis of the zeta potential measurements as 
described in section 4.4.3. This is because insulin carries a net positive charge 
below its isoelectric point of 5.3 (Park, 1999). The nature of these attractive 
forces are relatively weak and therefore allows easy dissociation of insulin from 
the SLNs, reflected as the burst release effect. 
Desorption of insulin from the nanoparticle surface of physically-adsorbed 
insulin-SLNs will destabilise the charge on the SLNs. The modified surface 
morphology, with rough surfaces and porous edges seen on the surface of the 
physically-adsorbed insulin SLNs after 60 minutes of incubation in the release 
medium (Fig. 4.15(B)), is a result of surface erosion due to the inability of the 
lipid matrix to retain its integrity. At a faster drug release rate, there is a greater 
tendency of lipid Gelucire 50/13 matrix erosion taking place via surface 
disintegration due to the flexibility of the surface during swelling (Khan and 
Craig, 2003).  
Conversely, the insulin-loaded SLNs did not exhibit surface erosion (Figure 
4.14(B)) as compared to the physically-adsorbed insulin-SLNs. Insulin released 
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from the insulin-loaded SLNs is governed by diffusion through the nanoparticle 
matrix which is consistent with the controlled release profile of a solid solution 
drug incorporation model. Such a system only displays the erosion 
characteristics when the diffusion of the drug is faster than the matrix erosion, 
and therefore diffusion largely controls the mechanism of drug release (Aguilar, 
2013). The surface erosion of the nanoparticles was not apparent in the 
absence of insulin burst release (Fig. 4.14(B)). It can therefore be attributed to 
the rapid release of insulin from the nanoparticle surface which had 
compromised the lipid matrix integrity, causing external morphological changes 
of the nanoparticles such as surface erosion. 
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Figure 4.13  STEM image of unloaded SLNs 
 
 
 
  Figure 4.14  STEM images of insulin-loaded SLNs over release duration of 
  (A) 0 minute and (B) 60 minutes. 
 
 
 
 
 
 
 
 
 
 
 
  Figure 4.15  STEM images of physically-adsorbed SLNs over release  
  duration of (A) 0 minute and (B) 60 minutes. 
A B 
B A 
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4.5 Concluding remarks 
It is shown here that two of the three hypothetical drug incorporation models 
have been achieved and successfully prepared. Following the fabrication of the 
insulin-containing SLNs, a simple and reliable method to investigate the location 
of insulin within the SLNs lipid matrix was developed as it is indeed crucial for 
this study. Zeta potential measurements have been shown to be a potential 
indicator here, which is able to fairly suggest the location of insulin within the 
solid lipid nanoparticles. In addition, these findings have been further supported 
by in vitro drug release studies and STEM imaging. 
In summary, the drug incorporation models that are possibly adopted by the 
fabricated SLNs formulations in this study are illustrated in Figure 4.16. 
 
                     
(A)                      (B)   
Solid solution model        Core-shell model with  
             drug-enriched shell 
 
Figure 4.16  Possible drug incorporation models adopted by (A) insulin- 
  loaded SLNs and (B) insulin physically-adsorbed SLNs. 
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CHAPTER 5  
 
 
Cellular uptake studies of 
Different Insulin-SLNs  
Localisation Models 
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5.1 Introduction  
5.1.1 Cellular uptake of drug-loaded nanoparticles  
Improved bioavailability is one of the main key goals in the development of a 
successful oral delivery system. For an orally administered system, the 
bioavailability is strongly influenced by the physicochemical properties of the 
nanocarriers and the drug uptake process across the gastrointestinal epithelium. 
Several methods have been explored in an attempt to improve the 
bioavailability of proteins following oral administration, such as the use of 
mucoadhesives, penetration enhancers, protease inhibitors and encapsulation 
of the payload in nanoparticles (Carino and Mathiowitz, 1999). Nanoparticles 
can offer protection to the incorporated insulin from the harsh environment of 
the gastrointestinal tract and also at the same time facilitate permeation across 
the epithelial barrier (Damgé et al., 2007; Sarmento et al., 2007a, 2007b).  
Recent studies have emphasised the importance of understanding drug uptake 
process and the fate of nanoparticles after oral administration in order to 
develop more efficient oral nanocarriers (Plapied et al., 2011). It is also vital to 
understand how these nanoparticles behave within the harsh environment of 
the gastrointestinal tract during the drug uptake (Deli, 2009). Once the mucosal 
layer is traversed, the drug-loaded nanoparticles have to be transported across 
the intestinal epithelium mainly via the paracellular and transcellular pathway, 
endocytosis and/or receptor-mediated endocytosis via either the enterocytes or 
M cells, before the drug is free to enter the systemic circulation. The drugs may 
appear as free or encapsulated in the systemic circulation post-absorption, and 
will therefore influence the pharmacokinetics as well as their biodistribution in 
the body (Plapied et al., 2011). 
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Possible mechanisms of drug uptake across the intestinal epithelium are 
illustrated in Figure 5.1 (Shah et al., 2006). 
 
 
 
Figure 5.1  Schematic illustration of mechanisms of drug uptake across the 
  intestinal epithelium: (1) passive transcellular route, (2) passive 
  paracellular route, (3) carrier-mediated transport, (4) carrier-
  mediated efflux, and (5) vesicular transport.  
  (Adapted from Shah et al., 2006).  
 
 
The transport of therapeutic proteins across the enterocytes can occur via 
several pathways, primarily through the cell membrane of the enterocytes 
(transcellular) or via the tight junctions between the cells (paracellular), although 
uptake by this route is relatively small (Balimane et al., 2000; Kavimandan and 
Peppas, 2008). Passive transcellular pathway is favoured for non-polar and 
lipophilic drugs. However, insulin, a hydrophilic peptide, has a low octanol-water 
partition coefficient of approximately 0.0215 (Lee, 1987). Therefore, passive 
transcellular transport of insulin across the hydrophobic cell membrane is not 
favourable. Instead, the preferred route is the transcellular pathway which 
involves the binding of proteins to specific receptors, known as receptor 
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mediated endocytosis (Morishita et al., 2002). Aqueous paracellular pathway is 
another possible alternative route for insulin transport across the intestinal 
epithelium (Kavimandan and Peppas, 2008). However, as mentioned earlier, 
insulin is highly susceptible to enzymatic degradation and any possible uptake 
by carrier proteins may be negated by the degradation. 
A study has suggested that the delivery of insulin using poly (methacrylic acid-
g-ethylene glycol) [P(MAA-g-EG)] polymeric microparticles facilitated the 
transport of insulin across epithelium via the paracellular route (Kavimandan et 
al., 2003). The drug uptake was governed by the physicochemical properties of 
the nanoparticles once the drug is encapsulated within the nanoparticles. 
Nanoparticles can be used to improve the transport of the encapsulated drugs 
across the epithelium, owing to various mechanisms such as mucoadhesion to 
mucosa, nanoparticle internalisation in enterocytes and permeation enhancing 
effects (Sarmento et al., 2007a). Nanoparticles can be transported via the 
transcellular route, either through the M-cells of the Peyer’s patches in the gut-
associated lymphoid tissue (GALT) or through enterocytes via receptor-
mediated endocytosis (Clark et al., 2001; Hussain et al., 2001; Sarmento et al., 
2007a). The pathway taken by the drug-loaded nanoparticles for internalisation 
into the cells depends largely on the physicochemical characteristics of the 
nanoparticles as well as the type of cells, for example M cells of the Peyer’s 
patches are more likely to take up larger nanoparticles (>100 nm) (des Rieux et 
al., 2007; Hillaireau and Couvreur, 2009). It has been reported that the fate of 
the nanoparticles is also influenced by the composition of the nanoparticles, 
whether the nanoparticles will remain intact after traversing the cells (Plapied et 
al., 2011).  
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5.1.2 Caco-2 cell line 
The development of in vitro models such as cell culture has opened up vast 
opportunities to researchers to better understand and predict how particles are 
taken up by intestinal cells, since it is not always feasible to conduct in vivo 
studies. Cell culture studies have proven to be a useful alternative tool as the 
data from cell culture studies have been validated by the findings from 
published in vivo studies (Delie, 1998).  
Caco-2 cell line is a continuous line of heterogeneous human epithelial 
colorectal adenocarcinoma cells originally obtained from a 72-year adult 
Caucasian male. It is one of the collection of one hundred and twenty seven cell 
lines first established from gastrointestinal tumours in the 1970s for the purpose 
of performing studies to understand cancers and the related cytotoxic drugs 
(Fogh et al., 1977). The human intestinal Caco-2 cell line has been widely 
studied over the last thirty years as a model intestinal barrier, owing to the 
capability of this cell line to undergo spontaneous differentiation in long-term 
culture to achieve a cell monolayer that expresses resemblance to the mature 
enterocytes in terms of the morphological and functional characteristics 
(Hidalgo et al., 1989; Pinto et al., 1983; Sambuy et al., 2005). The differentiated 
cells form a monolayer that exhibits a cylindrical polarised morphology, with 
microvilli and tight junctions as well as uptake transporters and several intestinal 
enzymes (eg. peptidases, esterases) (Sambuy et al., 2005). Hence, it is suitable 
to use this cell line as an intestinal membrane model for this present study. 
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5.1.3 Aims and Objectives 
Insulin-containing SLNs of the solid-solution model and the core-shell model 
with a drug-enriched shell, were successfully prepared and the location of 
insulin within the SLNs were ascertained as described in Chapter 4. In this 
chapter, the propensity of these SLNs to be taken up by Caco-2 cell line was 
investigated. To our knowledge, no literature has so far correlated the location 
of drug payload within a nanoparticle with the mechanism of uptake across the 
intestinal epithelium, and this is the first report on such a study. As mentioned 
in previous chapters, the propensity of SLNs to be taken up in the 
gastrointestinal tract depends largely on its physicochemical properties. We 
believe that possible interactions occur between the SLNs and the epithelia 
prior to uptake and that the localisation of insulin within the SLNs might point to 
such possible interactions.  
 
5.2 Materials  
Caco-2 cells (ATCC® designated No: HTB-37™) were obtained from the 
American Type Culture Collection (ATCC, Manassas, Virginia, U.S.A). Culture 
medium consists of Minimum Essential Media (MEM) with L-glutamine and 
Phenol Red (Gibco® BRL Life Technologies, New York, U.S.A.), standard Fetal 
Bovine Serum (FBS) (Cellgro® by Mediatech, Inc., U.S.A.) and Penicillin-
Streptomycin (Pen-Strep) liquid (100X) (Gibco® BRL Life Technologies, New 
York, U.S.A.). Other supplements included in the culture medium were Sodium 
Pyruvate (100 mM) and MEM Non-Essential Amino Acids (NEAA) Solution 
(100X) (Gibco® BRL Life Technologies, New York, U.S.A.). 0.25 % Trypsin in 
ethylenediaminetetraacetic acid disodium salt (EDTA) (Cellgro® by Mediatech, 
  
164 
 
Inc., U.S.A.) was used as the trypsinising solution for cell detachment. For the 
purpose of washing the cell lines, Calcium (Ca2+) and Magnesium (Mg2+) free 
Phosphate-Buffered Saline (PBS) at pH 7.4 was obtained from (Cellgro® by 
Mediatech, Inc., U.S.A.). Both trypan blue and dimethyl sulfoxide (DMSO) were 
obtained from Sigma Aldrich, U.S.A.). Insulin-free SLNs and insulin-containing 
SLNs were prepared as described in Chapter 3 and 4. 
 
5.3 Methods 
5.3.1 Cell culture protocols 
Cell culture protocol for Caco-2 cell line was adapted and modified from ATCC. 
The human colorectal adenocarcinoma Caco-2 cell line was grown under 
standard culture conditions of 37 °C, 70 % humidity and 5 % CO2, in a culture 
medium of MEM, supplemented with 20 % FBS, 1.0 mM sodium pyruvate, 1 % 
non-essential amino acids and 1 % Pen-Strep antibiotic solution.  
For thawing of cryopreserved cells, the cell culture medium was firstly pre-
warmed to 37 °C in a water bath for 30 minutes prior to use. The frozen Caco-
2 cell line contained in a cryovial was removed from the liquid nitrogen vessel 
and placed in the water bath at 37 °C until the content was completely thawed. 
The contents were then transferred to a 25 cm2 cell culture flask (Nunc™, 
U.S.A.) with 5 ml of pre-warmed cell culture medium. The cell culture flask was 
subsequently placed in an incubator at 37 °C, 70 % humidity and 5 % CO2. The 
cell culture medium was changed 24 hours after seeding. 
The cultured cells proliferated until the cells occupied all the available spaces 
on the substrate, known as reaching confluency (Freshney, 2000). At this point, 
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subculturing or passaging of these confluent cells was necessary to provide 
more room for continued growth, avoiding senescence from occurring as a 
result of prolonged high cell density. The cell culture medium and trypsin as well 
as PBS were warmed to 37 °C in a water bath prior to use. The medium was 
aspirated from the culture flask using a sterile serological pipette and the 
adherent cells were gently rinsed with Ca2+ and Mg2+ free PBS to remove traces 
of the medium. 0.25 % trypsin-EDTA (1 ml for 25 cm2 cell culture flask; 3 ml for 
75 cm2 cell culture flask) was added into the flask and then incubated at 37 °C 
for 5 minutes to detach the cells. The flask was then gently swayed and tapped 
to aid cell detachment. Next, the cells were viewed under an inverted 
microscope (Nikon Eclipse TS100, Japan) to ensure the cells were fully 
detached from the bottom of the flask. Fresh culture medium (5 ml for 25 cm2 
cell culture flask; 15 ml for 75 cm2 cell culture flask) was added into the culture 
flask and the re-suspended cells were centrifuged for 5 minutes at 1500 rpm at 
4 °C (Universal 320R, Hettich Centrifuge, Germany). Thereafter, the 
supernatant was discarded and the soft cell pellet was re-suspended in fresh 
culture medium. The single cell suspension was then diluted and split into 
different flasks. A change of culture medium was carried out every 48 hours to 
ensure a conducive environment for the cells, until the cells achieve confluence 
and ready to be subcultured. 
The concentration of cells in the culture was estimated by performing a cell 
counting procedure on the cell suspension, calculated using the following 
equation (Eq. 5.1):-  
C =   
n
v
   x   d 
            (Eq. 5.1) 
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where C = concentrations of cells (cells / ml); n = average number of cells (cells 
/ mm2 area); v = volume counted (10-4); d = dilution factor due to trypan blue 
solution. 
 
5.3.2 Cellular uptake  
The Caco-2 cells grown to confluency on T25 flask were harvested. The cells 
were seeded in a 12-well sterile tissue cell culture plate with flat bottom (BD 
Falcon®, U.S.A.) at the seeding concentration of 1 x 105 cells/3.8 cm2 well and 
incubated at standard culture conditions (37 °C, 70 % humidity, 5 % CO2). After 
24 hours, the old cell culture medium was aspirated and was replaced with fresh 
culture medium into each well. 400 µl of treatment solutions, representing 
physically-adsorbed insulin-SLNs and insulin-loaded SLNs formulation, were 
pipetted into each of the wells in triplicates (n=3). Untreated cells and cells 
treated with insulin-free SLNs were used as controls. For blank, the experiment 
was carried out using culture medium only, in the absence of cells. The plate 
was incubated again (37 °C, 70 % humidity, 5 % CO2) and removed at time 
intervals of 30, 60 and 90 minutes for viewing under the inverted microscope 
(Nikon Eclipse TS100, Japan) to examine and distinguish the differences in the 
Caco-2 cells upon treatments with insulin-containing solid lipid nanoparticles.  
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5.4 Results and Discussion 
5.4.1 Maintenance of Caco-2 cell line 
Caco-2 cell line was maintained at standard cell culture conditions as detailed 
in Section 5.3.1. The cells were grown in 25 cm2 (T25) tissue culture flask with 
a vented cap (Orange Scientific, Belgium). Daily culture check was performed, 
including examining the media colour and media clarity. A microscopic check 
on the cell confluence, morphology and contamination was also necessary by 
viewing the Caco-2 cells under an inverted microscope which was equipped 
with a camera (Nikon Eclipse TS100, Japan) (Fig. 5.2 and Fig. 5.3). The cells 
were passaged according to the subculturing protocol in Section 5.3.1, 72 to 96 
hours after seeding when the cells achieved confluence.  
 
 
         Figure 5.2      Caco-2 cells 24 hours post seeding.   
          (100x magnification)      
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Figure 5.3 Confluent Caco-2 cells 96 hours post seeding, viewed under 
  an inverted microscope at (a) 100x magnification and (b) 200x 
  magnification.    
       
(a) 
(b) 
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5.4.2 Cellular uptake 
Cellular uptake of insulin-containing SLNs across Caco-2 cells were studied 
over a duration of 90 minutes. The Caco-2 cells were initially seeded on a 12-
well tissue cell culture plate (BD Falcon®). The plate was incubated for 24 hours 
to allow the cells in each individual well to achieve confluence. Figure 5.4 shows 
the microscopy image of confluent Caco-2 cells prior to treatment, which depicts 
healthy cells. The cells were thereafter treated with insulin-loaded SLNs and 
physically-adsorbed insulin SLNs, while the controls were untreated cells, 
insulin-free SLNs as well as free insulin solution. These treated cells were 
incubated for a total study duration of 90 minutes. During the treatment period, 
microscopy images were taken at a half hourly interval. The photomicrographs 
of Caco-2 cells which represents the cellular uptake of these nanoparticles 
based on the respective treatments that were carried out on the cells, were 
taken at regular time intervals of 30, 60 and 90 minutes (Fig. 5.5). 
 
 
 
Figure 5.4 Photomicrograph of Caco-2 cells seeded on a 12-well cell  
  culture plate prior to treatment. (100x magnification) 
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Figure 5.5 Photomicrographs of Caco-2 cells from the cellular uptake  
  studies taken at 30 minutes, 60 minutes and 90 minutes after 
  treatment. (100x magnification) 
        30 minutes    60 minutes           90 minutes 
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Based on the images in Figure 5.5, we can say that the untreated Caco-2 cells 
(control) remained healthy and confluent throughout the study duration. When 
the Caco-2 cells were exposed to insulin-free SLNs, the cells appeared to be 
confluent and morphologically similar to those seen in the untreated group even 
after 90 minutes of incubation period. Interestingly, the Caco-2 cells that were 
exposed to the insulin-loaded SLNs and the physically-adsorbed insulin SLNs, 
displayed contrasting observations in terms of the appearance of the Caco-2 
cells. Here, we observed that by exposing the Caco-2 cells to the insulin-loaded 
SLNs, cell death had occurred as early as 30 minutes of treatment. The images 
showed cell shrinkage and subsequently cell detachment from the substrate, 
leaving traces of dead cells in the individual wells. In contrary, this occurrence 
was not apparent in the treatment group of physically-adsorbed insulin SLNs. 
Over the incubation period of 90 minutes, the Caco-2 cells remained confluent 
with minimal cell death. The cell morphology here also appeared similar to those 
cells exposed to insulin-free SLNs.  
It is important to note that these observations were made based on viewing the 
cells under the inverted microscope to determine any differences in the 
appearance of the Caco-2 cells upon exposure to different SLNs formulations. 
Cellular uptake of the nanoparticles by the absorptive cells was not evident in 
this case (Fig. 5.5). Nevertheless, the differences in the cell appearance may 
allow us to predict possible differences in the uptake of SLNs by the cells, 
though further investigation such as fluorescence imaging of the cells was 
certainly required to confirm such findings.  
The insulin-free SLNs prepared as described in Chapter 3, was composed of 
tripalmitin as the core lipid material. Tripalmitin has often been used in 
pharmaceutical preparations for its biodegradability and safety benefits, where 
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it is of the generally regarded as safe (GRAS) status. Several studies have 
addressed the safety issues and the in vitro toxicity and tolerability of SLNs 
(Doktorovova et al., 2014; Petersen et al., 2011; Severino et al., 2014). It has 
been reported that SLNs and NLCs usually show better in vitro tolerability as 
compared to their polymeric counterparts (Doktorovova et al., 2014). In order to 
prove that the lipid nanoparticulate carrier itself was non-toxic to the cells 
investigated, blank SLNs were included as a control in a study. It was, therefore, 
shown here that the tripalmitin SLNs formulation displayed good in vitro 
tolerability and was non-toxic to the Caco-2 cells. The influence of SLNs particle 
size on cell viability in vitro has been reviewed by Doktorovova et al. (2014) and 
it was reported that the highest cell viability was observed within the range of 
100 to 300 nm (z-average). The reported z-average values were in good 
agreement with that of our SLNs formulations. On this basis, insulin-free SLNs 
have shown to be non-toxic to the Caco-2 cells being investigated (Fig. 5.5). 
It can be recalled that insulin-loaded SLNs had caused cell death as early as 
30 minutes of exposure. In contrary, physically-adsorbed insulin SLNs did not 
exhibit cell death over the duration of study which was similar to that seen in 
insulin-free SLNs. The contrasting observations were particularly notable for 
these two different types of insulin-containing SLNs formulations despite both 
having z-average values which were within the range of 100 – 300 nm, 
reportedly being optimal for cell viability (Doktorovova et al., 2014). The extent 
of uptake and translocation of nanoparticles after oral administration is 
dependent on factors such as particle diameter, surface charge, surface ligands, 
shape and elasticity as well as their colloidal stability (Florence, 2005). 
Generally, absorption increases with decreasing particle diameter for 
nanoparticles with diameter below 1 µm. For particle diameters exceeding 1 µm, 
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particle uptake by the M-cells of Peyer’s patches have been mainly implicated 
(Florence, 2005). Considering that the particle diameters for both these 
prepared SLNs formulations were of nano-sized range, the uptake of these 
SLNs was deemed to be efficient. Therefore, the different effects seen between 
both the insulin-containing formulations on the Caco-2 cells could potentially be 
directly related to the variances in the rate and the extent of SLNs uptake. 
Lecithin has been reported to promote oral absorption of drug by favouring the 
passage of the SLNs through the intestinal wall (Bargoni et al., 1998). Orally 
administered cyclosporine formulation containing lecithin permitted 45 times 
more cyclosporine to be taken up by cells than when excluded (Yanagawa et 
al., 1989). In this instance, both of these SLNs also contained lecithin in their 
formulations which favours the uptake of nanoparticles. Cellular uptake and 
translocation of nanoparticles have also been reported to be influenced by 
surface charges of the nanoparticles (Florence, 2005; Hoshino et al., 2004; 
Jiang et al., 2008). Surface charges can affect the uptake of nanoparticles 
through surface charge-specific interactions. It was reported that for polymeric 
nanoparticles, the positively charged polymeric nanoparticles were found to 
interact mostly with clathrin on cell membranes, whilst the negatively charged 
polymeric nanoparticles were mainly internalised by lysosomal endocytosis 
(Bhattacharjee et al., 2013). However, internalisation mechanisms for SLNs 
have been proven to be predominantly active transport, via both clathrin- and 
caveolae-mediated endocytosis, but not through macropinocytosis (Fan et al., 
2014; Martins et al., 2012). Neutral and negatively charged nanoparticles were 
reported to have lower affinity of interaction with the negatively charged cell-
membrane surface, hence lower levels of internalisation as compared to the 
positively charged nanoparticles (Verma and Stellacci, 2010). However, 
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another study found that the negative charges on the surface of SLNs does not 
appear to affect the uptake of the nanoparticles to the extent that results in a 
reduced uptake as observed for polymeric nanoparticles with negative surface 
charges (Bargoni et al., 1998). Although the zeta potential values for insulin-
loaded SLNs (-45.8 ± 1 mV) were higher in magnitude than that for physically-
adsorbed insulin SLNs (-40.8 ± 1 mV), both SLNs have negative surface 
charges and therefore uptake via interaction with clathrin or caveolin would 
involve similar uptake mechanisms. Since the hydrodynamic size and surface 
charges of nanoparticles can influence the way cells respond to the SLNs, the 
contrasting behaviours observed between both types of insulin-containing 
SLNs is attributable to other possible contributing factors outlined below. 
As observed, the two insulin-containing SLNs formulations caused cell death to 
different extents and they can be distinguished by the rate of death of the cells. 
We have observed a shorter time to cell death with the insulin-loaded SLNs. In 
contrast, the physically-adsorbed insulin SLNs when incubated with Caco-2 
cells did not reveal widespread cell death, but minimal cell death. For insulin-
loaded SLNs, insulin is molecularly dispersed within the lipid matrix and 
therefore the components of the lipid matrix exposed on the surface of the SLNs 
are recognisable as hydrophobic surfaces by the enterocytes. On the other 
hand, physically-adsorbed insulin SLNs were predicted to have a drug-enriched 
shell where insulin was mostly found adsorbed on the surface of the SLNs by 
electrostatic attractive forces. Hydrophobic surfaces of nanoparticles are 
believed to favour cell-nanoparticle interactions that can result in better uptake 
of nanoparticles by the intestinal epithelium, as compared to those with 
hydrophilic surfaces (Eldridge et al., 1990). Thus, the differences seen in the 
effects of these insulin-containing SLNs on the Caco-2 cells (Fig. 5.5) could be 
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influenced by the surface hydrophobicity of the SLNs as a result of different 
localisation of insulin within the SLNs.  
From the observations made, although not conclusive, we cannot discount the 
possibility of these observations being correlated to the cellular uptake of the 
SLNs. Since our findings suggested a distinctive differences in the appearance 
of the Caco-2 cells, it is indeed justifiable to further investigate the cellular 
uptake of the SLNs which has adopted different insulin localisation models by 
means of performing fluorescence imaging on the Caco-2 cells. This finding is 
therefore crucial as this key parameter can potentially influence the cell uptake 
of SLNs, which have not been discussed before. 
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5.5 Concluding remarks 
Despite three different drug incorporation models being proposed by Müller et 
al. (2000) (Fig. 1.8), these models were suited to the incorporation of lipid 
soluble drugs. Having incorporated a hydrophilic drug in the lipid matrix, there 
was certainly a constraint in getting all three hypothesised localisation models. 
In this study, we have thus successfully fabricated insulin-containing SLNs 
which fitted the two different types of insulin localisation models, namely the 
solid-solution model (insulin-loaded SLNs) and the core-shell model with a 
drug-enriched shell (physically-adsorbed insulin SLNs). Furthermore, we found 
that these two different insulin localisation models demonstrated distinctive 
differences in the appearance of the Caco-2 cells upon exposure to these SLNs. 
It is important to note that it is not reasonable to accept these observations as 
the cellular uptake of the SLNs into the Caco-2 cells. However, the findings here 
potentially indicate that the cellular uptake can indeed be different for both of 
these SLNs, subject to further investigation by performing cellular uptake 
studies to confirm these findings. We have also shown that the insulin-free 
SLNs produced were non-toxic to the Caco-2 cells. 
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6.1 Conclusion 
Diabetes is a progressive, chronic metabolic disease which remains as one of 
the leading causes of mortality worldwide. The major concern in this mortality 
data lies in the alarming increase in global prevalence with almost half still 
undiagnosed. Unfortunately, there is no cure for diabetes. Insulin is the 
mainstay of treatment for diabetics when other oral hypoglycaemic agents fail 
to achieve optimal blood glucose levels. Insulin, a polypeptide hormone, 
functions as the body’s blood glucose regulator. Recent advances in 
biotechnology have brought vast opportunities to the medical sector by 
increasing the production of biopharmaceuticals, giving rise to the availability of 
insulin for therapeutic use. However, delivery of insulin to patients is indeed a 
real challenge. Being a protein, insulin is susceptible to enzymatic degradation 
along the gastrointestinal tract. Thus, insulin is currently administered via 
multiple subcutaneous injections albeit less well-received by the patients. There 
is a need for a desperate search of feasible alternative approaches, especially 
the more practical and acceptable oral route. Colloidal nanoparticulate delivery 
systems have been widely explored in recent years due to their ability to 
encapsulate, protect and deliver biopharmaceuticals via the oral route (Bilati et 
al., 2005a; Vonarbourg et al., 2006). In fact, solid lipid nanoparticles are 
favoured over other colloidal carriers especially for its lack of toxicity of 
physiological lipids as compared to polymeric nanoparticles.  
In this study, we aimed to develop an insulin-containing colloidal 
nanoparticulate delivery systems based on solid lipid nanoparticles as a 
potential oral insulin delivery carrier. By utilising natural non-toxic constituents 
to formulate the SLNs, it was hoped that this potential carrier would offer the 
benefit of non-toxicity. Within this context, we aimed to establish whether the 
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localisation of insulin within the SLNs influenced the uptake of the nanoparticles 
by absorptive cells. To realise this objective, the insulin-containing SLNs are 
firstly formulated and characterised to optimise the nanoparticles. Following the 
fabrication, formulation and processing parameters were manipulated in order 
to achieve different insulin localisation models. Thereafter, we attempted to 
identify the location of insulin within the SLNs matrix by exploring viable 
methods to distinguish the different types of insulin localisation models that 
have been achieved. In order to investigate the influence of different insulin 
localisation models on the uptake of nanoparticles, in vitro cell culture studies 
were employed to distinguish the differences, if any, on the uptake of such lipid 
nanoparticles by absorptive cells.  
As part of preformulation studies, a simple and reproducible HPLC method for 
insulin analysis was developed and validated with respect to linearity, precision 
and accuracy, followed by stability-indicating studies on insulin using HPLC and 
DLS technique to ascertain optimal storage and working conditions. 
The solid lipid nanoparticles, comprising of palm oil lipids, were successfully 
fabricated using W/O/W double emulsion solvent evaporation technique. 
Production and processing parameters were optimised in order to attain 
desirable parameters, such as z-average, PdI, zeta potential and other physical 
properties. Selection of suitable lipid core compositions was investigated by 
employing either tripalmitin or palmitic acid, as the sole lipid or a combination of 
both, based on their unique feature that contain identical C16 saturated fatty acid 
chains. The optimised SLNs formulation consist of solely tripalmitin as lipid 
matrix and lecithin as emulsifier. The optimised SLNs has a mean size of 293.3 
± 5.2 nm and zeta potential of about -39.9 ± 1.3 mV. The size and zeta potential 
of the SLNs indicated a suitable and stable lipid nanoparticulate delivery system 
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to potentially deliver insulin. The SEM and TEM images verified that the lipid 
nanoparticles were spherical in shape with an approximate size diameter 
measured at 250 nm, which corresponded with the z-average value obtained 
from dynamic light scattering. No obvious particle aggregation of the SLNs 
formulation was detected when viewed under polarised light microscope, an 
indication of physical stability of the formulation, which was in good agreement 
with the zeta potential measurements obtained from DLS.  
Using similar compositions, insulin-containing SLNs with two different 
localisation models were successfully achieved by means of carrying out 
modifications to the production parameters. In this study, it is indeed crucial to 
develop a simple and reliable method in order to ascertain the localisation of 
insulin within the SLNs lipid matrix. Zeta potential measurements have been 
shown to be able to suggest the location of insulin within the SLNs. To further 
complement the findings, drug release studies and STEM imaging were 
performed on both types of insulin-containing SLNs. This method which utilises 
DLS technique to measure zeta potential of the SLNs and applied in conjunction 
with drug release studies is certainly considered a milestone as it confirms its 
potential ability to serve as a useful indirect indicator of the drug location within 
the nanoparticles. The two possible drug incorporation models adopted by the 
insulin-containing SLNs formulations are the solid solution model (insulin-
loaded SLNs) and the drug-enriched core-shell model (physically-adsorbed 
insulin SLNs).  
From the in vitro cellular studies, we found that both these formulations with 
different insulin localisation models demonstrated distinctive differences when 
these nanoparticles were exposed to the Caco-2 cells. Our insulin-free 
tripalmitin SLNs was also found to be non-toxic to the Caco-2 cells, hence 
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potentially safe for oral delivery. The localisation of insulin was believed to be 
the reason behind the differences seen in the appearance of the Caco-2 cells. 
It is important to note that the contrasting observations made here potentially 
indicate that the cellular uptake can indeed be different for both of these SLNs, 
although further investigation is necessary to establish the cellular uptake of the 
fluorescent tagged insulin into the Caco-2 cells as part of future studies. 
However, this finding by itself is particularly significant as it highlights the 
importance of characterising drug localisation in nanoparticles, which has not 
been previously discussed, since it can potentially determine the cellular uptake 
of the insulin-containing SLNs and hence ultimately impact the drug 
bioavailability. For that reason, due emphasis should be given to the 
characterisation of drug location within the SLNs as one of the key parameters 
to be characterised during the formulation optimisation phase.  
In conclusion, much interest has been focused on developing nanocarrier drug 
delivery system to deliver insulin orally in recent years and if found successful, 
it is expected to make a breakthrough in diabetes management. In this study, 
successful fabrication of insulin-containing SLNs with different localisation 
models has shown significant differences in cellular uptake of the nanoparticles. 
Characterisation of such parameter, which had not been addressed before, 
ought to be carried out in the development stages of SLNs formulation, in a bid 
to predict the efficiency of cellular uptake and ultimately the drug bioavailability 
in advance. Therefore, localisation of insulin within the SLNs is one of the 
significant contributing factors to the successful development of a promising 
oral insulin delivery in the future. 
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6.2 Suggestions for Future Work 
Recent advances in the field of nanotechnology and biotechnology have 
brought vast opportunities to the development of nanoparticulate drug delivery 
systems that are safe and effective to deliver protein and peptide therapeutics. 
However, much research is required to deliver these nanoformulations orally as 
it still remains a challenge to ultimately achieve the clinical stage. Having 
successfully fabricated the two different types of insulin SLNs formulations 
(insulin-loaded SLNs and physically-adsorbed insulin SLNs), ongoing research 
will be focused on the gastrointestinal absorption aspect of the orally 
administered insulin-containing SLNs formulations in order to evaluate their 
gastrointestinal transit as well as the bioavailability of insulin. Here, we discuss 
some suggestions for future work as a further extension to the present one. 
Insulin adsorption studies on the physically-adsorbed insulin SLNs (core-shell 
model with a drug-enriched shell) can be performed to evaluate whether the 
adsorbed insulin tends to form monolayers or multilayers, according to the 
Langmuir or Freundlich isotherms respectively. Moreover, it can provide better 
understanding of the nanoparticulate system in terms of its ability to associate 
with the drug, either governed by the incorporation approach (physical 
entrapment) or by means of great affinity of the peptide for the lipids 
(physicochemical association), as well as the drug release from the surface-
associated nanoparticles (Garcia-Fuentes et al., 2005b). In terms of evaluating 
the long-term stability of these nanoparticle formulations, an accelerated 
stability study can be performed using a stability separation analyser 
(LUMiFuge) by studying the real-time separation behaviour of the samples 
(Vitorino et al., 2011). 
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Further evaluation in terms of the in vitro cellular studies of the current SLNs 
formulations is important as part of this work extension to develop a safe and 
efficacious oral insulin formulation. A cell viability study can be performed using 
diphenyltetrazolium bromide (MTT) assay to determine the effects of the insulin-
containing SLNs formulations on the Caco-2 cell growth. Subsequently, 
performing a Caco-2 cell permeability assay is crucial to evaluate the response 
of the Caco-2 cell monolayer to the fabricated SLNs formulations as well as to 
assess the drug absorption process across the monolayer (Ma and Lim, 2003). 
When cultured as a monolayer, Caco-2 cells are able to differentiate to form 
tight junctions and expresses proteins and enzymes which mimics the human 
intestinal epithelium (van Breemen and Li, 2005). As an extension work from 
Section 5.4.2 to further improve the data and to evaluate the uptake 
mechanisms of the insulin-containing SLNs formulations, insulin is labelled with 
FITC which is a fluorescence tag. The Caco-2 cell monolayers treated with 
FITC-insulin SLNs will be examined under a confocal microscopy and the 
fluorescence-labelled insulin can be detected through green fluorescence (Yin 
et al., 2009).  
In vivo studies are useful as a proof of concept for the developed insulin-
containing SLNs formulations. The bioavailability of the orally administered 
insulin is very much influenced by their transit rate in the gastrointestinal tract 
which is indeed a critical factor to determine the drug absorption (Kimura and 
Higaki, 2002). In order to study the biological efficacy of these SLNs 
formulations, they can be evaluated by means of sampling blood glucose levels 
as well as performing biopsies on the intestinal epithelium, ie. the follicular 
mucosa (Peyer’s patches) and the non-follicular mucosa (Damgé et al., 2007). 
The formulation will be administered orally to overnight fasted diabetic rats and 
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the plasma glucose levels of the rats can be determined by measuring the blood 
sampled from the tail vein of the rats at regular time intervals. Investigations on 
possible insulin absorption mechanisms and intestinal uptake can be examined 
by administering FITC-labelled insulin SLNs via intra-luminal injections in an in 
situ isolated intestinal loop (Damgé et al., 2007; Sarmento et al., 2007b). The 
biopsies of the intestinal epithelium sections can then be observed through 
confocal microscopy to detect the appearance fluorescent points representing 
the fluorescence-labelled insulin inside the structures.  
It has been suggested that the main SLNs uptake pathway may be via the M-
cells overlying the lymphoid follicles as well as the Peyer’s patches and non-
patches (Bargoni et al., 1998). These formulations can be evaluated in terms of 
the extent of lymphatic uptake by administering radiolabelled SLNs formulations 
into the duodenum of the anaesthetised rats. Two catheters separating the 
lymph and the jugular vein allow simultaneous collection of each lymph and 
blood samples respectively (Bargoni et al., 1998). The radioactivity found in 
both lymph and blood samples can be detected by gamma-counting which can 
provide insights on the extent of lymphatic uptake of the SLNs formulations. 
Gastrointestinal transit rate of the orally administered drug has a significant 
influence on the drug absorption as it also determines the residence time of the 
drug in the absorption site which is particularly important since there is site-
difference in drug absorbability (Kimura and Higaki, 2002). It is possible to 
analyse and estimate the drug absorption kinetics and the bioavailability of the 
orally-administered insulin SLNs formulations by applying the GI-Transit-
Absorption Model, developed by Kimura and Higaki (2002), which takes into 
account site differences by dividing the GI tract into eight segments (stomach, 
duodenum, upper jejunum, lower jejunum, upper ileum, lower ileum, cecum and 
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large intestine). This can potentially provide additional information on the 
contribution of absorption in each different segments to determine the 
substantial absorption site of the formulation in vivo. 
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